var title_f22_49_23312="Sagittal MRI LSS";
var content_f22_49_23312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sagittal MRI in lumbar spinal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23312=[""].join("\n");
var outline_f22_49_23312=null;
var title_f22_49_23313="Barretts esophagus CPC Light";
var content_f22_49_23313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a biopsy specimen from the distal esophagus in a different patient showing intestinal metaplasia diagnostic of Barrett's esophagus. The diagnostic feature is the presence of goblet cells (arrow), characterized by apical basophilic cytoplasm, a dilated lateral cell border and a compressed basal nucleous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23313=[""].join("\n");
var outline_f22_49_23313=null;
var title_f22_49_23314="Bennett fracture of the thumb";
var content_f22_49_23314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bennett fracture of the thumb",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Bennett fracture of the thumb is an oblique, intra-articular fracture of the thumb metacarpal base. The smaller proximal fragment of the metacarpal shaft includes the palmar and ulnar corner of the metacarpal base and is fixed to the base of the index finger metacarpal and the trapezium by virtue of the anterior oblique ligament. The larger fragment of the metacarpal shaft is displaced radially, proximally and dorsally by the pull of the abductor pollicis longus (APL) that inserts on the dorsal radial corner of the metacarpal base. This is an unstable fracture pattern that requires fixation after reduction of the fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23314=[""].join("\n");
var outline_f22_49_23314=null;
var title_f22_49_23315="Spore shapes";
var content_f22_49_23315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Spore shapes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 407px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGXAh4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimTSxwwvLM6xxIpZ3c4CgdST2FeY6/8AEG81J5LbwjGscAO3+0503B/eGP8AiHo7cdwGHNAHp8siRRtJK6oijJZjgD8ayZfFPh+J9kuu6Uj/AN1ruMH+deNX2gXGsyrPrM1xqco5zePvUH1Ef3F/4Cop40SW3TbHGqp/dVQBQB7lZ31pfIXsrqC4QdWhkDgflVivnV9Ighu1uVt/s90vS4tmMMo/4GhB/DNdZ4f8darpDbdaZ9W0zIHnpGBcwD1ZVAEij2Ab/eNAHr1FQWF5bahZw3djcRXFrMu+OWJgyuPUEdanoAKKKKACiiigAooooAKKxvFHiOx8N2Kz3peSWU7ILaEbpZ2/uqP5k4A6kiuCvPEPi3V5Q9tNDotr1EdvGs8x/wB55AU/AJ+JoA9WorxqTXPFthP8mvmbP8F5ZxOo+nliM/mTT7fxb4ttJxNJd2OoRk5e3ltfJBHorqSV/ENQB7FRXJeFvHema7MtnMH03VCSBaXRAMmO8bD5XH05HcCutoAKKKKACiiigAooooAKKKKACiuH8RfEXT9Pu2stIgfV71CVk8lwsMJHZ5cEZz1VQxHcCuRvfF/i6+dvLvLLTouy2tr5jj6vISD/AN8CgD2aivEV1zxSgDDxNqDMO0tpalD9QsQP5EVsaZ8QdctFI1Wxs9SQfx2ZNvKR/uOSpP8AwNaAPVqKyPDniLTfENq02mz7njwJoJFKSwk9nQ8j27HqCRzWvQAUUUUAFFFFABRRRQAUUUUAFFeSa3ql/wCKtbv0sdRvbTRrOQ20QtZmhM8iEh5N6ENjdlQN2PkzznifQPF2oeHLz7H4lkuL7S5CBFebC8tuf7sgUZdP9rBI/iyOQAeqUVk6X4l0LVpvK0vWdNvJu8cFyjuPqoORWtQAUUUUAFFFFABRRRQAUUU2WRIYnlmdY40UszscBQOpJ7CgB1FcBqfxKtTO0Hh2xk1bHW63+VbZ/wBl8Ev9VUj3rnrrxV4zuWJS402zjzwsNm0jD6s74P8A3yKAPYKK8Zi8T+MbZt51W0nx1S5sBtP4oykfrXR6R8SoRKkPiSzGnqR/x+xSeZbA/wC2SA0f1I2j+9QB6HRSIyuiujBlYZDA5BFLQAUUUUAFFFFABRRRQAUUVj+MNXbQvDGo6lFGJZ4Ij5MZPDyn5UU/Vio/GgDzv4gazJ4j1qbQ7Vj/AGRZPsuwBxdTDB2H/YTjI7twfukG5pWlqiqSvNZHhOxMNvGs0jTSjmSVusjk5Zz7liT+NdxYoARQBFHY4XpUc9jweK6OGEMtR3NsAuRQBxF9YKQQVrl7+1e1ffHnGea9FvIRg1zeqW29G4oAzvBevN4b1SNWLHRL6UJPHni1mY8Sr6KxOGHQEhv72faK+e3hSSSezuF3W86mN19VIwR+tewfDrUJtR8IWDXcpmvIA1rPIervGxQsfdtob/gVAHSUUUUAFFFFABXP+L/FNn4ato/NSS5vp8i3tIvvykYySeiqMjLHgZ7kgHoK8cukbWvHes3bkuFm+xw552RxfKVH/bTzCfr7UAVXur/W9fGo6xJGZVXy4beIHy7dCQSFJ5YkgZY4zgcACu+02ziezLnGcVjzaILcq+MVes7gxR7CeKAMjWbHzLlSo4BrWtdESa0yVBOKbcOHfNbWnXKrb7RQB5f4r0OIKyzRh48hsHsQeCD1BHqORXafCjxDcajb3ulandNc3tkVeOWT78kD52lvUhlZSfQKTyag8WIHjY4HNcJ4R1L+yvG2k3OMLJN/Z8pHdJiAo/7+CL9aAPoCiiigAooooAKKKKACvMPiL4hu77VZPD2lTPb2sKr9uuInw7swyIVI5X5SGYjn5lAxzXpd1PHbW0s8zbYokLufQAZNeHeCoJbmFLq8+a7uibq4b1kkO5vwBOB7AUAbOheHYYbeKOGFY4kGFRVwAPYV0cehJt+6PyrT06AADjitZVULQByU+iIB92sHVdGCqSgwRXo8yKwrHvrcMrcUAeXR/abTUY7uwmFrqkA2wznO0jOTHIP4kPcduowcGvZ/Cutw+IdEt7+FfLdspNCTkwyqcOh9wcjPfg968t8QWgjkLLxWh8O9QfT/ABQtqAPsmro2cfw3Ma5B/wCBRg5/65D1oA9YooooAKKKKACiiigArz3xR4uutRvLnRPCjqsiZiudU+8tu2cMkY6NIPXop9SCBq/EzV59M8Prb2E7QahqUws7eRfvR5BZ3HuEVyD64rG8M6XBp9lDb26BURQB/wDXoAm0bRodN0+G2tk2xRqFUfSmanp6yr8y11EEIKioru3AQ8UAeW61oMEw/wBJtop1ByN6AlT6g9QfcVs+EvF15o13BZaxPJd6TNIsUVxKd0tox4USMeXjJwNx5UnkkcjYvoAQykVx2p2kbtLBMgeCZTG6noykYIoA9yorlPhnqc2o+F0hvJ2uL3T5Wsp5W+85TBRj7tGyMfcmuroAKKKKACiiigBk8scEMk0zrHFGpd3Y4Cgckk141rWrXXjq7IbzIfDyt+5tSCpuMHiSX1BxlUPGME5PC9b8XbuX+x7HSYSQNSuRHOQcHyEUu4+jEKh9nNZmj2oRFGOTQBNpWjIEUKg/Ktf+ygF+6K0bJAiCrmQRQByF9pi7SCtcjqthLaOZI8le4r1K8iDqeK5rVLZXRlIoAw/h54iOhX9tpc7gaLdOIoQ7H/RJj91B/wBM3OAB/CxAHDYHsFfO+p2kf2mW0nz5E4KnBwR6EHsQeQfUV7R4C1mTXfC9pd3W0Xqbre6C9BNGxRyPYkZHsRQBifF/xnfeENF0xdEtILrW9Y1CLTLFLgkRLLJnDPjkgYxgEdR71x8XjHxLp9l4xhu/F/hXWb7StFvbryrGEpc2l1CAAGQkqYwcg5Gc7R3Nei/EHwdY+N9CTTr+a4tpYJ0u7W7t22y206Z2yKfUZI/H1wa46w+EB/tDxBqOteIp9Q1LWNHm0WSZLKK3Cxy8tIVThpMjOe/OfYANN+K4h0Hw9DJpOra9rs2hW2r6gumwx4hR4wWc7mUZJzhBz9OKpXXxUu7jx5of/COWl7rWg6joDailnaQxiZpPN25JcrjaAQRnr2Nac3wnktTYTeG/E17o93FpEOi3Uq20cwuYIl2q21vuP/tD8qaPhEumz6RceE/EN3o1xpmlHSoZPs8dxuRnLs7BuNxJJ4xz+VAElt8ZNI1O10g+HtI1nWNQ1G1kvBYWsSCW3ijcxuZdzgD5wVABOSPcZiu/jf4d+y6JJpdpqGoXGrQPcRW6+VC8ao5Rg5ldV3BlYbQSTg9sEssfg5FoK6PP4Q8Q32j6rYWclhJetBHcm5ikkMrb1cYz5hLAjp05qpq3wNs7rw1puhWWsmKwtIJIn+16dBdu7u7O8yu43RuSx5U4wBxxQBr+KPi/pWgzWts2k6tc38lgupXFoqxRyWkLDOJN7geZ1GxSTwfxTx/4gtde8AeH9R0qQvYareWzoWGCVw0gBHYgoOOxFUtW+Ctg9xpdzouptZ3Vlp8WmM17Yw36TRRjCMySLgOP7y444xWj420H+yfhvptp55uP7MurdzL5SRbsybCdiAKo/eE4AAAFAFbQkCwgjvXSWZwwrmtEceSB6VvW8m00AdHAwwOaS6lUKeay1ucDg0yS4z1NADLpgQaw79flNaU0mTWdekbDmgDidQ+W/XHrXd/B5z5HiSAn5I9TDL7breFiPzyfxrhLz97qQA7GvQvhDatHo2q3jDi91KV1P+zGqQ/ziNAHd0UUUAFFFFAFHXb46XomoX4jMptLeSfYOrbVLY/HFeT+AFNuqG4lWadmaWWUdHkdi7sPqzE/jXsVzEJ7eWJsYkUqcjI5GOlfPfh6Wbw/HHpl8phvLFEtriMnO11Uc+6sMMD3BFAHsOpzLJCMelYEpYISvWsu01qS8wiZx610lhaCaIbjyaAOcfUGhP7xTVqz1uIcbh9K1b7Qt4OADXJ6tonl56qfUUAXNY1aOdD8w2ivPyTLco0X32vrUR4/v/aI9v64qbUYZ4G2M5Kt3zXUfC/w82q6+t3Og/s/SnD5P/LW5K5UfRFYN/vMnoaAPbKKKKACiiigAooooAyvFsTz+FdZiiz5kllMq49SjAV5l4NdJYIXjxtZAR9CK9iIBBBAIPBBrw7wXDLo9zNo11uE+mym0Yt1ZVxsf/gSFG/GgD1G0OEFWyxIrNtJOAKthqAJiTjmqV2w2mp3kwKz7qQEHmgDlNfUMHNc/FctYtYXsf3rXULZz/uNKsb/APjjtW/rbAq3Nc6YGu/stnGMtc31rH9F85Cx/BQx/CgD3qiiigAooooAKKKKAPMfiZIZvG/hy3P3IbW5nx6sWiUH8Bu/OtnTCNorM+K9s9vq3h/WUUmJGlsZj/d8zayE/wDAo9v1cVY02cFFINAHURNhAaSZtyGqkc2V6055gEIzQBlXw+Y1yGtcTD611l7IOSelcfrFxGkjSTOqQxgu7noqgZJP4UAdN8IgTN4ocf6v7fGvtuFtET+hX8q9Erk/hhYva+FIrmeFobjUJXvXRhgqHPyAjsRGEB9wa6ygAooooAKKKKAPOPicT/wk/h4H7v2W7P477epdNx8tO+MMEkWm6Xq0a5Syuglwe6xSjZn6B/KJ9gT2rM0e73IMnmgDs4GGyp0rJt7kY61aW7GKALcxAU1g3+Nxq/Pdgqeax7yX5WJNAHA+Jzi8QjqDXovwmYnT9bX+FdR+UembaBj+rE/jXnWs/wCkaiiIMnNek/CONj4Sa9YYW/upbiP/AGo87I2/FEU/QigDtqKKKACiiigAooooAKy/FGkrrvh3UtLd/L+1wPEJB/AxHyt+BwfwrUooA8Q8M6hJsCXiCK6jYxTx5+5Kp2uv4MDXXxyBlBBqv8Q/CdwLyTX9CgMszAfbrSMfPOFGBJGO7gAAj+IAdwAee0XWo5bdJEkEkTdGH6gjsR3B5FAHXbzQXPrWYmoRkZDU2TUYwPvCgDQkcAcmsXVb0RxtzUN3qq7TtOTWFd3KmKS5vJBHAgyWb/PJ9qAIHebBa2VXvbh1t7VG6PM5wgPtnknsAT2r3Lw3pMehaDYaXC7SLawrGZG6yEDlj7k5P41xvw58Lzpcrr2sQGGfYVsbWRcPbxsPmd/SRumP4V46lq9EoAKKKKACiiigArzf4q+GprmeHXdPtnuJIojBeRRDLtECWV1H8RUlvl6kMcZIAPpFFAHgWg6hCYw1tNFPEP4o2Bx7EdQfY11dlrgjwQwrtvEXhTRvEKf8TKyjadeUuY/kmjPqsg+YfTOD3zXFav8ADfULciTw/qaXKdGttSO3j/ZljXI/FGz60AaSeJUK4OCaxtX1dZgTwKzpfBviy3UtLpllOB0Wxv8Ae/5SpGP1quvhLxRdNtTRJIT2N3dQqn5ozn9KAMbVLuJleedgltCNzuf88n2r2L4aaPPovhG1hvY/LvZ3kup07q0jlgp91Uqv/AayfB/w9TTrmDUNeuEvtQhbfDDEpW3t2/vAHl2HPzN+AWu+oAKKKKACiiigAooooAK8u+I1m+m+M9N1hP8Aj3v4fscvtLGWdPzUyf8AfAr1GvOvi5fw3UWn+HrdPM1OaeG9BHS3ijlBLn3YBkA75b0NAF6yuAUU+orRScY61zQnS1iVWYcCm/2ugH3qAOinnGOtZd5dBUOTWPcayNpw1Yl5qTzEqpPNAE2qXYkfCnrV/wABafLf+MbeUD/RdKjaeVvWaRSkafghkY/VPWsKzgutR1EafpEQuNSI3Hdnyrcf35WHQei9Wxx3I9i8K6Db+HdISytmMkjMZZ52HzTyt95z9ew7AADgUAbFFFFABRRRQAUUUUAUNe0m11zR7rTb9WNtcJsbYcMvcMp7MCAQexArycyah4V1GPTfEC/u5WKWt8o/d3AHQE/wyY6qffGR09nqC+s7a/tJbW+t4rm2lG14pkDo49CDwaAOGtb9XX5WBFWDcgrih/hppEbN/Zt5qunRk58uC4Dov0EqvtHsMCsi58JeKNOuCun3VnqlmfutO5gnT2OFKt9Rt+lAEmqT7YWOegrI8LaDN4rvo7iVSmgwTEyyHGbt42/1Sj/nmGBDE9dpUcZNXl8H+KdUnEd9NYaZZ5+eSOVp5iO4Vdqqp9yWx6GvSNH0210fS7XTrCPy7W2jEUa5ycD1Pc+p7mgC5RRRQAUUUUAFFFFAEN7awX1nPaXcSy286NHJG3RlIwQfwrxbUtPuvBepxWF7I8umzPssL1zkvxny5PSQc4P8QGRzkD2+quqafa6rp9xY6jAlxaToUkjccMP6fXqKAPNra/JUZ/OrX20Y61hjSNd0XW7zSLLSdQ1OzRw1nckrgxFQcPIzAblbcvPJAB5zVP8A4Sa0jma0uLa5j1NW2Gw8otcbvQRrkt9RkHqDjmgDpHvRzWNqeqMwMcfU1Su9ftreO5W+t7qwnhjMrxXcLRPsH8QDD5h7jI7da3dB8B6nqscdzrl0NOtJU3/ZbXJuCCMgPKeEPqFGR2bvQBzeh6Ld+JNUl0+yd441+W+vF6W6Ecop/wCepHQfwg7j2B92tYIrW2it7aNYoIkEcaKMBVAwAPYCoNK02z0jT4bHTbaO2tIRhI4xgD/EnqSeTVugAooooAKKKKACiiigAooooAK4/wAUeA7DWLia+sZW0zVZAN1xCoZJSOnmR9H+vDe9dhRQB4vf+HPEukqPP0v7fH3m02QP+Jjcqw+i7vrWV5rltr6Zr3mf3P7Ius/+i8fjXvtFAHienaDr2pnFloc1shHE+pOIE/74G6T81H1ruPC/gK1024gv9Xn/ALT1SI7o2KbIYD6xx5OD23MS3XBAOK7SigAooooAKKKKACiiigAoorxH47S6XH498BLfXE8W67xeiOaVAbbB27ghxjf360Ae3UV4Rq3izxvD4R8da9Bq0anTNal0uwtP7OU7UF5CiyFur4jZxjA65zkA1H8TPE/jzwzrlppUWuQQQixNwmpy2Qjhu7gzP+6YCOTAVNo2KVY/e3HOKAPe6K+err4j+KE8YW0F5qhsJpvEdjpqaOLAeXJZSbN0/mOm/LFiB8wxjpmrGm/EjXb+80bRLuWYam+p6haapE1gyBYUSUwjdt2g4C9Dk/nQB77RXyafHHibwr8N/Ctp4furuxmt9DS78uW3QxXDeawKjMLs7YAyoaMAc7q9q8D6v4k13x14jF5qKQ6Npk8UcdkLNcyCS3Vv9bnOAxJ6H0zQB6RRRRQAUUUUAFFFZnibWbbw74d1LWL44trG3e4fHUhQTge56D60Aadee+NPCGs3nilda8PzWW+W2S2niu3ZMbGYqylVbP3yCMDoPevIvh/498V+Hh4hi8R3N42oalpZ1jTjrwkiginUnzIULHiPDqRghRt7da2dM+L2u23hSbxDeyR6jY6VqcNtq3lWseFikTrDLFK8cm1ynIPRsEdCQDuR8NNRuLDzLzxJKNUJ3YjtkNsv+ztPzn67x9B0qj/wgfiaPK7tGuMdG+0Sw5/4D5b4/OsDXfHvju00fTAZ9KstRk8M3XiC6D2TPtMRDrCoLjadpCknPOTjtUF18UvFth4f8UXVxJpU93bWWk6hZlbVkSIXcqq0bDeS20Hhsjnn2AB0v/CC+JWBzDoyHsTfSt+nkj+daWl/Da5c51zV/wB2Rzb6dEYQfYyMWc/VdhrkrHx74ztPE1vaanf6Vd2kPilPD06xWLRNMskRkEgPmNt24wFwc9zWLD8UPGOt3Or2aXWl6fK8OoxfYT5a3dk8McjRlEEvmuxCckooBOR0xQB9B6LpFholgllpNrFa2ynOxB1J6sx6sx7k5J71erwn4f8AjTxTq7eCdHsNe0bUGvdE+3Xd5LbNI6MhiDRMVl5kG4hmP8XJUdKp6P4+1K20Xw9arfaX4cstRv8AVFuNWu42lihMMrbIx5kmAz8/ebHB2jtQB9BUVn+Hrpr7QNMu2uYLtri1ilNxAhSOUsgO9FJJCnOQCSQDWhQAUUUUAFFeSfGXWl0Dx58OL+8uZ7bS4rq7N26B2Xb5IC7lUHPJHaub+IXxG8Ux+K8+HdQgsNFNpbXWnSXFsxi1EMcyBv3LuT/CEUowyDzQB7/RXgdx4n8dXfiqSK1102ljJ4pudBSH+zon8uAQh1l3EZJBPGeM9d3Ssz/hYnjOTwjoV1f6nNpjSaZfS/bodNWU319DcNHFbshQhNyqG+UAkk4IoA+j6K+f/FfjDx/5Gv3dtfHR5tI0TT9SaxFgkoeeQEywlmBIAII45HqO/bfGPxJrWi+D9LvdEvYbC4uLiMTO6/MUKElUZo3RGzjBdccEdcUAelUV8wSap4q1LV5/E2n6hqOl6rb+BmvWku9PiaWYx3U7CMrjYNwVcEKCQQQBnFaOrfE7xWPFmiLZ3M8EUkmmLdWM1sgjlWdEMjRjyi5UFj85lXB42mgD6Oor5+8O/ELxVqPiq3t7LUW1S4Graha3GkCyRY47WLf5cplC5U7gq8tg56ZrS+CnjPxZr/ibyPEmoQSJJZvJPp725jms51cDAAhXamCRh2Yk4IJ5oA9vooooAKK8E/aXaZvE/gWH7atlZSx6kJ5ZmnEKnyo9hfySGJDfdx3x1GRT/h9rfjDUV8BaMl5d6Sk+iSXN4dQthczO8UyoCWbBG9eRnOAw4J5oA94orwPQfH3jCTWz9skvbqbytUfU9Ii00Z0tYQxtzG20GRnwoAZiG3cYxWBo/wATvHEmh+JpYLxr/wAqwtLu2uHtklktBJNslJVIYlcouWK4YAj7xAIoA+m6Mc5715D8CZDceIPH1yNRn1SObUIGS+mhERuB9nUbtqqo9uABxXC6b498Y+IdS1bToNRvhbXmlai0cEtsi3NpNF91cJCmxj0Cl5DyDkHFAH0Tqmj6bqzWzapYWt21tIJYTPEH8tx3XPQ1fr5v8JatrDa38KLi48W6i9jc6eba4323yG5HlZt5Dj5mO7ZvbkbSQckmoNK+KHjifV9R/s37TqKyaffTQadd2qia3niPyqypEm0/9M98hI7gkUAfS9FfOWrX1/4kn8FLZeL7rVbsa1AWun0pIvsMjW824ABFVu3ysCV4yTnFeq/B/V9Y1jwrcHxFcfar+z1C6sjcmEQmZY5CquVXgEj04oA7iiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKr6he2unWct3qFzDa2sK7pJp3CIg9Sx4FAGLL4K8PTeI112fTI5dUSQSpLI7uEcAAOqE7Q2B1AzXRVw138UNAjQNYR6nqano1nZuUPuHfarD3BNMtPijokhP22z1nT0H8dxZMyj6mPfge54oA7yiqWj6tp+tWCXukXtve2j8LLBIHXPcZHcenUVdoAKKKKACiiigApskaSoUlRXQ9VYZBp1FAEbwxOys8aMyghSVBIB64rK8SeGdK8R6G2j6rbeZprukjwRuY1fawcA7cZG4A471s0UARvDE5y8SMdpTlQflPUfSkNtAQQYYiCACCg5A6D8Kra1q+n6JYPe6ve29laIQDLO4UZPQDPUnsBya4TUPirCZGTQtB1HUEH/AC8TlbSJvpv/AHn/AI5QB6KbeEtnyo87t+do+96/X3pRFGJjKI0EpG0vtG4j0zXmVt8V5UcDVPC9/Gnd7O4iuAvuQSjfkCa7Tw34r0XxJ5q6RfJLPCAZrd1Mc0Wem6NgGA98YNAGvHbwxEGOGNCAQCqgYz1oNvCYTEYYzETkptG0856fWpaKAADAwOlFFFABRRRQAUUjMFUsxCqBkknAFcBf/FLS1l2aJp2p64g/5b2aRrD+Dyugce6bh70AegUV5hP8RddumVdM8LfZV/il1G7Tj6JFvz+LLUP/AAnXiu1G+bStKvlB5jilkt2x7E7wT9cfhQB6rRXMeFfG+keIpRaxPJZ6qE3tp94ojmAHUqMkOo/vISPeunoAKKKKAM/RNG0/Q7eaDSrZbeKaeS5kVSTukc7nbknqa0KKKACiiigAooooAKKKKACioLy8tbKLzL25ht4/78rhB+ZqvY61peoSbLDUrK6f+7DOrn8gaAL9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeXfGDXbm4ubfwnpbvG11GJ9Qnjcq0cGSFjUjkFyrAn+6rdyCAB/iD4n+ZetY+D7SLUWjcpNfzEi2jYHBVAPmlI9Rhf9okEVjHxh4tjk8x9TsOf4G04+WPwEgb/AMeqzoeixW9rHFFGqIihVVRgADsK0LrSkMRylAEvh/4lf6Ulr4qtoLJZXWOHULdy1u7McBXB+aIk9Ccr/tAkA+k14Dq1isTSRvGrwSAq8bDKsp6gjuK7b4S65MDP4avpJZntIxPYzysXaW2JAKsx6tGxC5PJVk6nJoA9IooooAKKKKACiiigAooooA57xp4ptfC+nJLIhub+4YxWdmhw9xJjOM/wqByWPAHvgHyi5tb/AF69F/4kmF9dbg8UGP8ARrQ9hEh7/wC2fmPqBwL1/dyeIPGup6jI++1tpG0+yQdESNsSt9WkDZPdUSuisrRcAAUAc02mzPyS1VbmyuIV6kivRY7Fdv3aqXtipUgqKAPMbN7vStTGoaLONP1LducgHybr/ZmQcOP9r7y9iO/tngrxLB4o0UXccT291E5gu7Z+WgmABK57jBBDDggg15jrunBQSoqP4f37aV46sXMpW31VTYTpn5TKqtJE/wBQFkT33j0FAHuNFFFABRRRQAUUUUAFZHizXbfw14dvdWuwzpboNsa/elkYhUQe7MVUfWtevOPjQwltvDtk3Ky6j5zj1WOKQj8nKH8KAOJhsr7XNRGqeIJ/tmoE7l6+TbZ/ghQ8KMcbvvN1JNdFFo+UHy1paJaJ5a4FdPDbIEHyigDz2+0U7DhefauT1HT5IbqKeKWW2vYCTb3kPEsB9j6Hup4I4INez3lmrKcCuM8RaeCjECgDqvhx4wPiSzltNRRINbswPtEa8JKpyFmj/wBhsHjqpyD2J7Kvm4X0mgX0GvQKxn0pjK4Q8y2//LaM+uVywH95VPavo6GRJokliYPG6hlYdCD0NAD6KKKACiiigDyD4j6/L4h1afw9Yu6aPaNs1CRePtUnU24P9wAjf/eJ29AwK6VYRqibVAVQAABgAVyvhaKa10uO2vs/boJZYrosclp1kYSN+Lhmz3zXbaa3yCgDZstPSQcipbjSVC/dFT6dN0BrYAV1oA848QeGre9RfNjIeNt8ciMUkibsyOMFW9wQafoHjnUPDbpZ+MJHu9LUYTVwv7yL0E6KOR/00UcfxActXdXNorqeK5nVNLSQMCo/KgD0OKRJoklidXjdQyupyGB6EHuKdXi+g6xN8P7zy5fMk8KytmWIDP8AZ5/56IP+eX95R0+8O4Ps0brJGrxsrowDKynIIPQg0AOooooAKKKKACiiigDN8Q63Y+HtJm1HVZvJtosDgFmdicKqgcsxJAAHUmvKNU1zxP4qPzXE+g6exOLSykAuGXt5k45B74jxj+81XPiHetq3xCt9KYBrPSbZLjae9xKWAb6rGvH/AF1NbGl2YCqAKAOKPgaxnm+0XFlDc3Pee5XzpT9XfLH8TTLrwRp7AGXS7NyvKloFJB9RxxXrdvYKEBIp89ghjJxQB5Jp+o+I/DE5fStSmubbHNhqUrTRH02ucvH+BKj+7XqvgvxfY+KbaQRI9rqNuF+1WM334iehBHDocHDDg4I4IIHNa5pyMjEKM157f3Fx4e1OHWrBN15p2ZQo6zQ/8tYvfcucDswU9qAPoyio7eaO4t4p4WDRSKHVh3BGQakoAKK5j4i+MrPwN4bbVb2Ce6d5Utra1gGZLiZz8qL6dCc+gPU4B5nSvifd2/iW30Tx34Zm8M3V5bS3VpL9sS7hlWJS0ilkA2sqgnGD+oyAem0VgL4y8PMumMurWzLqcMlxZkMT50ca7nYewHJrFtvir4NvrPU5tN1u3uXsLR7yWLDRsY1GSwDAZHTkZ60AdzRXn3hn4u+Etb8H/wDCQy6pb2MEexbiGV8vBI+dsZAHzMdpIC5PBrqvDHiTR/FOmm/8P38N9aBzEzx5+Vx1VgcFTyOCB1FAGvRRRQAV4N4YZtZ1/WtbnIeS+vZHQ9QIVOyID28tFP1JPevbdbuWstGv7pPvQW8ko+qqT/SvFfhbHs8LaYO4t4x/44KAPRtNthtHFXru2XyulRad0FXZzuQ0AcHr9quGOK5W3vpNL1DTdWgba2m3StNzgNbudkwPsFbf9YxXea6nyNXB3VkLxb+xzgXUEkJ/4EpH9aAPoCisPwJqT6z4J0DUpSTJd2EE7567mjUnP4k1uUAFFFFABRRRQAUy4k8mCSXGdilsfQU+myIskbI4yrAgj2oA8E+Goz4X0d3O6SW0imdvV3UMx/Ek16Ppyjg15p8OC8GgaZbS/wCttoVtXz/ei/dt+qmvTNObgUAbMQG2ql6o2mrkPK1U1BgFOKAOR10DyzXEOSl/o7pwy61p+3/gV1Gp/wDHWauv8QTDBGawfDtmNT8W+HbTPS8N9IP9iFSwP/fwxD8aAPeqKKKACiiigAooooAK8y+MgZNQ8MTH/V+dPDn/AG2QMB+SP+Vem1xXxh0x9R8BX81uubvTSuowY6kxHcyj/eTev/AqAKvh0holNdTEBiuJ8J3Ky20bIwYEZBHeuygk4FAE0qAoa5TX48I/FdWzZWua18jy2oA80uYlkvHiYZSQFWHqDXsfw7Yv8P8AwwzdW0u1J/79LXj16yx3rSZ4RWb8hXsXw7G34f8AhkDoNMtR/wCQloA6CiiigAooooA8E1wtD4z8UwsNjR6gr49VeCJgfxJP4g1taTOAqgmrvxf0g2l9aeJLeIGBkWx1Ejqqbv3Mv0VnZSfSTPRa5vTpzG+xuCtAHeWkuMVt20/ABNclp9wGAya2oZgAMUAb6sGqvc2wcEgVHazcc9Kvo4YUAcdrOnLIjBlB+tY3w+1xvCurQ+GtRcLo90+zTJDn9xKSSbcn+6f4PQ5T+6K769txIpwK4XxZokWoWU8Eyna6kHaSCPcEcgjqCOhoA9Yorhvhh4nn1W0uNH1iRn1vTQoklZQPtMTE7JhjucEMOzA9iK7mgAooooAKKKKAPHfHFtJpXxQN06/6Lq1nG0b/APTWElXX/vl4yPo3pXUabIML71q/EDwwvinQTbRyCDULZxc2NwekUyggZ/2SCVYejHviuD8IaxJdCW0voXtNRtXMNxbSEbonHbjqCMEHoQQR1oA9JgkyoGakkbCYzWZby4QUlzcEjg0AUtWYFWrzrWAv2+PJAUZJz0xXXa3fLDExY1w1tplx4y186LbeYsEig6hOnAt7c9Vz2kcZVR1Ay3bkA9i+GokX4d+GBOCJBpltnPX/AFS9feujpsaLFGkcahUQBVA7AU6gDifi54MuPG3hiC0068js9VsLyLUbGaVS0YmjztDgc7SGI9s5welc9p3g/wAW+I/H2h+I/Hx0S2t9DhmW0stNaSXzZZV2u7lwMLgDA56fXPq9FAHiXgb4R634b1LXZzqtlsgsLnTvDRUNIbJJZJJN0gZQNwLKOM5GR9anhL4VeKo/Elnq/iK8s2mTSbjT7mZtTub2WaSRdolAlUKo77FIA/l7xRQB4Afhb4xvPh/4d0W7k0q3v/DF0ktk9tfTot2o3htzqqvE2Cu0rnv0zXoHwk8KX/hmDWJNTs7W0n1C5E7LFqE987sFwWkklAJY+w6dTXf0UAFFFFAFXVrb7bpV5ajGZ4Xi5/2lI/rXiPwskLeFtL3fe+zR5/75Fe8V4H4VLaXrmt6RPhGsb+aJV6YjLb4//IboaAPU9OPAq7KcKax7GYYBzxVyWcFOtAGRrWCprioP+QyMV1+rSjy2JPFcHqdwbex1a8i+/BayyJ/vBSR+tAHqXwgH/FsPDJ7NYxuv+6RkfoRXX1meF9NGjeGdI0wAAWVnDbcf7CBf6Vp0AFFFFABRRRQAUUUUAeH6rbSaF481exkTbbzyHUbRh0dJTmQfUS7yfZ09a63S7kOowa0fid4bl1zSYb3TVLaxphaa2UHHnKQPMhOeMOAME9GCntXC+G9VS4t4poi4Rv4XUqyEHBVgeQwIIIPQgigD0iCfCdazdTuQqMSarRXm6POayNZvcRtzQBg61cmZ9i9Sa6T4M6WlxJqHiR1bbL/oFkx6GGNvndfZ5Mj3EanvXFJaXeuarb6Ppspivr3JaZRk2sA+/N9edq56sy9s177ptlb6bp9tY2USw2ttEsMUa9FVRgD8hQBYooooAKKKKACiiigApk0aTRPFINyOpVh6g9afRQB4X8MmlsbFtMuGLTadNLYMT1JhkaPP4hQfxr061lBUc15y3+iePfFEK8Kl8GH/AAOGKQ/q5rq7a8CqDuoA6V5AEPNcr4iuAI25qe51QLGcsK4vxBq28FVOSelAHL+IpJpbLUVtAWuZYzbQAd5ZD5aD/vphX0lptpHp+nWtnD/qreJIU+igAfyrxL4caNLrvi6GXIOnaRILi5bqHuCv7qL/AIDnzD6ER+te7UAFFFFABRRRQBBqFnb6jY3FlfQpPa3EbRSxOMq6MMEH2INeC6lpNz4Z1o6NeszKAX065dsm5gB+6T3kQYDeow3c4+gaxvFvh2y8T6Q1jfbkZWEsFxHjzLeUfdkQnuM/QgkHIJFAHlNjfbcc810Fle7wMmuIure/0jVX0rWlWLU0G6OReI71B/y1j/8AZl6qT3BBOhYXpVgrcH0oA9BtbjHetGGf3rjrK96ZPFbNvdDHWgDpBKCtZGqorZIpUu128mq91MGU80AcHrEzeH/EWma/FJ5S2cwW4PZraQhZQfYDDj3QV7lXi/jKzj1PRryykIC3ELwk+gZSP616T4C1Z9c8HaTfz4Fy8AS4XOdsyfJIv4OrD8KAN+iiigAooooAK8t+J9rBp3jPw7qlvGEub/zLK4ZePMVFMkZPqVw4B9GPtj1KvO/jXbsNF0TUkBI07VYXcjskqvAfwzMp/CgDRsX3RjJ7VFqMmxCRVPTLxGgUqwPFQa1eIkDEntQBxviCW81C9ttP06RUvLy4S2idhuCFj8z477VDNjvtr2bwt4e0/wAM6THp+lRbIwS8kjHMk0h+9I7fxMfX8BgACvKfh/ZPq3xItbjB+z6VBJduf+msoMUY/wC+DP8AkK9toAKKKKACiiigAooooAKKKKACiiigArxr4s2MmjeMbLXIoiLPUo1triReiTpnyy3++pK59Y1HUivZaoa9pFlr2kXOmapAJ7O4Xa6E4PByCCOQQQCCOQQCKAPO9H1BZrdSGGfrWkbjI5avOtastV8B3Zg1l2l0vIFvquMRuDwFl7RyfX5W4IOTtFpdZnlACZKkcEd6ANzX74CMohyTWNpGnSazrulaPGQBJMt7ec8rbRMGx/wNwifQt6VRkneS+S0hjkvdUkXdDYQcyP8A7Tf3E55dsAfXAr13wD4W/wCEdsp5754p9avSHu54wdoAzsiTPOxASB6ksxALGgDqqKKKACiiigAooooAKKKKACvL/iB4Wn02/n8RaDbvNDMd2pWUQLMx4HnxKOrAfeUfeABHzDDeoUUAeH2WrpNbxzQSrLBIoZJFOVYHuDVDV79y0Sxwy3M8zeXb20PMlxJjIVR+BJPQAEnABNeha98OLe51GS+0G+OkSzsXuIfIE1vK5OS/l5BVyeSVIB6kE81o+D/BFl4ena+nnk1LWHUqb2dFBjU4ykSjhF4HAyT3JwKAE+HnhQ+HLCae/dJ9ZvSHupVHyoBnbCn+wmTj1JZv4sV1tFFABRRRQAUUUUAFFFFABXN+P/EreFtBF5DbC5upp47WCN22J5jnALt2UdeOT0HWukqpq2mWWsafLY6paw3dnLjfFMoZWwcjj1BAIPYigDw8TWujW0t3r2s28moXkplnuZnWISSHHAGcAAAADsAOvWlGqu6CSAiSFuVZDkH8RXrGkeCfDekzNPZaPaC4ZdhnlXzZSv8Ad3vlse2cVXuvh54TuJZJRoVnbTSHLy2YNs7H1LRlT+tAHk82pyyAqEbNUdPsb/XtY/szR8SX5x50xXfFYqf45eev91OrH0GSPVl+FnhoT+Yf7WZP+eZ1W52/+h5/Wus0bSNO0SyFnpFlb2dsGLeXCgUFj1Y46k9yeTQBB4X0Kz8N6Jb6Zp6ny4gS8j/fmkPLSOe7Mckn3rVoooAKKKKACiiigAooooAyPFHh3TvE2m/Y9UiYhW3wzRnbLA+OHjb+Fhn8RkHIJFeNa/pOpeFZCmvoZ7BVymsQx4iIH/PYD/VN7/cPYj7o98ooA8Cs7w+UktvKk8DDKvGwYEexFatvqwAG7Iru9R+HXha9eWRdKjsp5SWeXT3a1Zm9WMZXcfrmufn+FAQn+z/FGrxL/cuY4J1H47A35saAKMeroR96mTauu3hh+dWh8LtVXBTxTGx7iXTFK/8AjsgP61XHw68RGbyzf6MsX/PwIpWb/v1kD/x+gDA1fV0ijEkgdtzBI40Xc8rn7qIvVmJ4AFepfDTRbnQ/CVvb36+XeTyy3c0W7cIWlkZ/LyODt3AEjgkE96r+EPAOn6BcLf3c0uqauAQt3cKAIQRgiJBxGCOCRlj3JrsaACiiigAooooAKz/EGlQa5od/pd5uEF5C8LMpwy7hjcD2I6g+oFaFFAHgRt/EvhiRrTVtLv7lYuBfWVs08M4H8eI9zJnurAY7EjmoZb3VNWwlho2r3jscKiWckak+8kgVFH1NfQdFAHJ/Dnwu/hrR5Teukuq3snn3bocqpxhY1/2UXCg8Z5bAJNdZRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyaKOaJ4pkWSNwVZHGQwPUEd65Z/h34TL5i0W3tl/uWjNbof+ARkL+ldZRQBm6LoOk6FHImjabZ2KyHMn2eFUMh9WIGWPua0qKKACiiigAooooAKKKKACsDx74otPBfhDU/EGoRyS29lGGMcf3nZmCqo9MswGe2a36yvFOgaf4o8P32i6xEZrC8j8uVQcHrkEHsQQCPcUAec6z8UdZ8Opqlp4l8P2llq0ejy6xZLBeGeKVU+9E5KKVcd8Ag84Prtaf8V/D0mlXNzqDXlldWkNvJNbTWkqSP52BH5SEZcM2QMfjioJPhNY3kOpHWdb1jVr2701tJju7tot9tbt1CBEVSx4yzAk4+uWL8IdLltL0anq+rX+oTrbJFfyGJJbVbdt0IjCoEGDycqc96ANuw+I3h28Wy/f3FvJdX7aWIri3eN4rpV3GKQEfKSvIzwe1Z9/8WvDNloNhrb/ANpyaReI0iXcdjIyKiuVLNxxyCQOpAzjFQ3/AMJtKv8AwjqWjXeo6lLdahfjU59ULItx9pBXDrtUKuAoUAKABnvzVXxR8GdE12OwiS+vrGG00kaMqQpDIDAORjzEbY2erLgkcZoAuRfFjRR4h8SWF9DeWtjolvDdSai0EjQukiFskhfl6Dbk/Pn5c4roPBvjPSfFrX8elm6jubFkW5t7qBoZY943ISrdmAOD7Vz978KNJvJ9XE9/qBstXsILC+tAYwkvkJtikB27lZevBwT1B6VseAvBNv4OW8EF9LeG5Ea5ktreHaqbtv8AqY03H5jktk9OnOQDrKKKKACiiigAooooA84+MHxLbwANNW10ptVnnElxcRrJsMFrHt8yXoehZcDvz6Voan8TdBsvENrosK3t/e3EMVwBZw7wsch+RjkgnPX5QT60viX4Y+HPE/iC61fxBDNfzzWi2SRSuPLt0BY5jAAIJLEkkntWJJ8FNAuLfRra/wBT1q9tdKjiigiuJIWysTZQbxEHTHA+RlyBz3yAbdr8TfDtzdRW0Ml0bl3vI3h8k7oTajMvmD+EcjGeuRisFvjn4WW3edrTXxEttHe7jpsmDbOSvnj/AKZhhgsep6Zq1oHw1S1+IHjjxFffZ0TXY1trZLZyWiiKKJWbcuA7sqnjI470+b4P6BLpzWTXmqCJtCj8PkiWPd9nSQyBvuf6zJ69MdqAJtd+LXhzRdcuNLuYtVlltpoIJpraxeWKN5kDxAsvUsCAAMnPakf4ueG00ODUGTURNNeTaetg1vtuRPFzIhUkAbRySTjkd+Knvvhfot5f6hdy3WoiS9vLG9kCyJgPaKFjA+ToQo3ZyT2Iqvf/AAk0C8gmVrjUY7ltWuNZjukeMyQzT/6xVDIVKHptZW+poAo6b8ZNJ1TxJZWOnadqFxpl1pL6oL9Im+QJJsZWTHAUhgWzgMMY5zV2y+J2n6vd+Gzpa3MFlqs7RrJfWEsXnKITJmJjgEDHLcjsKmj+F+mR3VhdR6rrCXNtYzac8iyRD7TBLIZGWQCPH3jkbAvQDpV23+HukwWfhK2E168XhkEWgdkPmgxGP978vPyk9NvP5UAT+EPHGn+LJyNJstU+xNG8sF/NamO3uFVgpKOfc8AgZGSMgGuqrk/Bnge28IyKmm6trMumxRNDb6dc3Cvb26swb5BtDEjGAWZsAkDrXWUAFFFFABXiPww+M1/4t8W6fpN9p2nwRXy3W1oppFeNoTjBDqFcsBnCEkDJOMV7dXnGgfB7w3o91ZyibVL2Ky+0G1trq5zFA04IkZVULyQSMnOM8c80AUIfjp4XaPWDPbalbyaXaC9miYQSOYzIkfHlysAwZ1yrFW56VvL8SdObXbLR/wCx/EI1C7hNykJ09gyxCbyt7gnKLk5yQOPcgViJ8D/DC2FxZvd6zLBNp/8AZYWS5U+Vb+akoVPl4wyDn3P1rum8OWR8ZJ4mJm/tFLBtNA3Dy/KMgkPGM7tyjnPSgDzu5+OWg3thra+HxLJfW+m3t7YS3CoYLpreNmPCvvA4z8wQkZxXV3/juz0L4b6b4q8QqypcW1tJIlso/wBZKq4A3MAoy3VmAA6ms+1+E2g2drfWVpdatDpl3BcW/wBgW6/cxLMrK+wEZ6OxAJIB5xXQ6j4Us73wna+HxdX1tZ20cUUclvNtk2xgAAnGGBA5BGD6UAcJqPxeli1nQDY6FqFzpl/a3k0sEUKTXZaEpgxlJTGV+ZsncemM54q5rXxt8MaPp2kajdQ6gdP1K1ju47gCFdiuxXBRpA7MCpyEVsDmtTw78K/Dnh+ewm01bpJLOO5QEyg+Ybjb5jMMYz8oxjAGOlY918DfC0+nCxW51iC3NlHYSrFdAefEjFk3/LyQT2wPagDXuvilo1trsmnS2Wq+XFqaaRNeiBTbxXDgFAx3bsHcBkKcd8cVF4b+LnhrxD4si0DTjdGe4aZLa4YJ5U7RZLhQHLrwGILqoIBxmqml/CyFvFmsavrt7PcW8+sjVrWxhmKwb1RQjSrgbmVlJHOOmc1teHvh1pHh7Whf6TdanBCsssyWAuc2yPIDuIXGcZYnbnAJyBQB2dFFFABXjPxc+K+p+C/GU2k2S6ItvDog1Uf2g7pJcv57R+RFg8uQMgYPQ9q9mrCk8K6XJ40XxTJEz6stiNOVmbKCISeZwv8Ae3d6AOHvPjd4fsNdtdJv7W6hu2NtHdAyQg20s6qyoUZxI+3cNzIhC9/Sp5/jJott4rvdCurG8Sa3W7ZZI5reYSfZkZ5AVSUshKoxUOFzx0zXR3/gPSbvxDPrMU+qWN5dGNrsWV9LBHdFAAvmKpwcAY7ZHBzWQnwi8MJf/aUGpBQ120dubxzDEblGSbYhOFyHb8aAN7wn4tt/Evh3+24dN1SysmiWeP7ZCFeaNow4ZFVmyMHHuRxkYJ821T43x6h4Pu9X8L6fIHguLVR58kExaOSdYyDHHKXjcgnCuFr1zTNHtNN8O2miWokFja2qWcYLncI1QIPmHOcDrXHR/CHwuBdvOuo3VzcmHzLm5vHll2xSCRF3N23AE9z3NAFSb4vWEOkajdXGi6la3lhfrp9xZXc1tbujtGZFbe8oQgqOAGJJIAB602D4y6Te6Zpt3pOja1qD31hPqKQxLCrJFBIY5dxaQDIIOAM5xx1FbGq/DLw/qWqXOpSfb4NQnvFv/tNtdPFJHKsflfIV6ApwRXPS/BjTRqekxWd9fWug2On3Vk0EV1Ik8nnzea2ZAclTlgQeuRQA3Wfj14S0ySzyLmaCa1t7uWQPDGYY5wCnyPIHkIBBYRhto5NetVxVz8NPD73MU9gdS0l0tYrJxpl9LbCWGMYRH2tztGQD97B612tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVfUL6002zku9QuYbW1jGXmmcIij3J4FAFiiuc0nxx4X1e4Fvp2v6bPcMcLELhQ7fRScn8K6OgAooooAKKKKACiiigAooooAKKKpa1qtloml3Go6pcJbWduu6SRsnHYAAckk4AA5JIAoAu0V50nxQSdd1n4Z1xo88PN5EW4eoBk3D6EA0H4q2cDqNQ8Pa9bR/xTLFFOq/hHIzn8FoA9ForN0DXNM8Qaet7o17Fd2xO0tGeVPdWB5U+xANaVABRRRQAUUUUAFFFFABRRRQAUUEgAknAHevA5rzVvGbS68ur6lbWrOX0+KzuZLdYoc/IxVSA7MMMS24c4HHUA98orivhX4mufEOjXUGqkNqumzm2nkChRMpUNHLgcDcrDIHG4NjjFdrQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBleJtesfDejz6lqbsIY8KqRruklc8KiL/ExPAH9Oa8+/4WpqNu5uNR8OImnDlxb3pluEXudhjCsQOqhvpu75utagfGfjKW4id20fSXe2tF/gkmGVln9+8a+ysR9+pdW0tTb5jGGFAHrtndQXtpDdWkqT206CSKWNtyupGQQe4IqavJvg3rB0++ufCtwCsG17zT2J4C7h5sP4M24D0YgcLXrNABRRRQAUUUUAFFFFABRRRQAVzfjPxdZeFoLcTRS3V9dMVtrOHG+TGNzEnhUXIyx9QOSQDtarqFtpWmXeoX8ohtLWJppZD0VVGSfyFeQ6DaXXiC8vPEWsRyJd3oGyGQ5+zQAkxwgdBgHLerFj6UAd74W8b2Gt2movdodLuNOG+6iunUKkZBIlD9ChweeMFSCBisWD4saU97H9o07UbTSpJNi6lOEWMD+GRl3b1Qn+IqMZBIA5HEavoNrfX6faYmcxnaMSMoZdwbawBAdcqp2tkZA4rZ1jRw2nZ2Bsrg5GQR3BHpQB7ECGAIIIPIIpa84+DmtSPZ3Xh2+n82400K9qzH5ntGyEBPcoVZD7BCeWr0egAooooAKKKKACiiigAooooAK8f8cXT6/4/lsXQPY6GsYRGGQbqRA7P/wGN4wPTe1ewV434ecX+sa3edXl1S7Qn18uZoV/8djWgCO/0VLu1kgu4I7iBxho5UDq31BpmgeJb3wRNHFdSz3fhoYWSORjJLYjP34zyzRjuhJKgZXgbT3K2eYskVzHiKx2KXQc0Aeq280VxBHPbyJLDKodJEYMrKRkEEdQR3qSvLvg7q5tbi98L3MoKQL9r05T1EBOHiHqI3Ix6LIg7V6jQAUUUUAFFFFABRRRQAV5b8Wr173xLoGgocwIr6lcr6lSEhB/4Ezt9YxXqVeR+IZBe/FDVSCD9ktra0x6HDy/+1h+VAG/pemJJAMqMYrF8Q2UcKsAORXZaOmLf8K5rxWMs9AHOfDRha/EaJohs+22c0MwHAkKFGQn1KjeB7Ma9trxDwIP+K90g+9x/wCizXt9ABRRRQAUUUUAFFFFABRRRQBzfxKvH0/4eeJruE4mh024aM/7fltt/XFcZ4PsEtvDcVugwkcYRfoBgV1XxaUv8NPEqDq1jIo+pGKyvDcWNHUeooAwfhXdfY/iLrOnHIF5YrOo7ZhlKnHvidfyFewV4hYK1j8W/DkyHas009tIT/deCR8f99xR17fQAUUUUAFFVNT1Kx0q2Fxql7bWUBYJ5lxKsa5PQZYgZ4NZx8XeHBaNdLrulvbLKkLSpdIyh3OFUkHgnsO9AG5RWLceK9Bt/tXn6vYx/ZbhLSfdMB5Uzfdjb0Y9hW1QAUVXe+tEN0GuYQbVd843jMQxnLDtwM803S9QtNV0+C+025iurOdd8U0TBkceoI60AWqKKpJqtg+sSaUt5AdSjhFw1sHHmLGTgOV64zxmgC7XL/EvWrjQvBeoXVgQNQkC2tof7ssrBFbHfbu3Eeimuory74tTtdeKvCmkqx8pPtGoygeqKsSA/wDf5z/wGgBng3SI7HTba1iB2xoEBPU4HU+9b+p2IWAnFLocYyvsK2dUQNbH6UAeJeJVudOv7fUdP3C9sZhdW4H8TLnKfR1LIfZjXvuj6jbaxpVnqVhIJbS7hWeJx3VgCP51454th43jqpzXVfBC8R/DV/pa9NMvpIkB/uSBZx+A80qP92gD0SiiigAooooAKKKKACiiigDzv4wXkssWjaBASBqNwZrk/wDTCHazD/gTtEp9i1aelWoj0zIGMCuY8YTNc/Fc2+cx2mlwEezSSzbv0jT9K7SAbNMx7UAcPeKBfn610dxGJNI5HasC7Gb0n3rp0X/iV+2KAPOtDuU0j4haJck7PMnawc9MpMvA/wC/iRV7tXzz4yIt7yC4XhoLy0nB9ClzG39K+hqACiiigAooooAKKKKACiiigArxb4cgta3Dn+O+u3/O5kP9a9prxb4b8Wk6Hgpe3Sn6i4kFAHpqAeR+FYGuRhoW4roYwPK/CsbWl/cvQB5i9yuj+JtG1Zm2fY72NXIOMxSnynB9gHDf8AFfQNfNnj2NpNB1pVJD/Y5mQjswQkH8wK+jLCcXVjb3A6TRrIPxGaAJ6KKKACiiigAooooAK8S0iT7Z428V3nXzdUkjz/1yRIf/AGka9trw7wGocXM6ksLi8ubnce/mTu+f/HqAPUbD5LXPtXI+Kn+8a7C3XFp+FcT4mb71AGR8O18zx/py/wBy3upfy8tf/Z69rrxn4XEP8QkAHMelXBJ9N80GP/QDXs1ABRRRQAUUUUAFFFFABRRRQBwfxkv1g8MW2nLzcapfQW6KOpRXEkh+myNh+Iqxosfl2KJ/s1yfiS+PiH4lSxqoNloa/ZY2/vTuFeU/gBGv1D13NlDthAx2oA878fWVyjw32musd9azJcQs33d6MGAb/ZONp9mNeqeE9ftfE2g22p2XyiQbZYictBKOHjb/AGlOQfz6VzPiKzWWBgR1HNcT4N1dvCfi8CV1TSNTlS3ugeBHOflim/4EdsbfVD/CaAPc6KKKAPFP2tSg+GunGV4kjGs2xZpU3oow+Sy9x6jvXn2o3GjT/DS4Gi6p4e1Err2m+a+jaP8A2cq/vDtDjHzH72D2r6sooA+Y9Z1W90e5+Ilxptw1vM3i+xiZlAOVYKCOfUUvxB8Y3dv4g+JEE3jXVNM1DTJrb+w9PtpVHnyGNSU2bSzgsQCM4+bJr6brC0nwrpela7rOr2sTG91WWOa4aRtw3Iu1So/h4oA8B8NTyWHxY8eza54g1DTNduLCzuobAyIi3shsXZ0KlMssTHChSMY5Jwaks/Fmo3WkfDi38T+Kb7w/4e1DSpbi51O3dYWuLpWIWMy7SEwvzY4z09MfSjRRtKsrRoZE4VyoyPoaJoo5kKTRpIh6qwyPyoA+W/if43ngZoPDfizWRNY6NDd297c6l9mS9GCweOEQkzuwxuJKjjtya7z4f3s+p/G6O/u2DXN14Ls55WAwC7SBjx25Ne0+Wm9X2LvUYBxyB6U6gAryrx7j/hZtiWA3DTBs9eZW3fyWvVa8x+Lto9rrvhnXYx+7R5dPuD6LKA6Mfo8W0e8lAG3pDBXFbd581sa5nTJQdrZ4NbNzcjyMe1AHBeLR+6epvgYx/tjxQg+7ss3/AOBFZAf0UVR8W3A2Fc8k1u/A6xaO18QX7fduL1YYj6pFEgP5SGQfhQB6bRRRQAUUUUAFFFFABRRRQB5H4kBh+MF8HH+u0yzkQ+uJLhT/ACH5124Yf2f+Fct8UgLHxd4Zv9pCXSz2Lv2LjbLGPyWat6Obdpw+lAHNXPN5+NdPkDSh9K5SR91/j3rormUR6aB7UAeXeNEM93DAnLz3lpbqPUvcxr/WvoivCtEt01j4jaLakFxDM+oSAfwpCuFPt+8eP8jXutABRRRQAUUUUAFFFFABRRRQAV494UhFnq2t2w4Meq3jEege4eQfo4r2GvIoJAnxG8XwgbQl7Eyj2a0gYn/votQB3kLny6ytYf8AdNn0q7DMvlDmsHxDdKsLDPWgDzfxvMI9C1qTG7bZzYA7koQB+JwK+hdKt2tNLs7ZjloYUjP1CgV4LaWo1zxHpGjlDILu6WeUD+GCFhI5PsSET/toK+hKACiiigAooooAKKKKAIruZba1mnf7sSFz9AM14n8Lxnw1pBPLG1iJPqdgr1Xx3P8AZfBHiG4Bx5WnXEmfpExrzn4fQiDS7CL+5Ci/koFAHoTsUsvwrgvEkud2a7++AWy49K818TP97FAFv4MQ+b4r8R3XVYbS0tlPoxaZ2/Qx167XnfwWtRHpeuXW3/j51E4PqEhijx/30r16JQAUUUUAFFFFABRRRQAU2WRYonkkYKiAsxPYDrTqz/EcTzeH9Tiiz5j2sqrj1KECgDx34cSSajYJqlwu2bUGa9cHsZWMmPw3Y/CvVrRf3I+leYfDWRJPDulPHjY1rEw+hQV6daHMYoAq6pEHiavKvF1hDcNLbTqfJuEaJ8dcHjI9x1Fet3v+qOa848Wxj7w7GgD0f4e6y+v+CtI1GY5uZIAlx7TISkg/77Vq6GvOvghIf7C1u1/htdXnVR6eYkcx/WU16LQAUUUUAFFFFABRRRQAUUUUAFYnjXQU8TeF9Q0lpDE86AxSj/llKrB43/4C6qfwrbooA8Z8Gau17p4W4Xyr2BmguIj1jlQ7XU/Rga6Se4IiOT2rI+KGkyeH9Y/4SyxX/QJ9seqRqv3GGFS4+mAEc9gEPQGs671tJLTEeSxHSgDC8VX+HZ418yRSEij7ySsQqIPcsQPxr2vwRoQ8NeFdO0kyebLAhaaX/npM7F5H/F2Y/jXmPwt0Jtd8Sf23cKkmlaY7C3Y8+dd42lh6rGpZf99j3SvaqACiiigAooooAKKKKACiiigDmfiPocuv+E7q3s0V9RgK3VmGbaPPjO5RnsGwVPsxrifDXiGHUdDSYFoxjDJINrIw4KsOxBBBHqK9crz7xZ8NIdV1WfU9E1JtIvLpg10PI86GYgY37Ny7XwOoPOOQaAOSGr2z6jsLgNnI9xnrWlr+qJDp5BkUDbkknAA7kmt2T4V6D/wjUunRIV1J3+0DVmRWuRcdpM46dtgwu3K4ArG0f4X391eRnxdf2Vzp8TBvsdpEwFwQcjzGY8JkA7AOehYjIIBp/BrRJYNLufEF/Fsu9W2mBWGGjtFz5QPoWLO5/wB8A/dr0Wjp0ooAKKKKACiiigAooooAKKKKAKOtavYaHp0t/q93FaWkeN0khwMngAdySeAByT0ryrSZBqfiPX9fWOaG11C4RrdJ4zHJ5aQxx5ZTyuWRiAcHBGQDxXVfEvwxq+vXGjXuhzWTT6e0p+y3rskTlwoEgZVYh1AYD5TxI3SubXwP44uIjLPrGhW0na2SCWZf+/uU/wDQKANibUY4Yzg9q4zxFq6GOaSaVYoI1LySMcBFHUmtJ/BXjplKvF4efsG/tOdc++37Ofyz+Nb/AIV+Gi2t3b3/AImu01C7gkEsNtAhjtoXHRiCSZGHUFuAeQoPNAEvwj8PTWdlPrupxGO+1FVEETrhre1HKKwPIdsl2HYkKfu16FRRQAUUUUAFFFFABRRRQByfxacp8LPGBHX+yLsD8YWFcn4T2qiqP4eK9C8W6V/bvhXWdJBAN/ZTWoJ6DehXP614b4f1qaBhb3AMOoRDbc2snyyxOOGBU84znBHB6gkUAevajOPsuM9q8319/MmCA8lquy+Ii0WGBz9K5HxBfyfZppUXM7qYrePvLK3CKB1JJI6UDPW/gtCU+HOm3DZJvXnvs+qyzPIv/jrLXcVS0PTotI0TT9Nt/wDU2dvHbp/uooUfoKu0CCiiigAooooAKKKKACiiigDwbwrt0O9vdFzgabdSWig9kDZj/ONoz+NemWN8hiHNc78UvC9yl+fE2i27TyCIR6jbRAmSWNc7JI1H3nXJBHVlxjJUA8xpeveZbpLBIJoWHDoc/h7H2oA9GvbwMp5rhvEsokZY15JNMm1x3XaiOW+lY1vFf+I9VOmaJIGv34luQu+KxTu7npvxnanUnHQZIBnofwShb/hG9Tvv+WeoapPNGf7yoFgB+h8nI9q9Cqpo+nW2kaVZ6dYp5draRLDEuc4VRgZ9Tx1q3QIKKKKACiiigAooooAKKKKACiiigBrosiMjqGRhhlIyCPQ1wD/CfQt5S2u9WtbA5zZQ3AEeD/CrFTIg9lcADpivQaKAK+n2VtptjBZWEEdvaQII4ool2qijoAKsUUUAFFFFABRRRQAUUUUAcD4b+LPhfX9Qt7S3mvLVrpZ2tpby2aKKfyc+bsc/KdoBJ54Arb8T+MtG8PeH7vV7i5S6ht7T7d5NrIjyywZA3opYZXJHOcc9a4DwT8FbbSfDssOs3j3Ws+TfW9tMszvBaLc7gzRxnADFWG71xWM3wh8V3uly2mp6noZMfhf/AIRy2Nukq4CyxsjuTnPyxnOAOT070AepWHjnRrnUPEFtPKbBNDFubu5vGSKECaISIQxbsCAc456ZrXtdf0e7igltNW0+eO4jaaF47lGEiL95lIPIHcjgV5V4m+EWp6xe69dRapbQyXV/pt/armQKWtbfymSQrggEkkFSSMA1z3jX4W6vB4P0Ww0eFYNcm1iaN5tPMs6QW13GY7lpHlOcEDJPHOMDPNAH0Db3dtc2iXdvcQy2rrvWZHDIy+oYcEe9cpq3xK8LWFra3EOq2mowT6hBprvYXMUwt5JSQrSkPhVG0knrgdDSal8PNHk06eOxhmScac+nwRS31z9lCGAwqHhWQIRtPOAD3BBwa870j4Na5FZWlrqOqWM9lBq2n3gsnLzokFuW3xiR13MGDYCN8o555NAHrU3jHwzDpkWpTeI9Gj06ZzHHdPfRCJ2HVQ+7BI9AalvvFHh+wWFr7XdKtlmRZYzNdxoHRjhWGTyCRgEda8ov/hHrgW+h0rUdNg0+61u91B7NTLArQzRRoi74sOpQoxKqQrbuTxXPf8Kt8TR6pb+H4ItNkg/4Q5dIuNSuoZHhRmuZS3lcDMgVgQDj1oA9+utf0e01S30261bT4NRuMGG1kuUWWXPTahOT+ArSrw+9+C94viZ7y1vbS+sJTZORfTXEckL20aIrARsFk4TIzjBOORXuFABRRRQAUUUUAVNX1G20jSrzUb+QR2lpC88r/wB1FBJP5Cua8M/Efw3r/g9/E0d8thpUUrQTPfssJhdTja2TgE5GBnnIqT4n+GLrxl4Tl0G2vvsNveTRLeSqPnNuGDOqdgxAxzxyc15/cfBm/gTXbWx1mG9sNQvLfUo11JWWWK5QENIrW/lbGOVIZR/CAQeaAPT7Lxh4avrcz2niDSZoRbvdlkvIyBAh2vIeeEU8FjwDwajufG3ha1uYba48SaNHcTeX5cTXse5g67kIGc4Ycg9D2rx/xh8KtcutN8FaVJqV7ql/9sng1TUQMAWEp3yxuzEs33VCliSST0rp/FfwmfW9V8TXUdzZRx6pLpbQI8JPkJak71+jDAGPTmgDuh418L/2RHqp8RaQNNkkaJLpryMRs6gkqGJwSACcenNP0vxh4c1a5NvpmvaZdzrb/amjhuUdli/vkA8Dkc+9cJB8Kpo9TSdruza3XxXL4h8nyjjy3hEYjx03AjOelZWm/BF4dI0vT7jUrdEg07VLC4lt4iHf7XIWVh67QcYPX6UAd1qnxP8AB1hoF5rI1/T7uytJY4JTaTpKwd2wowD9T9FY9Aa0bjxr4cSCU2+uaTczrB56QR38IaRShkXGWAwyqSCSBgE5wCa8vHwVv5fC2s6Zc3+mi9ura1tob0fa5mYQSrIm8TTOFXCY2oBjccccV01v8OrmXUPGWo6nJpj32u6bBZwmGAhbV0gkjcruyQpLjoc4HNAHTv438PWtlpE2r6xpumy6nBHPBBcXsW5g4BG0qxVhzjcpKnsTXS15Ppnw21rQ59PuNH1PSZJTodpol6t/ZtMu2FcF4sMODz8jcEgE16xQAUUUUAQ3t1BZWc91dyrFbQRtLLI5wEVRkk+wArifD3xP0jWImu5LDVtK0UxGeLV9UgW3s5U3AAiQtxncMbgue1ddr2lwa3oeo6Vebvs19bSWsu04Ox1KnB9cE151pXgnxJaeC7vwx4j1bT9U8OQaVJp8ENpYsl1KoTahZi5XcqgAbRycZPFAHV+IvG+kaLf6dZGZLu7u9Tg0t4baVGe2kmR3RpVzlQVQn1OeKxtZ1jwNr2iwXfjQaDbxGSdIP7Qu7Z2/dPtcxurnkcZCnI3AEA8VyHgH4Y6ufA/hOXWrjydfi12HXtRNwNzsER41iyO4Qp9Dmtjw78KptO1LwrPfXdndwaPPqs0sTREiUXbAqADx8uOc0AZfjHTvhh4Z0AavNqdwkM1s1za29rr84N2oGf3SmXBzwBjit/RF+H/hqOTUdM/s7+3I7M3Ahu9SSS9C+T5xTfPISmUG45IXHJO0ZrkLb4I61p/h5bDT9a0wzT6FJod29xbO+1DM8gaIhgRnfgg5HGeeldRB8LHWHxx5txZSXWv6ZDYW0xhy1sUsvs7HPXBPPHagDspfGnh60XS01TWNNsLrUYo5YLee8i3uHHGMMQwzwCCQexNVLz4h+GI7DXJ7HWLHUbjR7Sa8ubS0uEeXZEpLYXPtj0yRmua034d6zomqreaRqOkyLd6dZadfJf2bS7Rbrt3QkMMBgSdrDGQDz0rm4fgzr8lzdzap4htr2aTS9Q01bhxMZH+0KVR2VnKIFyPkjCjjvngA9p0TUI9X0aw1KBHSK8t47hFf7yh1DAHHfmrtZvhrTn0jw5pWmyOsj2dpFbs6jAYogUkflWlQAUUUUAFZHivxHpfhXRpNU1y5+z2iMqAhS7O7HCoqgEsxPYVr1xnxV8JXni3RNOTSbqC21XS9Rg1Wza4UtC0sROFkA52kMentQA3T/iRo17eaVafZdXtbrUbp7OOG8sXt3R1j8z5g+DgryCM1u6z4k0vSdDutWnuopbWC1mu8QurNLHEpZ9gz8xAFcbL4a8X63r/hTVfET6DC+kahLcPFYyTMPKaAoAC6/M2455CgD1rhbb4PeMBoek6Nc3ugNZ6Rpmr6dayxvMskn2uIqjOChAwSMgdB03dKAPcPD2v6b4gsIrvS7qKZWjSR41dS8W9dwVwCdrYPQ1zHizwn4Hn1MXOsm20zUrtuJYb9rKS4bpk7HXzD9Qa5rwR8LNQtL6e51+W001f7KttKSLw9dzQtL5TbjPJKBGwcnjA7cEmq3j34Uavq/iOwvfD15awiC1itGvdQupLqYoshYiSKWN1mHJxl0OTySKALfhPw78O/EU0yRPfXNxFczW32PUNVmZnMTFXIiMuGXIPJBr0HQb3wzaWctloN1o8NrZAmSGzkjCQDvuCnC/jXmmmfCO+sr/StQj/sePUrbxHdarNdoreY9tLv2pu2Asw3LlSQOOtchf8Awm8WaVpXiHU706fe3L+H7ywMenNI8tzI7Bk2QiJVQYGNi559c8AH0TDrGmzw3M0Oo2ckVqSJ3SdSsJAyd5z8vHPNTWF9aajarc6fdQXVu/3ZYJA6H6EcV4Ovwf1vWtA1Oa4k0rRrq8tNPigsbRX8lhbnfm4yqncxOCAp24/ir0f4T+ErrwjpWpQ3sNpBLeXhumjtbp7hNxRVLFmRME7egUdutAHc0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV578Ydc1HT7HTNL0Wd7W71KVvMuIyN8UMYBcpnoSWRc9gxPXFAHoVFeZfCjxfe3l5P4c8QzmfUII/Otbp8B7qIHDBgABvQlckdQwPXNem0AFFFFABRRRQAUUUUAFFFFABRRRQAVT1jUrTR9LutR1GZYLO2jMksjdgP5n271cryn4waiuq6rp3haElo48anf4PARSfJRv8AecF/+2Q9aAPQfDGvWXiXRodT0wyfZ5Cy7ZUKOjKxVlZT0IIIrVrzv4Ibv+Ee1bP+r/tN9n08qLP/AI9ur0SgAooooAKKKKACiiigAooooAKKKKACiivFfGura9qnjlrDQ9Uu7O6h1WHTbOGKTbCQsEVxNLKuPn+V2G08YTjBOaAPaqKKKACiiigAooooAKKKKACiiigAooooAp6zqdno2lXWpanOsFlaxmWWRsnao9hyT6Ack8Csvwh4rsfFMFy1nFc281swWa3uVCyIGGVbgkYIzgg9iDggiuR+L939v1PQfDSDcsznULoeiRECMH6yMGH/AFzrD8Gy/wBi/Euz3Psi1GF9PkU9GdQZYifptlH/AAOgD2qiiigAooooAKKKKACiiigAooooAK5v4ha/J4d8L3N1aeWdRlZbaySTo07nC5HcDlj7Ka6SvLvHki6z8RdK00MTHpFsbyROxlmJSM/VUjl/CSgDj7zQ57TTI3udR1WeYoPMma/mDOe7HDYBJ54r0/4T6++ueEoku3Z9R05zY3TOcs7IBtkJ770KP9WI7VmeIbDdppGP4a5j4V6k2l+PZNOkIFvqtswUek8ByPxaN3/79CgD2yiiigAooooAKKKKACiiigAooooAK8l8aytqPxatrPgxWGmK30eaVsj8oU/MV61XjjZl+MniZm/5ZfZoh9PIRv5uaAMHxxBLoOpWuuWUbNdabKLqMIcFwv30+jpuU/71e9WN3Df2NveWkgkt7iNZYnHRlYZB/I15r43tPNtSyjJxVj4H60Ljw9N4fnTZdaIViQdntmLeSw+gVkPuhPcUAek0UUUAFFFFABRRRQAUUUUAFFFFAFHXNVs9D0i81PU5hDZ2sZllfGcAdgO5PQAckkCvFrZL2TSdQ17WVCarq0vmPGDkQpjCRA9wqgDPcgnvXQeLr1vG3jCPQLJkk0TSZRJeuOfNul5EfptjyCf9sgdUNYfxR1AW1k9vZgF1XZCg/ikb5UH4sVH40Adx8EonX4eWdzJ1vZ7i7X/ceZzH/wCOba7uqOg6bFo2h6fpdt/qLK3jto+P4UUKP0FXqACiiigAooooAKKKKACiiigAooooAK8ScNB8ekzxE+tM/wCLaQq/zUV7bXjHiP5fi5aMn+s/ti2/W1AP6ZoA9nooooAKKKKACiiigAooooAKKKKACiiigDyeN01r4n+IbvGRZeVpqNjqsaeYf/H5pB/wGub+Ie/T5/7Qh4ksJY75D7wuJCPxVSPoa3fhV/pD6nenl7vUbycn2a4kI/IYH4VB8RbYSmWMrkSKyEeuQRigD2aisTwNfHU/BPh+/Y5a60+3nJ9S0an+tbdABRRRQAUUUUAFFFFABRRRQAV5HoStc+O/FV9MQXl1AxL7JFGkYH5qT9Sa9cryPwSd2p62W6/2vfj8rqUCgDtNajDWDD2ryNrgaV4v0e9PBg1O3UH0Ez/Z2P8A3zM1ex6kA1mw9q8N8enypDIvBjlhkH1WVSP5UAfSdFFFABRRRQAUUUUAFFFFABRRRQAV5Aox8XPFR9Wtj/5Lxj+lev15FK2Pi94lX1jtW/8AIeP6UAdVrNsJrRgeoFebeG7qTQfihpMqk/Zrxn0+dR6SDcjfhIij/gZr0+65tz9K8Z+IU76aJr+L/WWZW7U+hidZAfzWgD6TooooAKKKKACiiigAooooAK4b4k+KLjTxBoOgP/xUOoLlHC7haw5w0ze/UKD1b1ANafjnxZB4YsE2ILrVromOyslbDTP6n+6i9WbsPUkA814N0KTTFudZ1yb7TrF63nXM7d2xgKo/hRRgAdgPqaAJNK0y28H+HEt7ddrBOpOSfUk9yTyT3Ncn4Ntf+Ep+I0DSxmSz0kC+mY9PNOVgT3Od7+2xfWn+PPEE13cJZ2MMl1dTyCGGCL70rnoo9B3JPAAJPSvTPh/4YXwp4ejsnlFxfSsbi8uAMCWZgASB2UABVHZVFAHSUUUUAFFFFABRRXPeNPEY8P2EQt4kudUu2MVnbM+wOwGSzn+GNRyzYPGAMkgEAveINe0zw/Zrc6vdpbxu2yNdpd5W/uoigs7eygmubb4gKV3ReHtXVT0e5e3twf8AgLyhx+K1wnhjR9W8a6rNqdvqEsdpkwXOuvGBPc46xWikFY4Qe/OTn75yw72w+Fvg21AafQrbUZupm1PN27H1zJux+GBQAyPx85OG0C9f/rje2bH9ZlqRPiNpUZP9pWGt6coOPMmsHljH1eHeo+pIq1P8OfBU4xJ4S0DPZl0+JWH0IXIrNm+E/hbcHsYdQ01wetnqEyL/AN8bin6UAdNofiTRNeUnRdWsL/b95bedXZfqAcj8a1q8s1/4Ty30YEGvfa1T7sWt2EV6g9ACoRh9ck1hw/Drxja5jtmsI4xwptPEepWikf8AXNAVX8CaAPWvEmv6d4d083mqz+WhO2ONQWkmc9EjQcux9BXknguC+8SfFdtTuIwq2k0moXa5ysDvD5Fvb5HBcRje2OA2exFWdH+F3iCS8eXUb7TdLWQbZZ7KSW+vJU/u/aJwCv4hh7V6l4Z8P6b4Z0mPTtHgENurF2JJZ5HP3ndjyzHuT/LFAGrRRRQB5P8AtN6nqOlfDBrjRr29srs31vGJLO4aGQgtgqHBBGawdN1jxH8P/D8FzqWna3HPqWt2en+Xr+trqZEUm4M8bIfkPsevFew+JPD+l+JtOFhrlml5aCRZRGzMBvU5U8EHim+K/DWkeLNHk0rxDZJe2EjBzGzMuGHQhlIIPuCKAPOde+JfiG1k8fQaPocWo3OgXVrBbRxI7s6ypud3VTltvJwuOPxNc4fiNPr+jeFrjURpWoXJ8YWOnkWi3dmbcurEM8bMG3Dn5SWQjqDjA9Lg+Fngy30m80230RIrO7eKWdY55VZnj+428NuDDJ5BBOTnNWLD4c+FLCytbW20eMRW1+mqRl5ZHf7UmQsrOzFmIyfvEigDxHSPEuveHb74leNtbW31K90zUDpVvELqcRo7PGiqEJ2CIBgc43ZHXmux1v4meKvCk3ibTPEdnodzq2naKutW01gJVgZPNERjdXYtnccggjIr0s+DvD7WOs2b6XA9rrMzXF/E+WWeRsZY5PB4HTGMZFZmm/DHwfpum6lY2ujJ9n1KMQ3fmzyyvLGOiF3YsFHoCBQBx2o+OvHlrN4StDp3hmO+8Syy/Zh507xwxrAsil22g7slsgDGMDI61k+Gfiz4wvJvCtxq2maCmm6lrD6Hci2eYy+epYeYm7hU46HcTjqM8exXHhvSLm60e5mskefR932FyzfuMrsOOeflGOc1Rg8C+G7eGyhh0qJY7K+OpW673/d3JJJkHPXk8Hj2oA6WiiigDyP4Pgf2YMdDNN/6MapfHgxcp6+YKg+E4+zi+tTwbfUr2DH+5cSL/SpPiLJ5coY/wtn8qAOs+EP/ACSzwkPTS7cD6CMCuurlvhTEYPhh4Rjb7w0m13fUxKT+tdTQAUUUUAFFFFABRRRQAUUUUAFeQeGXEPivxPZ4KtBqsxKn/ppiYH8fMz+Nev15T4pgXRvikLndti1u0VwPWaA7XP4o8OP9w0AdrfEfYSfavDvGyGe7igHLTXVtCPq86KP5169f3Y/s5jntXmNgg1T4h6BZsNwkvlmbAztWBWmBPtvRB9WFAH0FRRRQAUUUUAFFFFABRRRQAUUUUAFeP2QE3xK8W3XJ3XccYz2CQRLj8wx/GvYK8i0r5PHPioDoL7P5xof60AddeHbbk+1eOeOrc6ozWCfevZI7QfWWRY//AGavVNbvEjs25AOK4DwhZS6/8SdNVMm109m1C5YdtoKxKf8Aec7h/wBcmoA99ooooAKKKKACiiszxBr+leHrMXOs30NpEx2oHPzyt12oo+Z2/wBlQSfSgDTrjvGPjm00ScabpsX9qa/JwllC3EWRw8zDPlr9eT2B5xzN54k8TeMmEOgwz+H9IJ+e5mUfa5l/2RyIgfXlv901b0zS9F8I2bi3VDOxLySMxZnc9WZjyzHuSSTQBF4e0CeK8l1/xTdC71mdRubGEjUciONf4UGTgdT1JJJNZnjfxcsMTRxMxOQipEpdmY8BVUcsxPAArO1rxPe6vqB03RLee/v2xiC3GSoPRnPSNf8AaYgemTxXa+Afh+NGul1fXpIr3XOfK2Z8qzUjBWPP3mI4LkAnoAo4oAZ8MfBMukudc19EOuTIUiiDbls4mwdgPQuSMsw9gOBk+h0UUAFFFFABRRRQA2WRIYnlmdY40UszscBQOpJ7CvB76S5+IHjGK2id4U1OPPmR5D2ulIwPX+F5mwfUBk/55mus+M3iK3t7JtFm5s2h+1aowPS3BwsPHUysCuO6LJ3xWz8LfDs+kaPNqWrA/wBtasy3FyGGDAuP3cA9kBOf9ose9AHX2drBZWkFraRJDbQIscUaDCooGAAPQAVNRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5J4bU6f498WWbcKupmZPcSxRyk/99Ow/A1Q+K915FpdT9THDJJj1whNafjQPpHxUs7ogLa6tYBAw/wCe0LHdn3KSJj/cNc54/VtW1LTtLjJ3391Bacf3XkHmH8Iw5/CgD23Q7P8As7RNPsR/y7W8cP8A3yoH9Ku0UUAFFFFABRRRQAUUUUAFFFFABXF/FfRpdT8MfbbGF5tT0mQX1skf3pNoIeMeu5C4A9dvpXaUUAeN/wBsw3nh+G7t5lkimjDowPDAjIP61P8ABTSRe6lqfieZG2Lu0+yLdCAwMzr7F1VP+2R9a6K4+FfhuaWZx/akKSyNIYoNRmjjUsSSFUNhRk9BwO1dhpOnWuk6Za6fp8QhtLaNYokBzhQMDnufc9aALdFFFABRRRQAUUUUAFFFFABRRRQBDfXdvYWc93ezJBbQIZJZZDhUUDJJPoBXjvhi5+2TarrkiPCmo3cs8Syrtbyt22MkHoSiqcds4rf+MWn+INWOj2ekaRLqml73muoo7iOMNKu3yhJvZcxjLsQM/Mq8cc5dt8PvFWoQKdS1jTdMJHMNvC9zt9txZBn/AICaAOd8Xa/kCGIPLI7iOOKIbnlc8KiDuxPavTPhd4Ubwzoby36r/bOoMJ70g7ghx8sSnuqA4z3O5v4qPB/w80rw5crfSST6nqwyFvLzaTHkYIjUAKmRwSBk9ya7OgAooooAyfFeu23hnw7fazfRTy21nH5jpAoZyMgcAkDvySQAMkkAV5zD8WdVvNrWHhe18l+Ve51YJkevyROP1r1wgEYPIPauVn+HfhCWV5P+Ec02KRzlmghEJJ9cpjmgDh7/AMSeKdVyH17TdEtz1Swt/Nm+nmSEr+SA1j+Z4f0q7bU9Rklv9QC7Te6hOXbHoGY/KPYYHtXpi/DfwkpydHjf2eWRx+RarNj4D8JWFx9otPDWjx3AORL9jjLj6MRmgDzOHxhqOuQbfCumXWooTtVrOP8AdZ/66nEf/j1a2nfDnW9ZeKfxXqgsoM7nsdPYs7ezTEDHuEXPo1etgBQABgDoBRQBmeH9B0vw9ZG00Wxhs4C29hGPmdj1Z2PLN7kk1p0UUAFFFFABRRRQAVmeJNatfD+jz6he7mSPCpFGMvNIeFjQd2Y4AHvVXxt4mtPCHhy41fUEeSKJkRUQgFnZgqjcxCqMkckgCvH4H8RfErVIbqz2+RyEvwhNlpykEMbfdg3EpBI8zGO3yAkMAWfBOk3HjDxpLd6lsktrK6F9qRzvSS8wDDbKe6QrsOe5VCR8zV7pWX4Z0Ky8N6JbaXpiFYIRyzcvI55Z3PdmOST6mtSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5D4o6Bea74bVtJRX1WwmW7tUYhfMYAho8ngbkZgCeASCelcX8N9J1HVfGEWr39jeWtjp0b7De27wvJcsNnyq4BIVC+WxglxgnBr2OigAooooAKKKKACiiigAooooAKKKKAPE9d8aeLJPjLqfhvSri4j0uz+xt/oujC8wJVBbzH8xPLXr82D344rotP+KsN7baDKmkT51W/vLBUSYMyG3DknoM7vL4HHXrXcWmhabZ65f6zbWqx6lfpHHczhjmRUGEBGcDAPYVgw/DLwbDrD6rFoFol+0skxlXcPndSrnGcAEMcjGKAOG0345fbIZEfQEh1OS4t7S20971knMs0mxVmV4l8sdyw3gcDPIrSt/iY+oaroME1vc6ZcDWbvSdQt4pI5ohJBCXPzmPcyYKkFdhzwfSuot/hp4Pt7K6tU0K2aG6VEk8xnkbahygVmJZQDyApGDzV2x8FeHbBNMWz0uGEabM9zalS2UlcEO5OcsxBOS2aAPPvCnxG1vxT488KFLIaZ4c1ayvbmGFpkmkuVjZQjv8AIDGeT8oYjnk8V7HXLaH8PvC2g6tHqekaPDa3sYkWN0d8IHOWCqTtAJ7AYHaupoAKKKKACiiigArgfjX4wk8G+DBcWV3bWep311DY2k1xjy4ndvmkbPG1UDMc8cV31Ub7SLC+1HT7+8tY5ruwZ3tZG6xM67WI9yOKAPGdD+M2oS/DLQ9XGnR6nqTzy2WpXKGT7PavEMmV/JjkbawKEbUwN/Ud9Sb4zmK7sLFdFguNQ1WCym0pYL8tFeee5ST5zECojIJOQSR1C122o/DzwnqU1xLfaDZTSXE7XMrMpy0jDDN16kAA+uBmo7nwHpc3i/w9riqkMeg2stvY2cUSrHGXAUtx6KMAdB1oA427+LWsf8JFLp+n+F7eaAa3PoEU0mpbDJcJGHVivl/KhB55JHbNV2+M+oXHh3Q73TPDUM13qNhf3skU1/5awfZHKyAERndnaxHTtn1HpieE9CS5FwumW4mF82ph8HP2ll2mX/eK8VDB4K8NwQW8MOkWqRW8M9vEoBwkc5JlUc9GJJNAHnB+N8trpOp32p+HDCI9OstTsYobrzTNFdOEQOQnyEEgnAbjpk4Bi1b4n+Lza6H9l8MrY3k/iCLTJFvDPBHdRvGzKYzNArqGKsCxTKlOh3cenr4N8OCF4jo1k8L2cenNHJGHVreP7kZByCo7VTX4deEF0h9LHh+x+wvMtw0RTOZFGFbPXIGQDnoSO9AHB+KfidqreFfG95Dok1nZ6BdSWL3trqUYlaVHi+4HhYDIkOSVIGO+eOssvGeqar4w1XTdJ0ezfStIvIrG8uri+MUxd1UkxxbCCF3Dqw3dq3pPCGgSaTqemPpVsdP1KY3F5Bg7ZpDtyze/yL+VJd+D/Dt34gi1y50eyk1eJldboxjfuX7pJ7kdickdqAN6iiigAooooA574h67P4Y8Da5rdnbi4uLG0knjjIJBYDgnHO0dT7A159H4o13wh4D/AOEv13xJB4nins7eddPWGG1CGWaJC0ciAkovmY+YHOByM17BNGk0TxTIskTqVZGGQwPUEdxXJ2Pw28GWFvqEFn4Z0uKG/Ty7lFgGJEzu2+wyAcDHIHoKAOa8R/FebS/E1/otjoAv7i31ex0mNvtojErXNu8wblCF2lNuMnOc5GMUtx8U7yy8VweGL/w6sWvT3FlFFbpfb1eOeNnllDeXysRjdTxzgdM11Om/D7wnpnl/2doFjbCO4iu0EUe0CaJSqPgdwGbn3Na1xoGk3HiC21yewt31e2iMEN2V/eIhzlQfTk/mfWgDy7R/jRPf3F1dt4Xvx4djivZRfRRzkxi2V2PmFoliBcRsAFkYg4Bwas/D/wAY+IvEHxLhh1iG2sNNu/DMOq29jb3HngeZOQrs5RSH28EDK8Ag88dvB4F8LQa1Lq0Og6emoSl2eZYR8xdSrnHTLAkE4yQTnqad4c8E+G/DV493oOjWlhcPF5DSQrglM7tv0z/KgDoqKKKAGyxpLGySoro3BVhkH8KcAAAAAAOABRRQAUjZwduM9s0tFACKMAZOT60tFFAHnHxz8Yav4N0DQ7jQFiN1f6xBp7b7VrkhJEkJ2RqQWbKjAB56d65LUPiH4hs9J1EXF1cR6tF4Yu9WRZdL+yKrx3HlqzRSFpA2OxO0g5xyK9f8QeHtL8Qf2b/a9t9o/s69j1C1/eMnlzx52P8AKRnGTwcj1FVNc8HaFrt9dXmq2Pn3Fzp76XK/nSLutnYM0eFYAZYA7hz70AeT+KPib4gstB8RtpBefUrWXSbcNJHEEtzdQozOg43ZLYw3QsP4Qa6W1+J8lhew6fqWmXdxBa3tto9/qZkiUpeSqpx5S9VBYAsOPQEV1M3w+8MTJfJLpm5b57WS4H2iUb2tgqwn73G0KvTGcc5qS68CeGrrxKuv3Glo+qLKk/meY4RpUGEkaMNsZ1HAYqSOxoA5L/hbp/4Ri81//hGNR/s6C7FlHJ9oh/0iX7R5O1BuyMHnLBR796bofxclv9dstNvvDF5YCXVZdFmnN1FIsV2ibwgCnLArglsADOBmuw/4Qbw7/wAI7/YX9nf8Sr7V9s8jz5P9d5vm7t27d9/nGcdsY4oj8DeHY7wXSadicam+sBvPk/4+2TY0mN2OVGNv3fagDpaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Burge HA, Burge W, Muilenberg ML, Pan PM and Solomon WR. Airborne pollen and fungus spore identification: Hands On Workshop, Postgraduate Course, University of Michigan Medical School, Ann Arbor, MI, May 1990.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23315=[""].join("\n");
var outline_f22_49_23315=null;
var title_f22_49_23316="Eplerenone: Patient drug information";
var content_f22_49_23316=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eplerenone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     see \"Eplerenone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Inspra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15245732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Inspra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eplerenone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High blood sugar (diabetes) with protein in urine, high potassium levels, or kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12423 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23316=[""].join("\n");
var outline_f22_49_23316=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165691\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245732\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021464\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021466\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021465\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021470\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021471\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021473\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021468\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021469\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021474\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021475\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=related_link\">",
"      Eplerenone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_49_23317="Blood smear African trypanosomiasis";
var content_f22_49_23317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F85845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F85845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Blood smear African trypanosomiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two",
"    <em>",
"     Trypanosoma brucei",
"    </em>",
"    subspecies that cause African trypanosomiasis,",
"    <em>",
"     T. b. gambiense",
"    </em>",
"    and",
"    <em>",
"     T. b. rhodesiense",
"    </em>",
"    , are indistinguishable morphologically. A typical trypomastigote has a small kinetoplast located at the posterior end, a centrally located nucleus, an undulating membrane, and a flagellum running along the undulating membrane, leaving the body at the anterior end. Trypomastigotes are the only stage found in patients. Trypanosomes range in length from 14 to 33 micrometers.",
"    <br/>",
"    (A)",
"    <em>",
"     Trypansoma brucei",
"    </em>",
"    ssp. in thick blood smears stained with Giemsa.",
"    <br/>",
"    (B) Trypomastigotes of",
"    <em>",
"     T. brucei",
"    </em>",
"    ssp. in a blood smear stained with Giemsa.",
"    <br/>",
"    (C)",
"    <em>",
"     Trypanosoma brucei",
"    </em>",
"    ssp. in a thin blood smear stained with Giemsa. The trypomastigote is beginning to divide; dividing forms are seen in African trypanosomes, but not in American trypanosomes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers of Disease Control and Prevention. Parasites and Health: Trypanosomiasis, African. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/TrypanosomiasisAfrican.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/TrypanosomiasisAfrican.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23317=[""].join("\n");
var outline_f22_49_23317=null;
var title_f22_49_23318="Contrast echocardiography: Contrast agents, safety, and imaging technique";
var content_f22_49_23318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Contrast echocardiography: Contrast agents, safety, and imaging technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23318/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23318/contributors\">",
"     Neil J Weissman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23318/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23318/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23318/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23318/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/49/23318/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast echocardiography is a technique for improving echocardiographic resolution and providing real time assessment of intracardiac blood flow. Agitated saline contrast provides contrast in the right heart and enables detection of right to left shunts. Opacification of the left ventricular (LV) cavity by contrast agents developed to traverse the pulmonary vasculature permits improved endocardial border detection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/1\">",
"     1",
"    </a>",
"    ]. Contrast echocardiography can also enhance delineation of Doppler signal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/1\">",
"     1",
"    </a>",
"    ]. Additional uses of contrast echocardiography are to assess myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/2\">",
"     2",
"    </a>",
"    ] and viability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development and safety of microbubbles for echocardiographic contrast and the optimization of the echocardiographic settings for visualizing contrast will be reviewed here. The current and potential clinical applications of CE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBUBBLE CONTRAST AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;As sound travels from one medium to another, the change in density (known as acoustic impedance) at the interface causes the reflection of sound waves [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/4\">",
"     4",
"    </a>",
"    ]. The greater the difference in the media densities, the more echogenic the interface. Gas is an excellent contrast agent since it is 100,000 times less dense than blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Agitated saline contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agitated saline solution administered via intravenous injection provides air microbubble contrast in the right heart. The air microbubbles are short-lived and diffuse into the lungs when traversing the pulmonary circulation. Therefore the microbubbles enter the left heart only in the presence of a right to left intracardiac or extracardiac (pulmonary arteriovenous) shunt. Saline microbubbles are therefore helpful in examining the right heart and identifying shunts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link&amp;anchor=H2#H2\">",
"     \"Contrast echocardiography: Clinical applications\", section on 'Clinical applications for agitated saline contrast'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link&amp;anchor=H16#H16\">",
"     \"Patent foramen ovale\", section on 'Ultrasound techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transpulmonary passage of contrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;To allow left heart evaluation, an ideal contrast microbubble must be small and durable enough to traverse the pulmonary circulation to pass into the left heart from an intravenous injection. Improvements in contrast agents have resulted from the exploitation of knowledge concerning both the mechanisms of echogenicity and the impediments to transpulmonary passage.",
"   </p>",
"   <p>",
"    Larger microbubble size enhances durability, which is proportional to the square of the bubble radius [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/5\">",
"     5",
"    </a>",
"    ]. However, a small bubble size (&le;10 &micro;) is required for successful transpulmonary passage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Agitated saline, dextrose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/0/14340?source=see_link\">",
"     diatrizoate meglumine",
"    </a>",
"    (Renograffin-76), and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    are largely inadequate for left heart evaluation because of both large bubble size and instability resulting from the rapid diffusion of air into the blood. These agents have therefore only been utilized for the left-sided assessment of myocardial perfusion via injection into the aortic root or directly into the coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/3,7-9\">",
"     3,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surrounding the gas bubble in a durable shell enables adequate durability while keeping bubble size small enough to traverse the pulmonary circulation. A number of microbubble capsules have been investigated but produced bubbles that were too large (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    dye) or too short-lived (eg, polysaccharide or gelatin encapsulated air) to opacify the left heart [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/10\">",
"     10",
"    </a>",
"    ]. Further stabilization of the microbubble was achieved through use of a 5 percent human albumin solution, which forms a thin shell of denatured albumin when sonicated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/11\">",
"     11",
"    </a>",
"    ]; this led to the development of Albunex as the first FDA-approved myocardial contrast agent. However, the clinical utility of Albunex was limited because microbubble air loss results in large decreases in echogenicity, although it causes only slight decreases in bubble diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further improvements in microbubble capsules have been incorporated into second generation agents. Gas diffusion was decreased via the use of inert gases (eg, perfluorocarbons) to form the microbubbles. Improved bubble surface stability was attained through use of innovative colloidal suspensions or emulsions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Second generation contrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the following second generation contrast agents, two (Optison and Definity) are currently FDA approved [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A human albumin-based shell enclosing perfluoropropane gas (FS069 or Optison) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. This agent is FDA approved and also approved in Canada.",
"     </li>",
"     <li>",
"      A phospholipid shell which enclosing perfluoropropane (perflutren or Definity) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/12,15\">",
"       12,15",
"      </a>",
"      ]. This agent is FDA approved and also approved in Europe (known as Lumity) and in Canada.",
"     </li>",
"     <li>",
"      A lipid (palmitic acid) shell which encloses air (Levovist) is approved in Canada, Europe, and some Latin American and Asian countries.",
"     </li>",
"     <li>",
"      A phospholipid shell enclosing sulfur hexafluoride gas (SonoVue) is approved in Canada, Europe, and some Latin American and Asian countries.",
"     </li>",
"     <li>",
"      A biodegradable polymer bilayer shell enclosing nitrogen gas (CARDIOsphere).",
"     </li>",
"     <li>",
"      A synthetic polymer shell enclosing decafluorobutane gas (Imagify).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Agitated saline safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although reports of complications are scant, case reports suggest that agitated saline injection can rarely cause ischemic complications such as stroke or transient ischemic attack. One report compiled five cases of cerebral ischemic events (3 ischemic strokes and 2 transient ischemic attacks) occurring immediately or within five minutes of agitated saline contrast study demonstrating a right to left shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/16\">",
"     16",
"    </a>",
"    ]. Available data are not sufficient to estimate the incidence of such events, although such complications appear to be rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Second generation contrast safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA approved Optison and Definity for cardiac indications after clinical trial experience including detailed safety evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Initial postmarketing approval surveillance over five years and in greater than one million patient studies demonstrated no medically significant risks other than rare allergic events at a rate of approximately 1 per 10,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/1\">",
"     1",
"    </a>",
"    ]. Central nervous system reactions have also rarely been reported and may or may not be associated with hypersensitivity reactions. Reported adverse events are generally infrequent and mild and may include headache, weakness, fatigue, palpitations, nausea, dizziness, dry mouth, altered sense of smell or taste, dyspnea, urticaria, pruritus, back pain, chest pain, or rash.",
"   </p>",
"   <p>",
"    The FDA subsequently received reports of serious cardiopulmonary reactions and four deaths following administration of ultrasound microbubble contrast agent (Definity or Optison). Most of the deaths occurred one to twelve hours following administration of the contrast agent in patients with severe underlying conditions. In October 2007 the FDA issued revised labeling requirements including a black box warning with new contraindications for use of these agents,",
"   </p>",
"   <p>",
"    Following these labeling changes, many raised concerns about the potential confounding effect of pseudocomplications on the evaluation of safety and pointed out that the risk is relatively small given the very large number of patients who have received contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The importance of controlling for background risk was later illustrated by a multicenter retrospective study of 42,408 inpatients and outpatients receiving Optison or Definity contrast agents who were compared to 15,989 matched patients undergoing echocardiography without contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/19\">",
"     19",
"    </a>",
"    ]. One death and five nonfatal myocardial infarctions were observed within 24 hours in the contrast group; the rate of these events was not different from those among matched control subjects.",
"   </p>",
"   <p>",
"    In 2008 the FDA revised labeling requirements for Definity and Optison to include the following warnings and recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serious cardiopulmonary reactions, including fatalities, have occurred during or within 30 minutes following administration of a micro-bubble contrast agent.",
"     </li>",
"     <li>",
"      Patients with pulmonary hypertension or unstable cardiopulmonary conditions should have their vital signs and cutaneous oxygen saturation monitored during and for at least 30 minutes following the administration of a micro-bubble contrast agent.",
"     </li>",
"     <li>",
"      Unstable cardiopulmonary conditions include acute myocardial infarction, acute coronary artery syndromes, worsening or unstable heart failure, serious ventricular arrhythmias or respiratory failure (including receiving mechanical ventilation)",
"     </li>",
"     <li>",
"      Contraindications include",
"     </li>",
"     <li>",
"      known hypersensitivity to perflutren",
"     </li>",
"     <li>",
"      for Optison only, known hypersensitivity to blood, blood products, or albumin",
"     </li>",
"     <li>",
"      fixed right to left, bi-directional or transient right to left cardiac shunts",
"     </li>",
"     <li>",
"      The inter-arterial injection of ultrasound contrast agents is also contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OPTIMAL ECHOCARDIOGRAPHIC SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast agent durability is dependent upon both bubble composition and ultrasonic characteristics. Alterations in the echocardiographic settings can therefore optimize both microbubble durability and contrast intensity. Guidelines for equipment setup and contrast agent administration are included in the 2008 American Society of Echocardiography (ASE) consensus statement on contrast agents in echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Harmonic detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second harmonic detection systems improve the signal-to-noise ratio of contrast images [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microbubbles resonate (shake) with exposure to ultrasound energy at frequencies that are multiples of the ultrasound frequency emitted from the transducer. This results in the emission of fundamentals (same frequency) and harmonics (multiples) of the frequency to which they are exposed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/22\">",
"     22",
"    </a>",
"    ]. By setting the imaging frequency of the echo system to a harmonic of the emitted frequency, the system \"filters\" out all returning fundamental frequencies from the myocardium and enhances the microbubble signal.",
"   </p>",
"   <p>",
"    The contrast intensity improves two to three times using second harmonics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/23\">",
"     23",
"    </a>",
"    ]. Other advantages to harmonic imaging include decreased artifact and shadowing, as well as enhanced contrast detection in areas of low microbubble concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Harmonic imaging also improves endocardial tracking even without echocardiographic contrast. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=see_link&amp;anchor=H10#H10\">",
"     \"Echocardiography essentials: Physics and instrumentation\", section on 'Second harmonic imaging'",
"    </a>",
"    .) However, the ejection fraction obtained by harmonic imaging along with contrast echocardiography provides the closest correlation with the radionuclide ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intermittent or transient imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a sound wave interacts with a microbubble, some of the energy is reflected, but a portion actively destroys the microbubbles. As a result, continuous ultrasound imaging results in depletion of the microbubble population, giving a suboptimal signal to noise ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased microbubble durability may be accomplished with intermittent or transient response imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/26\">",
"     26",
"    </a>",
"    ]. Ultrasound that is emitted only once per cardiac cycle, or as infrequently as every 5 to 10 beats, improves microbubble contrast intensity inversely with bubble transit velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/27\">",
"     27",
"    </a>",
"    ]. Controversy exists as to which part of the cardiac cycle should be imaged; however, either systolic or diastolic imaging appears to improve the contrast effect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Low mechanical index imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another technique to decrease the destruction of microbubbles is low mechanical index imaging. If a very low acoustic power is transmitted, fewer bubbles will be destroyed even with continuous imaging. Commercial echocardiographic machines now have this \"real time\" contrast imaging and studies assessing its utility are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gray discrimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of the naked eye to discriminate different levels of gray is limited. As a result, techniques which reliably quantify small changes in gray level (as with coronary ischemia or the assessment of myocardial viability) are under investigation using subtraction videodensitometry [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/28\">",
"     28",
"    </a>",
"    ] and post-processing color-coding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/29\">",
"     29",
"    </a>",
"    ]. Images may also be enhanced using Doppler technology with power-Doppler imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasound pulse inversion technology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mode of contrast injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of contrast injection can affect image quality. Steady state infusions offer an advantage over single or multiple bolus injections of agents by allowing titration to an optimal and uniform image and extending the duration of left ventricular opacification, allowing for time to assess multiple anatomic views [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23318/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1035271852\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contrast echocardiography is a technique for improving&nbsp;echocardiographic resolution and providing real time assessment of&nbsp;intracardiac blood flow. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Second generation contrast agents surrounding the gas bubble in a durable shell enable adequate durability while keeping bubble size small enough to traverse the pulmonary circulation and enhance the left ventricular cavity, improving&nbsp;endocardial border delineation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbubble contrast agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several studies have demonstrated the safety of these second generation contrast agents. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contrast agents require different echocardiography machine settings to enhance their utility. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Optimal echocardiographic settings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/1\">",
"      Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr 2008; 21:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/2\">",
"      Porter TR, Li S, Kricsfeld D, Armbruster RW. Detection of myocardial perfusion in multiple echocardiographic windows with one intravenous injection of microbubbles using transient response second harmonic imaging. J Am Coll Cardiol 1997; 29:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/3\">",
"      Rovai D, Zanchi M, Lombardi M, et al. Residual myocardial perfusion in reversibly damaged myocardium by dipyridamole contrast echocardiography. Eur Heart J 1996; 17:296.",
"     </a>",
"    </li>",
"    <li>",
"     Feigenbaum H. Instrumentation. In: Echocardiography, Feigenbaum H (Ed), Lea and Febiger, Philadelphia 1981. p.3.",
"    </li>",
"    <li>",
"     Berwing K, Schlepper M, Bahavar H, Buchwald A. Significance and selection of contrast solution for myocardial contrast echocardiography. In: Myocardial Contrast Two-Dimensional Echocardiography, Meerbaum S, Meltzer R (Eds), Kluwer Academic Publishers, Boston 1989. p.63.",
"    </li>",
"    <li>",
"     Meerbaum S. Development and validation of MC-2DE methodology. In: Myocardial Contrast Two-Dimensional Echocardiography, Meerbaum S, Meltzer R (Eds), Kluwer Academic Publishers, Boston 1989. p.24.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/7\">",
"      Kates MA, Meza MF, Barbee RW, et al. Potential clinical implications of abnormal myocardial perfusion patterns immediately after reperfusion in a canine model: a myocardial contrast echocardiography study. Am Heart J 1996; 132:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/8\">",
"      Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/9\">",
"      Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327:1825.",
"     </a>",
"    </li>",
"    <li>",
"     Meerbaum S. Introduction and general background. In: Myocardial Contrast Two-Dimensional Echocardiography, Meerbaum S, Meltzer R (Eds), Kluwer Academic Publishers, Boston 1989. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/11\">",
"      Feinstein SB, Cheirif J, Ten Cate FJ, et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol 1990; 16:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/12\">",
"      Kaul S. Myocardial contrast echocardiography: 15 years of research and development. Circulation 1997; 96:3745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/13\">",
"      Meza M, Greener Y, Hunt R, et al. Myocardial contrast echocardiography: reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. Am Heart J 1996; 132:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/14\">",
"      Cohen JL, Cheirif J, Segar DS, et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. J Am Coll Cardiol 1998; 32:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/15\">",
"      Kitzman DW, Goldman ME, Gillam LD, et al. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000; 86:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/16\">",
"      Romero JR, Frey JL, Schwamm LH, et al. Cerebral ischemic events associated with 'bubble study' for identification of right to left shunts. Stroke 2009; 40:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/17\">",
"      Main ML, Goldman JH, Grayburn PA. Thinking outside the \"box\"-the ultrasound contrast controversy. J Am Coll Cardiol 2007; 50:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/18\">",
"      Douglas PS, Weyman AE, Lindner JR, Wei K. Contrast echocardiography: Past, present and...future? J Am Coll Cardiol Img 2008; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/19\">",
"      Dolan MS, Gala SS, Dodla S, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. J Am Coll Cardiol 2009; 53:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/20\">",
"      Lindner JR, Firschke C, Wei K, et al. Myocardial perfusion characteristics and hemodynamic profile of MRX-115, a venous echocardiographic contrast agent, during acute myocardial infarction. J Am Soc Echocardiogr 1998; 11:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/21\">",
"      Lindner JR, Dent JM, Moos SP, et al. Enhancement of left ventricular cavity opacification by harmonic imaging after venous injection of Albunex. Am J Cardiol 1997; 79:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/22\">",
"      Kaul S. New developments in ultrasound systems for contrast echocardiography. Clin Cardiol 1997; 20:I27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/23\">",
"      Colon PJ 3rd, Richards DR, Moreno CA, et al. Benefits of reducing the cardiac cycle-triggering frequency of ultrasound imaging to increase myocardial opacification with FSO69 during fundamental and second harmonic imaging. J Am Soc Echocardiogr 1997; 10:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/24\">",
"      Nahar T, Croft L, Shapiro R, et al. Comparison of four echocardiographic techniques for measuring left ventricular ejection fraction. Am J Cardiol 2000; 86:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/25\">",
"      Wei K, Skyba DM, Firschke C, et al. Interactions between microbubbles and ultrasound: in vitro and in vivo observations. J Am Coll Cardiol 1997; 29:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/26\">",
"      Firschke C, Lindner JR, Wei K, et al. Myocardial perfusion imaging in the setting of coronary artery stenosis and acute myocardial infarction using venous injection of a second-generation echocardiographic contrast agent. Circulation 1997; 96:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/27\">",
"      Ohmori K, Cotter B, Kwan OL, et al. Relation of contrast echo intensity and flow velocity to the amplification of contrast opacification produced by intermittent ultrasound transmission. Am Heart J 1997; 134:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/28\">",
"      Porter TR, Kricsfeld A, Deligonul U, Xie F. Detection of regional perfusion abnormalities during adenosine stress echocardiography with intravenous perfluorocarbon-exposed sonicated dextrose albumin. Am Heart J 1996; 132:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/29\">",
"      Ismail S, Jayaweera AR, Goodman NC, et al. Detection of coronary stenoses and quantification of the degree and spatial extent of blood flow mismatch during coronary hyperemia with myocardial contrast echocardiography. Circulation 1995; 91:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/30\">",
"      Sutherland GR, Stewart MJ, Groundstroem KW, et al. Color Doppler myocardial imaging: a new technique for the assessment of myocardial function. J Am Soc Echocardiogr 1994; 7:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/31\">",
"      Tuchnitz A, von Bibra H, Sutherland GR, et al. Doppler energy: a new acquisition technique for the transthoracic detection of myocardial perfusion defects with the use of a venous contrast agent. J Am Soc Echocardiogr 1997; 10:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/32\">",
"      Venkatraman S, Rao NA. Combining pulse compression and adaptive drive signal design to inverse filter the transducer system response and improve resolution in medical ultrasound. Med Biol Eng Comput 1996; 34:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/33\">",
"      Albrecht T, Urbank A, Mahler M, et al. Prolongation and optimization of Doppler enhancement with a microbubble US contrast agent by using continuous infusion: preliminary experience. Radiology 1998; 207:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23318/abstract/34\">",
"      Weissman NJ, Cohen MC, Hack TC, et al. Infusion versus bolus contrast echocardiography: a multicenter, open-label, crossover trial. Am Heart J 2000; 139:399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5301 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23318=[""].join("\n");
var outline_f22_49_23318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1035271852\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBUBBLE CONTRAST AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Agitated saline contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transpulmonary passage of contrast agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Second generation contrast agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Agitated saline safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Second generation contrast safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OPTIMAL ECHOCARDIOGRAPHIC SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Harmonic detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intermittent or transient imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Low mechanical index imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gray discrimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mode of contrast injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1035271852\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=related_link\">",
"      Echocardiography essentials: Physics and instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_49_23319="Triazolam: Drug information";
var content_f22_49_23319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triazolam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38068?source=see_link\">",
"    see \"Triazolam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/37/7766?source=see_link\">",
"    see \"Triazolam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Halcion&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Triazo&reg;;",
"     </li>",
"     <li>",
"      Gen-Triazolam;",
"     </li>",
"     <li>",
"      Halcion&reg;;",
"     </li>",
"     <li>",
"      Mylan-Triazolam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Insomnia (short-term use):",
"     </b>",
"     Usual dose: 0.25 mg at bedtime; 0.125 mg at bedtime may be sufficient in some patients, such as those with low body weight; maximum dose: 0.5 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental preprocedure oral sedation (unlabeled use):",
"     </b>",
"     0.25 mg 1 hour before procedure; 0.125 mg used for elderly patients or patients sensitive to sedative effects (Dionne, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly and/or debilitated patients: Insomnia (short-term use): Oral: Initial: 0.125 mg at bedtime; maximum dose: 0.25 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15668561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; however, caution is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F230779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; however, use caution or avoid due to extensive hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.125 mg, 0.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Halcion&reg;: 0.25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F230811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088610.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088610.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take with a meal or immediately after a meal. Tablet may be crushed or swallowed whole. Onset of action is rapid; patient should take immediately before bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (generally 7-10 days) treatment of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12810249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral sedation prior to outpatient dental procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Triazolam may be confused with alPRAZolam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Halcion&reg; may be confused with halcinonide, Haldol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Drowsiness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (10%), dizziness (8%), ataxia (5%), lightheadedness (5%), nervousness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5%), vomiting (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, anterograde amnesia; complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls); confusion, cramps, depression, dermatitis, dreaming/nightmares, dysesthesia, euphoria, fatigue, hepatic failure (fulminant), memory impairment, pain, paresthesia, tachycardia, violent acts, visual disturbance, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In addition, the following have been reported in association with triazolam and other benzodiazepines: Burning tongue/glossitis/stomatitis, chest pain, dysarthria, libido changes, menstrual irregularities; paradoxical reactions (eg, aggressiveness, agitational state, delusions, falling, hallucination, mania, sleep disturbances, syncope); pruritus, sedation, slurred speech, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F230756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triazolam, other benzodiazepines, or any component of the formulation; concurrent therapy with itraconazole, ketoconazole, or nefazodone; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F230738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia, particularly benzodiazepines with short half-lives such as triazolam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients. Evaluate any new or unusual changes in behavior.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have also been noted. Patients will often not remember doing these activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; undergoes extensive hepatic metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory compromise, COPD or sleep apnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Avoid use in patients taking strong CYP3A4 inhibitors; use is contraindicated with certain potent CYP3A4 inhibitors. Use with caution in patients taking moderate CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; potential for oversedation, impaired coordination, and dizziness with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group, avoid use for treatment of insomnia, agitation, or delirium. (Beers Criteria). Pharmacokinetics of triazolam are altered in older adults compared to younger adults (higher C",
"     <sub>",
"      max",
"     </sub>",
"     , increased AUC, decreased clearance); the elderly also experience greater sedation and increased psychomotor impairment (Greenblatt, 1991).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypnotic: Appropriate use: Should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation. Prescription should be written for a maximum of 7-10 days and should not be prescribed in quantities exceeding a 1-month supply.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy. An increase in daytime anxiety may occur after as few as 10 days of continuous use, which may be related to withdrawal reaction in some patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F230768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Limit or avoid ethanol consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may decrease the rate of absorption. Benzodiazepine serum concentrations may be increased by grapefruit juice. Management: Limit or avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels/effects of benzodiazepines. Other herbal medications may increase CNS depression. Management: Avoid St John's wort, valerian, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triazolam was found to cross the placenta in animals. A case report describes placental transfer of triazolam following a maternal overdose. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines. Use of triazolam is contraindicated in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F230760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F230758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Halcion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (10): $30.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Triazolam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125 mg (10): $6.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (10): $6.66",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F230746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daytime alertness; respiratory rate; behavior profile",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F230761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arring (TW);",
"     </li>",
"     <li>",
"      Balidon (CN);",
"     </li>",
"     <li>",
"      Drowsy (TW);",
"     </li>",
"     <li>",
"      Halcion (AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CR, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, IE, IL, IT, JM, KE, KP, LR, LU, MA, ML, MR, MT, MU, MW, MX, NE, NG, NI, NL, NO, PA, PK, PT, RU, SC, SD, SE, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Hanlexin (CL);",
"     </li>",
"     <li>",
"      Hypam (NZ);",
"     </li>",
"     <li>",
"      Inzolam (MY);",
"     </li>",
"     <li>",
"      Novidorm (AR);",
"     </li>",
"     <li>",
"      Nuctane (AR);",
"     </li>",
"     <li>",
"      Rilamir (DK, FI);",
"     </li>",
"     <li>",
"      Sleep (TW);",
"     </li>",
"     <li>",
"      Somese (CN, CO, EC, MY, PE, VE);",
"     </li>",
"     <li>",
"      Songar (IT);",
"     </li>",
"     <li>",
"      Trialam (TW);",
"     </li>",
"     <li>",
"      Triram (KP);",
"     </li>",
"     <li>",
"      Trycam (TH);",
"     </li>",
"     <li>",
"      Zolmin (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F230737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F230755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hypnotic: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6-1.7 L/kg (Pakes, 1981)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 89% (Pakes, 1981)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; hydroxylation via CYP3A4 (initial step in metabolism) with subsequent glucuronide conjugation; metabolites likely inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.5-5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~80% as metabolites; small amounts as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berthold CW, Dionne RA, and Corey SE, \"Comparison of Sublingually and Orally Administered Triazolam for Premedication Before Oral Surgery,\"",
"      <i>",
"       Oral Surg Oral Med Oral Pathol Oral Radiol Endod",
"      </i>",
"      , 1997, 84(2):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/9269010/pubmed\" id=\"9269010\" target=\"_blank\">",
"        9269010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berthold CW, Schneider A, and Dionne RA, &ldquo;Using Triazolam to Reduce Dental Anxiety,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1993, 124(11):58-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/8227774/pubmed\" id=\"8227774\" target=\"_blank\">",
"        8227774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chan TH, Ho SS, and Li PK, &ldquo;Noncardiogenic Pulmonary Edema Associated With Triazolam,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(2):185-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/7897760/pubmed\" id=\"7897760\" target=\"_blank\">",
"        7897760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, Yagiela JA, Cot&eacute; CJ, et al, \"Balancing Efficacy and Safety in the Use of Oral Sedation in Dental Outpatients,\"",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2006, 137(4):502-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/16637480/pubmed\" id=\"16637480\" target=\"_blank\">",
"        16637480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenblatt DJ, Harmatz JS, Shapiro L, et al, &ldquo;Sensitivity to Triazolam in the Elderly,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1691-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/2034245/pubmed\" id=\"2034245\" target=\"_blank\">",
"        2034245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieblich SE and Horswell B, &ldquo;Attenuation of Anxiety in Ambulatory Oral Surgery Patients With Oral Triazolam,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 1991, 49(8):792-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/2072190/pubmed\" id=\"2072190\" target=\"_blank\">",
"        2072190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milgrom P, Quarnstrom FC, Longley A, et al, &ldquo;The Efficacy and Memory Effects of Oral Triazolam Premedication in Highly Anxious Dental Patients,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1994, 41(3):70-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/8934963/pubmed\" id=\"8934963\" target=\"_blank\">",
"        8934963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pakes GE, Brogden RN, Heel RC, et al, \"Triazolam: A Review of its Pharmacological Properties and Therapeutic Efficacy in Patients With Insomnia,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 1981, 22(2):81-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/6114852/pubmed\" id=\"6114852\" target=\"_blank\">",
"        6114852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sullivan RJ Jr, &ldquo;Respiratory Depression Requiring Ventilatory Support Following 0.5 mg of Triazolam,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1989, 37(5):450-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/2703644/pubmed\" id=\"2703644\" target=\"_blank\">",
"        2703644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/49/23319/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10017 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23319=[""].join("\n");
var outline_f22_49_23319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230772\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230773\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230809\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230777\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230778\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15668561\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230779\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230749\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230734\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230811\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874925\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230753\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230752\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12810249\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230819\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230807\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230756\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230738\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230803\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230743\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230768\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230744\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230759\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230782\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230760\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230758\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230746\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230761\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230737\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230755\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10017|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38068?source=related_link\">",
"      Triazolam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/37/7766?source=related_link\">",
"      Triazolam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_49_23320="Overview of the management of the child at risk for atherosclerosis";
var content_f22_49_23320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of the child at risk for atherosclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23320/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23320/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23320/contributors\">",
"     Jane W Newburger, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23320/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23320/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/49/23320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiovascular disease (CVD) generally presents in adulthood, atherosclerosis begins in childhood. For most children, vascular changes, if present, are mild and can be minimized with adherence to a healthy lifestyle. However, in some children, the atherosclerotic process is accelerated because of the presence of identifiable risk factors (eg, obesity and hypertension)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specific diseases associated with premature CVD (eg, familial hypercholesterolemia, types 1 and 2 diabetes mellitus and chronic kidney disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/1\">",
"     1",
"    </a>",
"    ]. Identification of children who are at risk for accelerated atherosclerosis may allow timely intervention to decrease the atherosclerotic process, thereby preventing or delaying CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the management of the child identified as being at risk for atherosclerosis will be presented here. Primary prevention of atherosclerosis in children, identifying the child at risk for atherosclerosis, and the risk factors for pediatric atherosclerosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=see_link\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large prospective population-based randomized control trial (RCT) studies in adults demonstrate that reducing risk factors associated with cardiovascular disease (CVD) will decrease the risk of CVD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Established risk factors for atherosclerotic CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although similar long-term outcome data based on randomized clinical trials are not available for the pediatric population, prospective observational studies link risk factors known to be associated with CVD in adults to early atherosclerotic changes in children and demonstrate tracking of CVD risk factors from childhood to adulthood. Furthermore, short-term RCTs have demonstrated improvement in CVD risk factors in high-risk pediatric populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk factors and development of atherosclerosis in childhood\", section on 'Atherosclerotic changes in childhood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, it is reasonable to assume based on the evidence from adult studies and limited pediatric data that timely intervention to decrease and possibly eliminate CVD risk factor(s) in children will decelerate the atherosclerotic process (primordial prevention) and thereby prevent or delay the onset of CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon a review of the literature, a 2011 expert panel sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) recommended therapeutic interventions for children with the following modifiable CVD risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Physical inactivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, therapeutic interventions to reduce or prevent accelerated atherosclerosis and CVD should be initiated in children with high-risk conditions (ie, familial hypercholesterolemia, types 1 and 2 diabetes mellitus, chronic kidney disease, heart transplantation, Kawasaki disease with aneurysms, chronic inflammatory disease, childhood cancer survivors, and some types of congenital heart disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"     \"Diseases associated with atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recent NHLBI guidelines, endorsed by the American Academy of Pediatrics, are consistent with previous recommendations from the American Heart Association (AHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DYSLIPIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyslipidemias are disorders of lipoprotein metabolism. In our practice, we utilize the following definitions for dyslipidemia, which are consistent with those outlined by the expert National Heart, Lung, and Blood Institute (NHLBI) panel and American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/5,7-10\">",
"     5,7-10",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef68183 \" href=\"UTD.htm?42/51/43836\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol (TC) &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Low-density lipid cholesterol (LDL-C) &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      High-density lipid cholesterol (HDL-C) &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Non-HDL-C &gt;145",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Triglyceride (TG) &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in children &ge;10 years of age and &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in younger children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults, large population-based trials established that treatment of dyslipidemia lowers the rate of atherosclerotic CVD (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    ). Similar high-quality evidence is lacking in children because of the long interval until clinical events could be expected and the large numbers of patients that would be required to demonstrate efficacy. However, prospective observational studies demonstrate that statin therapy in children with familial hypercholesterolemia (FH), at high-risk of cardiac vascular events improves dyslipidemia and measures of preclinical atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, recommendations based on expert opinion to initiate lipid-lowering pharmacotherapy in pediatric and adolescent patients were developed on the premise that many of these children are likely to have FH, and on the belief that the consequences of elevated LDL in non-FH patients are likely to contribute to accelerated atherosclerosis and cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/5\">",
"     5",
"    </a>",
"    ]. The approach to pediatric prevention in general and lipid disorders in particular uses global CVD risk assessment as outlined by the NHLBI expert panel centered on lifetime rather than 10-year risk. This approach differs from the adult primary prevention approach that calculates the 10-year CVD risk for the individual patient for decisions regarding pharmacotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894596#H894596\">",
"     \"Management of pediatric dyslipidemia\", section on 'Pediatric versus adult management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Deciding whom to treat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we manage children with dyslipidemia based on the approach outlined in the 2011 NHLBI expert panel guideline as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the vast majority of children with lipid abnormalities, lifestyle modification is the main focus of management to prevent or slow the progression of atherosclerosis. Non-pharmacologic therapy promoting healthy lifestyle changes is provided to all patients. This includes a diet high in fruits and vegetables, avoidance of additive trans-fats (",
"      <a class=\"graphic graphic_table graphicRef78256 \" href=\"UTD.htm?3/49/3870\">",
"       table 2",
"      </a>",
"      ), and an exercise regimen of daily vigorous activity (",
"      <a class=\"graphic graphic_table graphicRef75748 \" href=\"UTD.htm?20/10/20653\">",
"       table 3",
"      </a>",
"      ). For children with persistent high LDL-C, a low-saturated-fat, low-cholesterol diet is often used (",
"      <a class=\"graphic graphic_table graphicRef53962 \" href=\"UTD.htm?32/37/33371\">",
"       table 4",
"      </a>",
"      ). For children with elevated TG levels, a diet low in refined carbohydrates and added sugars, and rich in unsaturated fats, including omega-3 fatty acids, is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894533#H894533\">",
"       \"Management of pediatric dyslipidemia\", section on 'Dietary modification'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894547#H894547\">",
"       \"Management of pediatric dyslipidemia\", section on 'Activity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If lifestyle counseling fails to reach the targeted goal by six months in children with elevated LDL-C who are 10 years or older, we consider statin therapy. The decision to start pharmacologic therapy is based upon the severity of the child's dyslipidemia, the presence of other comorbid conditions (eg, diabetes or chronic kidney disease), the severity of family history of premature CVD (eg, homozygous FH), and the preferences of the child and family. The potential benefit of reduced CVD risk versus the unknown risk of long-term statin therapy is discussed with the family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definition, screening, and management of pediatric dyslipidemia are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/281?source=see_link\">",
"     \"Definition and screening for dyslipidemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link\">",
"     \"Management of pediatric dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, the National High Blood Pressure Education Program Working Group (NHBPEP) revised guidelines for the treatment of hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Management approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These included the following recommendations for blood pressure (BP) control, which are also incorporated in the 2011 NHLBI guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The targeted goal for blood pressure (BP) is less than the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile based upon age and gender (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"UTD.htm?7/45/7894\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"UTD.htm?7/46/7910\">",
"       table 6",
"      </a>",
"      ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If there are comorbid risk factors (eg, obesity and diabetes mellitus),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of target-organ damage (ie, left ventricular hypertrophy, renal scarring, or retinopathy), or diseases with high risk of early atherosclerosis (Tier 1), the BP targeted goal is lowered to the &lt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age and gender.",
"     </li>",
"     <li>",
"      Children who are pre-hypertensive (BP &gt;90",
"      <sup>",
"       th",
"      </sup>",
"      percentile and &lt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile) and do not fall into the category above should be managed with nonpharmacologic therapy (eg, diet and exercise) to reduce their BP to below the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment for hypertension includes both nonpharmacologic and pharmacologic interventions. Management decisions are dependent upon the severity of hypertension, the underlying cause, evidence of end-organ damage, and the presence of other cardiovascular disease (CVD) risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we use the NHBPEP guidelines for initiating treatment as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We begin pharmacologic therapy in children with severe hypertension (defined as BP levels that are 5 mmHg greater than the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age and gender), those with hypertensive target-organ damage (eg, left ventricular hypertrophy), or high risk diseases with a BP above the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age and gender.",
"     </li>",
"     <li>",
"      In the remaining patients with BP above the targeted goal, nonpharmacologic therapy, including diet that is rich in vegetables, fruits, and whole grains, such as the Dietary Approaches to Stop Hypertension (DASH) diet (",
"      <a class=\"graphic graphic_table graphicRef64935 \" href=\"UTD.htm?11/33/11806\">",
"       table 7",
"      </a>",
"      ), and activity, is initiated.",
"     </li>",
"     <li>",
"      If the BP persists above the targeted goal despite nonpharmacologic therapy, an antihypertensive medication is started. The targeted BP goal is lower in patients who have an additional comorbid condition or risk factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In determining which medication should be used for an individual child, the clinician should consider the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of particular drug classes in the patient&rsquo;s clinical setting. For example, in children who have insulin resistance or diabetes mellitus, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) is preferred over other classes of antihypertensives because of their established benefit in reducing microalbuminuria and preserving renal function. Once daily dosing is likely to increase compliance, particularly in the hypertensive adolescent.",
"   </p>",
"   <p>",
"    The treatment of hypertension in children and adolescents is discussed separately in greater detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link\">",
"     \"Treatment of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OVERWEIGHT AND OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overweight and obesity are associated with accelerated atherosclerosis in childhood and increased risk of cardiovascular disease (CVD) in adults. Treatment for obesity in childhood is difficult and involves lifestyle changes at many levels. A multidisciplinary approach involving nutritional modification, behavioral counseling, and increased physical activity appears to increase the success rate of weight reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/11\">",
"     11",
"    </a>",
"    ]. The targeted body mass index (BMI) is ideally less than the 85",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age and gender. These issues are addressed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=see_link\">",
"     \"Management of childhood obesity in the primary care setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INSULIN RESISTANCE AND DIABETES MELLITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance, hyperinsulinemia, and elevated blood glucose are associated with atherosclerotic cardiovascular disease. In addition, children with diabetes mellitus are at increased risk for other atherogenic risk factors, such as hypertension and dyslipidemia.",
"   </p>",
"   <p>",
"    In adults and adolescents with type 1 diabetes mellitus, randomized trials have conclusively established that poor glycemic control is causally associated with long-term vascular sequelae. In addition, adult and adolescent clinical trials demonstrate that intensive insulin therapy resulting in hemoglobin A1C levels below 7 decreases the incidence of cardiovascular disease. As a result, intensive glycemic control is recommended for children and adolescents with type 1 diabetes with age-specific goals for AIC levels (",
"    <a class=\"graphic graphic_table graphicRef63148 \" href=\"UTD.htm?27/26/28076\">",
"     table 8",
"    </a>",
"    ). Similar recommendations are made for children with type 2 diabetes, particularly as these children are more commonly overweight and some believe their cardiovascular disease (CVD) risk may be higher. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=see_link\">",
"     \"Management of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because both type 1 and type 2 diabetes mellitus are associated with CVD, diabetic patients should be screened with a fasting lipid profile. Both the American Diabetes Association (ADA) and NHLBI guidelines recommend all children with diabetes and an elevated LDL-C should be treated with lifestyle changes affecting diet and level of activity with targeted levels that are &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef75008 \" href=\"UTD.htm?34/21/35164\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In our practice, we generally use a threshold of 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to initiate statin therapy in children with diabetes when there is inadequate response to nonpharmacologic measures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=see_link\">",
"     \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894561#H894561\">",
"     \"Management of pediatric dyslipidemia\", section on 'NHLBI expert panel criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SMOKE EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because smoke exposure, including second-hand smoke, increases the risk of cardiovascular disease (CVD), all patients and their close contacts who smoke should be counseled to quit smoking on a regular basis. A number of approaches, including behavioral therapy, nicotine replacement therapy, and other pharmacologic therapies are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41497?source=see_link\">",
"     \"Management of smoking cessation in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=see_link&amp;anchor=H7#H7\">",
"     \"Control of secondhand smoke exposure\", section on 'Pediatrics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ACTIVITY AND INACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence in both adults and children demonstrates that daily vigorous activity and reduction in sedentary behavior decreases the risk of cardiovascular disease (CVD) and improves fasting lipid profiles. The American Academy of Pediatrics (AAP) and the National Heart, Lung, and Blood Institute (NHLBI) expert panel recommend age-based daily activity for all children (",
"    <a class=\"graphic graphic_table graphicRef75748 \" href=\"UTD.htm?20/10/20653\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=see_link&amp;anchor=H5129625#H5129625\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\", section on 'Physical activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a child who has been inactive, we generally start at a lower intensity and frequency moving to the ultimate goal of at least 60 minutes of moderate to vigorous physical activity for most days of the week. The exercise regimen is increased gradually week by week to avoid setting unattainable goals. Directions on the expected exercise goals should be specific and clear to both the patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family.",
"   </p>",
"   <p>",
"    We also suggest limiting inactivity, in the form of screen time (eg, computer, video games, TV), to two hours or less per day.",
"   </p>",
"   <p>",
"    Physical activity and cardiovascular health in children and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=see_link&amp;anchor=H5129625#H5129625\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\", section on 'Physical activity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     HIGH-RISK DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific disease states are associated with early cardiovascular disease (CVD) and accelerated atherosclerosis. In a scientific statement from the American Heart Association (AHA), a panel of experts reviewed the literature on premature cardiovascular disease in children and established disease risk stratification schema for coronary artery disease (CAD), which was revised by the National Heart, Lung, and Blood Institute panel in 2011 (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &ndash; Pathologic or clinical evidence of CAD before 30 years of age in patients with high risk conditions that include types 1 and 2 diabetes mellitus, chronic kidney disease, heart transplant recipients, and Kawasaki disease with current coronary aneurysms.",
"     </li>",
"     <li>",
"      Moderate risk &ndash; Pathophysiologic evidence for accelerated atherosclerosis before 30 years of age in patients with moderate risk conditions that include Kawasaki disease with regressed coronary aneurysms, chronic inflammatory disease, HIV infection, and nephrotic syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to adults in whom multiple risk factors are considered in evaluation of risk for CVD, the following additional risk factors are considered when making treatment decisions (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal fasting lipid profile",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Increased body mass index",
"     </li>",
"     <li>",
"      Fasting blood glucose greater than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Smoke exposure",
"     </li>",
"     <li>",
"      Sedentary lifestyle",
"     </li>",
"     <li>",
"      Family history of early coronary artery disease defined as heart attack, treated angina, interventions for coronary artery disease, stroke, or sudden cardiac disease in a male parent or sibling before 55 years of age, or a female parent or sibling before 65 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of these patients should include treatment of both the underlying primary disease and of any comorbid cardiovascular risk factors. The decision to initiate treatment and the nature of intervention are dependent upon the assessment of the degree of CVD risk for the individual child based upon",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    underlying disease and the presence of comorbid conditions such as hypertension, dyslipidemia, overweight, and hyperglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"     \"Diseases associated with atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, the decision to initiate therapy to reduce the risk of cardiovascular disease (CVD) should be based upon an estimate of the absolute risk reduction and the potential risk of significant side effects of the therapeutic intervention. Although data are available to estimate the risk-benefit of intervention for individual adults, such information for children is not currently available. In particular, the decision to intervene in children with multiple risk factors is challenging because evidence is often indirect, and the desire to limit the use of multiple medications must be balanced against the benefits of global risk factor reduction. In addition, the thresholds for initiation of pharmacologic management of one risk factor may vary depending upon the severity of other risk factors, for example, the need for more stringent management of dyslipidemia in children with type I diabetes. Nonetheless, intervention is warranted in certain clinical circumstances, such as in children with high LDL levels, familial hypercholesterolemia, or severe hypertension. In summary, therapeutic choices are based on the medical judgment of care providers based upon the best available data and the clinical setting, and the preference of patients and their family. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our management approach is as follows and is consistent with the 2011 guidelines developed by the United States National Heart, Lung, and Blood Institute (NHLBI) expert panel based on the number of risk factors and their severity (ie, dyslipidemia, hypertension, and overweight) (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23320/abstract/5\">",
"     5",
"    </a>",
"    ]. Therapy includes nonpharmacologic and pharmacologic interventions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Counseling for weight reduction in overweight patients including dietary factors and increased physical activity. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Overweight and obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Promoting a healthy diet rich in vegetables, fruits and whole grains, and low in trans-fats (",
"      <a class=\"graphic graphic_table graphicRef64935 \" href=\"UTD.htm?11/33/11806\">",
"       table 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Counseling to foster increased activity to an ultimate goal of at least 60 minutes of moderate to vigorous physical activity for most days of the week and limiting screen time (eg, computer and television) to less than two hours a day. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Activity and inactivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Counseling for smoking cessation for patients or family members who smoke, and prevention of second-hand smoke exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41497?source=see_link\">",
"       \"Management of smoking cessation in adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"       \"Smoking cessation counseling strategies in primary care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=see_link&amp;anchor=H7#H7\">",
"       \"Control of secondhand smoke exposure\", section on 'Pediatrics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with an underlying disease associated with an increased risk of CVD, treatment of the primary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"       \"Diseases associated with atherosclerosis in childhood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of modifiable risk factors such as overweight, dyslipidemia, inactivity, and hypertension as discussed in the above sections, with the strength of the intervention based upon the severity of the child's condition and the existence of other comorbid conditions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dyslipidemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?4/35/4660?source=see_link\">",
"       \"Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale to treat children who are at risk for atherosclerosis, delaying the onset of the atherosclerotic process and by extension, cardiovascular disease (CVD), is based on evidence from large adult population studies and more limited pediatric data that demonstrate an association between premature atherosclerosis and modifiable cardiovascular risk factors. These risk factors include dyslipidemia, hypertension, overweight or obesity, insulin resistance and diabetes mellitus, and smoke exposure. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Rationale for intervention'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision of whether to initiate therapy for an individual child at risk for atherosclerosis is based upon an estimate of the global risk for that child and the potential risk of significant side effects of the therapeutic intervention. Therapy includes nonpharmacologic and pharmacologic interventions. The initiation and aggressiveness of the therapy are generally based upon the number of CVD risk factors and their severity (ie, dyslipidemia, hypertension, and overweight), and the preference of patients and their family. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Approach to therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our management approach is as follows and is consistent with the 2011 guidelines developed by the United States National Heart, Lung, and Blood Institute (NHLBI) expert panel:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Counseling to foster increased activity, weight reduction in overweight patients including dietary factors and increased physical activity, and smoking cessation for children or family members who smoke, and prevention of second-hand smoke exposure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Activity and inactivity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Overweight and obesity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Smoke exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an underlying disease associated with an increased risk of CVD, treatment of the primary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"       \"Diseases associated with atherosclerosis in childhood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic treatment may be considered in children with dyslipidemia and hypertension . The decision to initiate treatment is based on the extent of abnormality and the presence of other risk factors or conditions associated with CVD, such as types 1 and 2 diabetes mellitus (",
"      <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dyslipidemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children who have elevated blood pressure (BP), we suggest using the National High Blood Pressure Education Program Working Group guidelines for initiating treatment as follows (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pharmacologic therapy is started in children with severe hypertension (defined as BP levels that are 5 mmHg greater than the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age and gender), those who have hypertensive target-organ damage (eg, left ventricular hypertrophy), and those with diseases that are associated with a high risk of CVD and a blood pressure above the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age and gender.",
"     </li>",
"     <li>",
"      In the remaining patients with BP greater than the 90",
"      <sup>",
"       th",
"      </sup>",
"      percentile but less than the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile, nonpharmacologic therapy including diet and activity is initiated.",
"     </li>",
"     <li>",
"      If the BP persists above the targeted goal despite nonpharmacologic therapy, an antihypertensive medication is started. The targeted BP is lower in children with comorbid conditions such as obesity or dyslipidemia. The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Drug selection is usually left to the discretion of the clinician, who should consider the clinical setting and whether a particular class of drug may be more beneficial or cause more adverse effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link\">",
"       \"Treatment of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children with dyslipidemia, we suggest using the NHLBI guidelines for management of their lipid disorders as follows (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Non-pharmacologic therapy promoting healthy lifestyle changes is provided to all patients. This includes a diet high in fruits and vegetables (",
"      <a class=\"graphic graphic_table graphicRef78256 \" href=\"UTD.htm?3/49/3870\">",
"       table 2",
"      </a>",
"      ), and an exercise regimen of daily vigorous activity (",
"      <a class=\"graphic graphic_table graphicRef78256 \" href=\"UTD.htm?3/49/3870\">",
"       table 2",
"      </a>",
"      ). For children with high LDL-C, we recommend a low-saturated-fat, low trans-fat, low-cholesterol diet. For children with elevated TG levels, a diet low in refined carbohydrates and added sugars, and rich in unsaturated fats including omega-3 fatty acids is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894533#H894533\">",
"       \"Management of pediatric dyslipidemia\", section on 'Dietary modification'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894547#H894547\">",
"       \"Management of pediatric dyslipidemia\", section on 'Activity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If lifestyle counseling fails to reach the targeted goal by six months in children who are 10 years or older, we consider statin therapy. The decision to start pharmacologic therapy is based upon the severity of the child's dyslipidemia, the presence of other comorbid conditions (eg, diabetes or chronic kidney disease), family history of premature CVD (eg, homozygous FH), and the preferences of the child and family. The potential benefit of reduced CVD risk versus the unknown risk of long-term statin therapy is discussed with the family. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link\">",
"       \"Management of pediatric dyslipidemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/1\">",
"      Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/2\">",
"      American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007; 119:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/3\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/4\">",
"      Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/5\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     AAP statement of endorsement. Expert panel on integrated pediatric guideline for cardiovascular health and risk reduction. file://pediatrics.aappublications.org/content/early/2012/03/21/peds.2012-0210.full.pdf?papetoc=.",
"    </li>",
"    <li>",
"     Lipid Research Clinics Program. The Lipid Research Clinics Population Studies Data Book - Vol 1. Governement Printing Office; DHHS publication NO. (NIH) 80-1527, Washington, DC 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/8\">",
"      Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation 2006; 114:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/9\">",
"      American Academy of Pediatrics. Committee on Nutrition. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998; 101:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/10\">",
"      American Academy of Pediatrics Committee on Nutrition: Statement on cholesterol. Pediatrics 1992; 90:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23320/abstract/11\">",
"      Nemet D, Barkan S, Epstein Y, et al. Short- and long-term beneficial effects of a combined dietary-behavioral-physical activity intervention for the treatment of childhood obesity. Pediatrics 2005; 115:e443.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5753 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-0400165D70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23320=[""].join("\n");
var outline_f22_49_23320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DYSLIPIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OVERWEIGHT AND OBESITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INSULIN RESISTANCE AND DIABETES MELLITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SMOKE EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ACTIVITY AND INACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HIGH-RISK DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5753|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5753|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/51/43836\" title=\"table 1\">",
"      NHLBI pediatric definition of lipid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/49/3870\" title=\"table 2\">",
"      Pediatric diet to prevent CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/10/20653\" title=\"table 3\">",
"      Pediatric physical activity for CV health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/37/33371\" title=\"table 4\">",
"      Further NHLBI dietary modifications for elevated LDL-C in childr",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/45/7894\" title=\"table 5\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/46/7910\" title=\"table 6\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/33/11806\" title=\"table 7\">",
"      Pediatric version DASH diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/26/28076\" title=\"table 8\">",
"      Plasma glucose A1C goals age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/21/35164\" title=\"table 9\">",
"      ADA lipid guideline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=related_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41895?source=related_link\">",
"      Control of secondhand smoke exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=related_link\">",
"      Management of childhood obesity in the primary care setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=related_link\">",
"      Management of pediatric dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41497?source=related_link\">",
"      Management of smoking cessation in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36329?source=related_link\">",
"      Management of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/35/4660?source=related_link\">",
"      Patient information: Children and heart disease (atherosclerosis) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=related_link\">",
"      Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_49_23321="Respiratory physiologic changes following spinal cord injury";
var content_f22_49_23321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Respiratory physiologic changes following spinal cord injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23321/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23321/contributors\">",
"     Eric Garshick, MD, MOH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23321/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23321/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/49/23321/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23321/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/49/23321/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/49/23321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11614706\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of spinal cord injury (SCI) in the United States is estimated to be 40 cases per million population or approximately 12,000 new cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/1\">",
"     1",
"    </a>",
"    ]. Since 2005, the most frequent neurologic category of SCI at discharge has been incomplete quadriplegia (also known as tetraplegia) at 41 percent, followed by complete paraplegia at 22 percent, incomplete paraplegia at 21 percent, and complete quadriplegia at 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common causes of traumatic SCI are vehicular accidents (39 percent), falls (28 percent), gunshot wounds or other assaultive injuries (15 percent), and sports-related trauma (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/1\">",
"     1",
"    </a>",
"    ]. Causes of nontraumatic SCI include tumor, vascular disease, demyelinating spinal cord diseases, and spinal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/2\">",
"     2",
"    </a>",
"    ]. Respiratory failure is common after SCI and respiratory complications are among the most common causes of death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], particularly in the years following acute injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/5\">",
"     5",
"    </a>",
"    ] and in patients who have required mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCI results in physiologic changes that affect many organ systems. The changes in pulmonary physiology that occur following SCI will be reviewed here. The diagnosis and management of acute and chronic SCI and the management of the respiratory complications of SCI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link\">",
"     \"Acute traumatic spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=see_link\">",
"     \"Evaluation and acute management of cervical spinal column injuries in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087650\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF LEVEL AND COMPLETENESS OF SCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary physiologic changes that occur following SCI are related to the extent of neurologic impairment. The American Spinal Injury Association Impairment Scale (AIS) is used to classify the degree of impairment, based on strength in key muscles and on the sensory exam (",
"    <a class=\"graphic graphic_table graphicRef60383 \" href=\"UTD.htm?14/56/15243\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/8\">",
"     8",
"    </a>",
"    ]. A worksheet for assessing SCI is available through the American Spinal Cord Injury Association",
"    <span class=\"nowrap\">",
"     (file://www.asia-spinalinjury.org/publications/59544_sc_Exam_Sheet_r4.pdf).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute traumatic spinal cord injury\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient&rsquo;s strength in key muscle groups is assessed and graded. A muscle grade of",
"    <span class=\"nowrap\">",
"     5/5",
"    </span>",
"    is normal, and a grade of",
"    <span class=\"nowrap\">",
"     3/5",
"    </span>",
"    means the muscle can be moved against gravity. The motor level is defined as the most caudal key muscle that is graded",
"    <span class=\"nowrap\">",
"     3/5",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     4/5",
"    </span>",
"    with the segment cephalad to that level graded",
"    <span class=\"nowrap\">",
"     5/5.",
"    </span>",
"    The sensory level is defined as the most caudal dermatome to have normal sensation for both pinprick and light touch. For areas that lack key muscles to test, such as between T2 and L1, sensory findings are used to estimate motor levels.",
"   </p>",
"   <p>",
"    Complete motor SCI includes AIS A (no sensory or motor function preserved below the neurologic level) and AIS B (sensory but no motor function preserved below the neurologic level) (",
"    <a class=\"graphic graphic_table graphicRef60383 \" href=\"UTD.htm?14/56/15243\">",
"     table 1",
"    </a>",
"    ). Incomplete motor SCI includes AIS C where motor function in less than half of the key muscles below the neurologic level have a muscle grade less than 3, and for AIS D more than half the key muscles below the neurologic level have a muscle grade of 3 or more. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29060?source=see_link&amp;anchor=H5#H5\">",
"     \"Muscle examination in the evaluation of weakness\", section on 'Manual muscle strength testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With quadriplegia, there is injury to at least one of the eight cervical segments of the spinal cord; with paraplegia, there is injury in the thoracic, lumbar, or sacral regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087657\">",
"    <span class=\"h1\">",
"     PULMONARY PHYSIOLOGIC CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary physiologic changes following spinal cord injury include: (1) impairment of ventilatory muscle performance; (2) changes in lung and chest wall compliance; (3) changes in ventilatory control; and (4) airflow limitation and bronchial hyperresponsiveness. In describing the occurrence of these changes, it is useful to consider SCI in three phases: (1) immediately following the injury; (2) the year thereafter; and (3) more than one year after injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97774901\">",
"    <span class=\"h2\">",
"     Timing of changes in ventilatory function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after SCI, flaccid paralysis occurs and affects all muscles caudal to the level of injury, a physiologic state is known as spinal shock. Subsequent improvements in pulmonary function are due primarily to functional descent of the neurologic injury level as spinal cord inflammation resolves, enhanced recruitment of accessory ventilatory muscles, retraining of deconditioned muscles, and the evolution from flaccid to spastic paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. Starting from several days to up to four to six weeks, spinal reflexes return and eventually become exaggerated as the syndrome of spasticity develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute traumatic spinal cord injury\", section on 'Transient paralysis and spinal shock'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H21#H21\">",
"     \"Chronic complications of spinal cord injury\", section on 'Spasticity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The timing of respiratory failure was examined in 72 patients with traumatic cervical SCI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/14\">",
"     14",
"    </a>",
"    ]. Among those who required mechanical ventilation, 90 percent of the episodes of respiratory failure occurred within the first three days after SCI. Improvement in respiratory muscle performance after SCI largely occurs in the first year following injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/13,15-17\">",
"     13,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087664\">",
"    <span class=\"h2\">",
"     Impairment of ventilatory muscle function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of ventilatory muscle impairment depends upon the degree and location of the injury, as well as the duration of time since the injury. The higher the level and more complete the injury, the more likely that there will be respiratory muscle dysfunction. Ventilatory muscles innervated below the level of a complete SCI are completely nonfunctional (AIS A or B), while the degree of ventilatory muscle compromise is variable in patients with incomplete injuries (AIS C or D) (",
"    <a class=\"graphic graphic_table graphicRef60383 \" href=\"UTD.htm?14/56/15243\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H12087650\">",
"     'Assessment of level and completeness of SCI'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute traumatic spinal cord injury\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H2#H2\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H269784144\">",
"    <span class=\"h3\">",
"     Muscles of respiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major muscle that mediates inspiration is the diaphragm, which is innervated by the phrenic nerve (third to fifth cervical roots) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/18\">",
"     18",
"    </a>",
"    ]. Accessory muscles of inspiration are the external intercostals, clavicular portions of the pectoralis major, scalenes, and sternocleidomastoids. The external intercostals are innervated by thoracic nerve roots, while the scalenes are innervated by cervical nerve roots C4 to C8 and the sternocleidomastoid and trapezius muscles are innervated via C1 to C4 and also cranial nerve XI. Patients with high SCI can sometimes utilize oral, pharyngeal, and laryngeal muscles for short-term ventilation by projecting boluses of air past the glottis (glossopharyngeal breathing), although these muscles are not traditionally thought of as muscles of respiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=see_link&amp;anchor=H10#H10\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\", section on 'Glossopharyngeal breathing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The muscles of expiration are the abdominal wall muscles (rectus abdominus, obliques, and transversus abdominus), innervated by the lower thoracic and lumbar nerve roots, and the internal intercostals, innervated by the thoracic nerve roots. Normally, expiration is passive and does not require use of these muscles. However, these muscles are crucial when forced exhalation is needed, such as during exercise or coughing. When the ability to generate forced exhalation for coughing is impaired, removal of airway secretions is ineffective. In addition, these muscles contribute to normal function of the diaphragm in three important ways [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intercostal muscles help to stabilize the rib cage, preventing inward collapse of the rib cage during diaphragmatic contraction for inspiration. In patients with cervical or thoracic SCI, paralysis of the intercostal muscles leads to inward motion of the rib cage during inspiration, thus decreasing the volume of air inspired for a given amount of diaphragmatic work.",
"     </li>",
"     <li>",
"      The integrated abdominal wall and thoracic cage musculature act as a fulcrum against which the diaphragm can contract. Loss of this fulcrum effect reduces the efficiency of the diaphragm.",
"     </li>",
"     <li>",
"      Flaccid paralysis of the abdominal wall muscles leads to relocation of the abdominal contents caudad, away from the diaphragm. The diaphragm is less steeply domed and, therefore, less efficient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087671\">",
"    <span class=\"h3\">",
"     Injury above C3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete injury above C3 produces near total ventilatory muscle paralysis because the phrenic nerve, which innervates the diaphragm, arises from the third to fifth cervical roots. In addition, the intercostal, abdominal muscles, sternocleidomastoid, and trapezius muscles are denervated. Due to complete paralysis of the respiratory muscles, patients with SCI above the C3 root have acute ventilatory failure and do not survive unless manual ventilation is rapidly instituted at the accident scene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to ventilatory dysfunction, these patients are unable to cough without assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087678\">",
"    <span class=\"h3\">",
"     Injury at C3 through C5",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries involving C3 to C5 cause variable impairment of diaphragmatic strength and variable impairment of the accessory muscles of ventilation (eg, scalenes, sternocleidomastoid, trapezius). Respiratory failure requiring mechanical ventilation is common during the first few days to weeks after the injury, either due to respiratory muscle weakness and fatigue or precipitated by atelectasis or pneumonia. As the initial muscle flaccidity transitions to spasticity and accessory muscles are recruited and strengthened, spontaneous ventilation is often adequate for weaning from mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to ventilatory dysfunction, these patients have an impaired cough due to loss of expiratory muscle strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087685\">",
"    <span class=\"h3\">",
"     Injury at C6 through C8",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complete cervical SCI but with intact diaphragm function are able to inhale via the diaphragm and accessory muscles in the neck. Exhalation occurs primarily through the passive recoil of the chest wall and lungs, because the primary muscles of exhalation (internal intercostals and muscles of the abdominal wall) are paralyzed. The clavicular portions of the pectoralis major muscles provide only a small contribution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Thus, cough is impaired and even if these patients do not have initial respiratory failure, they are at an increased risk of respiratory muscle fatigue in the setting of respiratory system loading (eg, pneumonia or excess secretions) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/18,22,23,26\">",
"     18,22,23,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H269784144\">",
"     'Muscles of respiration'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087692\">",
"    <span class=\"h3\">",
"     Injuries of the thoracic spinal cord",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with injuries of the thoracic spinal cord have intact diaphragm function. Despite some loss of intercostal muscle strength and impaired stabilization of the rib cage due to abdominal wall paralysis, they have less impairment of overall ventilatory muscle function, as described below. (See",
"    <a class=\"local\" href=\"#H107204772\">",
"     'Other etiologies of PFT abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The main respiratory impairment for these patients is an inefficient cough mechanism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087706\">",
"    <span class=\"h2\">",
"     Changes in lung and chest wall compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung and chest wall compliance, when measured 1 to 12 months after SCI, is reduced in patients with quadriplegia, compared with normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/27\">",
"     27",
"    </a>",
"    ]. The decrease in compliance has been attributed to the accompanying reduction in lung volumes and possibly changes in surfactant that can occur with ventilation at reduced lung volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/17\">",
"     17",
"    </a>",
"    ]. Although the abdomen is highly compliant in quadriplegia, the rib cage compartment of the chest wall is stiff because of intercostal muscle spasticity and ankylosis of the rib articulations with the spine and sternum. It is believed that ankylosis of rib articulations results from an inability to inspire to total lung capacity due to inspiratory muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/17,27-30\">",
"     17,27-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21505275\">",
"    <span class=\"h2\">",
"     Airflow limitation and bronchial hyperresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects with quadriplegia demonstrate reversible expiratory airflow limitation, which is usually only apparent when a bronchodilator is administered, as the predominant abnormality is a restrictive ventilatory defect. Loss of postganglionic sympathetic innervation to the airways is a potential mechanism contributing to airflow limitation, although the functional significance of direct sympathetic airway innervation is thought to be minor or absent. The reversibility of this airflow limitation was demonstrated by the administration of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide, an anticholinergic agent, which caused an increase in expiratory airflow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This reversibility suggests that unopposed vagal cholinergic (bronchoconstrictor) activity also contributes to airflow limitation. An alternate explanation is reduced airway smooth muscle relaxation secondary to lack of inhalation to a normal total lung capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10186?source=see_link&amp;anchor=H6#H6\">",
"     \"Neuronal control of the airways\", section on 'Lower airways'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormalities of sympathetic or parasympathetic nervous system activity may also be responsible for airway hyperresponsiveness noted after SCI causing quadriplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20308912\">",
"     'Bronchial hyperresponsiveness and bronchodilator response'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087713\">",
"    <span class=\"h2\">",
"     Changes in ventilatory control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with quadriplegia have an abnormally small increase in ventilatory drive in response to hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As an example, a study of nine quadriplegic subjects and eight able-bodied controls found that the ventilatory response to hypercapnia among quadriplegics was approximately one-fourth that of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/38\">",
"     38",
"    </a>",
"    ]. The mechanism for a blunted response to hypercapnia is not fully explained by respiratory muscle weakness, as patients with comparable respiratory muscle weakness due to other causes do not exhibit the same blunted response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One hypothesis is that the blunted response is related to a decrease in blood pressure in the sitting position. This was examined in a study of 12 subjects with quadriplegia that found a normal ventilatory response to hypercapnia in the supine position and a reduced response in the sitting position [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/39\">",
"     39",
"    </a>",
"    ]. The ventilatory response was normal in the supine position, but decreased in the sitting position. The ventilatory response correlated better with blood pressure changes than with improved chest cage mechanics associated with the supine position.",
"   </p>",
"   <p>",
"    Sleep-disordered breathing has been reported in individuals with SCI and is predominantly obstructive or a combination of obstructive and central. Sleep-disordered breathing following SCI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087727\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF PULMONARY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the techniques for performing pulmonary function tests (PFTs) need to be modified in the presence of SCI. In addition, changes in respiratory muscle performance following SCI result in abnormal PFT results that can be predicted based on the level and completeness of SCI and other factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087741\">",
"    <span class=\"h2\">",
"     Technical considerations in measuring pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standardized techniques for performing PFTs and calculating predicted values need adjustment due to the practical challenges posed by SCI patients. As examples:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6983258\">",
"    <span class=\"h3\">",
"     Measurement of height",
"    </span>",
"    &nbsp;&mdash;&nbsp;Height is used to calculate predicted pulmonary function values in the able-bodied, but precise measurement of height in SCI patients can be problematic since most cannot stand. Since recalled height may be inaccurate, it is suggested that supine length, taking care to straighten contractures, be measured for use in the calculation of predicted pulmonary function values in SCI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/40\">",
"     40",
"    </a>",
"    ]. Arm span measurements appear less reliable than recalled height based on a study of 88 individuals with SCI; arm span was found to be less accurate and explained less variability in measured length (r",
"    <sup>",
"     2",
"    </sup>",
"    = 0.62) than recalled length (r",
"    <sup>",
"     2",
"    </sup>",
"    = 0.78) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6983298\">",
"    <span class=\"h3\">",
"     Use of modified ATS standards",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many SCI patients, particularly those with complete quadriplegia cannot meet the acceptability and reproducibility standards for spirometry set by the American Thoracic Society (ATS) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/41\">",
"     41",
"    </a>",
"    ]. ATS standards require that exhalation last for more than six seconds, but in a study of 278 adults with SCI, the most common reason for unacceptable trials was failure to exhale maximally for a minimum of six seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"     \"Office spirometry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H9#H9\">",
"     \"Office spirometry\", section on 'Forced expiratory volume in 6 seconds'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ATS criteria also require a prompt onset of exhalation, but subjects with complete quadriplegia are more likely than others with SCI to have a delay at the start of a forced expiratory maneuver, resulting in an excessive back-extrapolated volume. As an example, in a study of 278 adults with SCI, those with excessive back-extrapolated volume had a back-extrapolated volume of 7.4 percent of the forced vital capacity (FVC), which is higher than the ATS criterion of less than 5 percent of FVC or 150 mL, whichever is greater [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with expiratory muscle weakness appear to have reduced acceleration of the respiratory system at the onset of a forced expiratory effort, causing the slight delay.",
"   </p>",
"   <p>",
"    When ATS standards are modified to allow expiratory efforts less than six seconds, as long as a 0.5 second plateau is achieved (presumably at residual volume), and a greater degree of excessive back-extrapolated volume, as long as the volume-time curves and flow volume loops are otherwise acceptable, then the FVC and forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) are reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/42\">",
"     42",
"    </a>",
"    ]. This finding indicates that despite respiratory muscle weakness, the FVC and FEV",
"    <sub>",
"     1",
"    </sub>",
"    can be assessed longitudinally at all levels and neurologic completeness of SCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6983322\">",
"    <span class=\"h3\">",
"     Mouthpiece for pressure measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to achieve accurate measurement of maximal inspiratory and expiratory static pressures, the mouthpiece may need to be adjusted. Measurement of maximal inspiratory pressure after SCI is generally acceptable using a conventional mouthpiece with a flange that fits inside the mouth (",
"    <a class=\"graphic graphic_picture graphicRef51651 \" href=\"UTD.htm?13/45/14047\">",
"     picture 1",
"    </a>",
"    ). However, measurement of maximal expiratory pressure muscle with a flange style mouthpiece results in the underestimation of maximal expiratory respiratory muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/43\">",
"     43",
"    </a>",
"    ]. For reliable results, a tube style mouthpiece that fits outside and around the mouth should be substituted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/43\">",
"     43",
"    </a>",
"    ]. In our laboratory, we construct this out of rubber tubing to fit over the outside of the mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link&amp;anchor=H2#H2\">",
"     \"Tests of respiratory muscle strength\", section on 'Technique'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19500523\">",
"    <span class=\"h2\">",
"     Effect of posture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posture has a significant impact upon lung mechanics in the majority of patients with SCI. Typically, individuals with SCI have an increase in vital capacity (VC) when changing from a seated to supine position, whereas the normal response to recumbency is a slight decrease in VC. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 14 patients with quadriplegia (C4-C7), the mean increase in VC was 0.41 L (16 percent of the seated value) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 74 patients with SCI, the forced vital capacity (FVC) and forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) were larger in the supine compared with the seated posture down to an injury level of T1 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/45\">",
"       45",
"      </a>",
"      ]. Smaller postural differences were observed in this study, possibly due to the inclusion of persons with both complete and incomplete SCI. Among those with quadriplegia, the mean FVC was 2.87 L when supine and 2.7 L when seated, and mean FEV",
"      <sub>",
"       1",
"      </sub>",
"      values were 2.41 L and 2.36 L, respectively. The expiratory reserve volume (ERV) decreased in the supine position and the inspiratory capacity (IC) increased proportionally more than the VC (2.21 L when seated and 2.56 L when supine).",
"     </li>",
"     <li>",
"      In eight patients with C4 to C7 motor complete quadriplegia, the mean IC increased significantly from the seated (1.34 L) to the tilted (1.61 L) and the supine (2.14 L) position, with no significant change in total lung capacity (TLC) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/20\">",
"       20",
"      </a>",
"      ]. Mean functional residual capacity (FRC) decreased progressively (by approximately 1 liter) from the seated (3.11 L) to the tilted (2.74 L) and the supine (2.15 L) position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A change from the seated to the supine position results in a decrease in FRC because the abdominal contents push upon the diaphragm. However, the muscle fibers of the diaphragm are longer at end expiration when supine and, thus, at a more favorable portion of their length-tension curve, resulting in a greater downward (caudad) excursion of the diaphragm during inspiration. Together, these effects result in an improved IC and VC when supine. On the other hand, gas exchange abnormalities are more likely in the supine position due to airway closure and any atelectasis that could arise from tidal breathing at lower respiratory system volumes (at a reduced FRC). When choosing a position to optimize respiratory system function, the advantage of a greater VC and IC must be weighed against the possibility of gas exchange problems due to airway closure and atelectasis (eg, arising from tidal breathing at lower respiratory system volumes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087755\">",
"    <span class=\"h2\">",
"     Expected values for spirometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three cross sectional studies of large cohorts have assessed spirometry in patients several years after SCI and temporally distant from any acute illness. These studies included 216 adults from the Bronx Veterans Affairs hospital, 239 from the Rancho Los Amigos National Rehabilitation Center in Los Angeles, and 339 veterans and nonveterans recruited from the surrounding community at the Boston Veterans Affairs Medical Center [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. The results of these studies are summarized here.",
"   </p>",
"   <p>",
"    The VA Boston study assessed the cross-sectional effect of a wide range of clinical factors on forced vital capacity (FVC), forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), and",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio. In this study, adjusting for stature and neurologic level and completeness of SCI, lower FEV",
"    <sub>",
"     1",
"    </sub>",
"    values were significantly related to greater age, greater years since injury (-6",
"    <span class=\"nowrap\">",
"     mL/yr),",
"    </span>",
"    greater lifetime cigarette smoking (pack years), previous chest injury or operation, a history of clinician-diagnosed asthma, self-report of wheeze (using a standardized respiratory symptom questionnaire), and a lower maximum inspiratory pressure. The cross-sectional effect of age on FEV",
"    <sub>",
"     1",
"    </sub>",
"    was similar to that observed in studies describing the effects of age in the able-bodied. The effect of years since injury on FEV",
"    <sub>",
"     1",
"    </sub>",
"    was greatest in the weakest persons with quadriplegia (ASIA A and C group, -12",
"    <span class=\"nowrap\">",
"     mL/year).",
"    </span>",
"    In addition, a reduction in",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    was associated with older age, greater lifetime cigarette smoking (pack years), previous chest injury or operation, self-report of wheeze, and a greater body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Bronx VA study, smoking resulted in a reduction in",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    in patients with quadriplegia and paraplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In the Los Angeles cohort, a consistent effect of current smoking was not observed, but a greater number of years since injury was associated with a reduction in FEV",
"    <sub>",
"     1",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After determining the factors other than SCI that affect spirometry results following SCI, the mean values for FEV",
"    <sub>",
"     1",
"    </sub>",
"    , FVC, and",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    in the Boston cohort were adjusted to determine the expected impairment based on neurologic level and completeness of SCI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/48\">",
"     48",
"    </a>",
"    ]. The adjusted mean values (95% confidence intervals) for FEV",
"    <sub>",
"     1",
"    </sub>",
"    and FVC in C4 to C5 complete motor cervical SCI were 55 percent (49 percent to 61 percent) and 53 percent (47 percent to 59 percent) of predicted values, respectively; 65 percent (60 percent to 70 percent) and 64 percent (59 percent to 68 percent) of predicted values, in C6 to C8 complete motor cervical SCI; and 80 percent (76 percent to 84 percent) and 78 percent (74 percent to 81 percent) of predicted values in T1 to T6 paraplegia. The",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio decreased with lower SCI levels in complete injury. Similar to the Los Angeles and Bronx cohorts, the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    was greater in quadriplegics than in paraplegics. The relationship between",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    and SCI level in complete SCI may be attributed to a reduction in expiratory flow during a forced exhalation due to weaker expiratory muscles and a lower driving pressure causing less dynamic compression of airways and subsequently less increase in resistance. Therefore, the",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    in persons with the weakest expiratory muscles (such as in quadriplegia and high paraplegia) is expected to be less sensitive to factors usually associated with changes in airway size (such as smoking) and may not reliably detect the severity of airflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087769\">",
"    <span class=\"h2\">",
"     Expected values for lung volumes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with complete cervical SCI will have a restrictive ventilatory defect (decreased total lung capacity [TLC] and FVC). The functional residual capacity (FRC) and expiratory reserve volume (ERV) are also reduced, but the residual volume (RV) is increased. The decreases in TLC, FRC, and ERV are attributable to inspiratory muscle weakness, while the increase in RV is due to expiratory muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=see_link\">",
"     \"Reference values for pulmonary function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the VA Boston study described above, the values for TLC, FRC, RV, and ERV were assessed and compared with the neurologic level and completeness of SCI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/49\">",
"     49",
"    </a>",
"    ]. These data may be used to estimate the expected average effects of SCI on lung volumes for individuals with SCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among subjects with complete SCI, the mean percent-predicted values for high and low cervical SCI were 74 to 78 for TLC, 75 to 79 for FRC, 106 to 112 for RV, and 31 to 32 for ERV, respectively.",
"     </li>",
"     <li>",
"      Among subjects with incomplete cervical SCI, the mean percent-predicted values for TLC, FRC, and RV were normal, but ERV was moderately reduced.",
"     </li>",
"     <li>",
"      Among subjects with complete or incomplete thoracic SCI, the mean percent-predicted values for TLC, FRC, and RV were normal, but ERV was mildly reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Greater body mass index (BMI) was significantly associated with a linear decrease in TLC, FRC, RV, and ERV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/49\">",
"     49",
"    </a>",
"    ]. Greater time since injury was also associated with decreases in TLC, FRC, RV, and ERV (range, -8 to -18",
"    <span class=\"nowrap\">",
"     mL/year).",
"    </span>",
"    Age was not a significant predictor of TLC once time since injury was included in the multivariate regression model. Greater lifetime smoking was associated with increased FRC and RV, and a history of COPD was associated with a greater RV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107204859\">",
"    <span class=\"h2\">",
"     Longitudinal assessment of pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series have observed that after SCI, the greatest rate of improvement in pulmonary function occurs in the first three months and is followed by further more gradual improvement up to about one year following the initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/12,13,16,18\">",
"     12,13,16,18",
"    </a>",
"    ]. Over the next many years, a gradual decline in pulmonary function is observed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 36 subjects with quadriplegia, the greatest rate of improvement in vital capacity (VC) occurred during the first three months with slower subsequent improvement up to 10 months; the overall increase was from 45 to 58 percent of predicted [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 12 subjects with motor complete injuries (including eight cervical), there was a mean improvement in forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) from 1.82 L to 2.54 L and in FVC from 2.03 L to 2.69 L between 90 days and 210 days after injury [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among five subjects with motor complete quadriplegia studied within 47 days of injury and followed for up to a year, there was an increase inspiratory capacity (1.84 L to 2.71 L) and expiratory reserve volume (0.11 L to 0.27 L) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to directly assess factors associated with longitudinal changes pulmonary function, 174 patients with chronic SCI in the VA Boston cohort described above underwent repeated measurement of FVC and FEV",
"    <sub>",
"     1",
"    </sub>",
"    over an average follow-up time of 7.5 years (range: 4 to 14 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/50\">",
"     50",
"    </a>",
"    ]. Neurologic level and completeness of SCI was not a direct determinant of longitudinal decline in FVC and FEV",
"    <sub>",
"     1",
"    </sub>",
"    . However, declines in FVC and FEV",
"    <sub>",
"     1",
"    </sub>",
"    were related to continued smoking, persistent wheeze, an increase in body mass index, a greater degree of respiratory muscle weakness (assessed by measurement of maximal inspiratory pressure), and the effects of aging. The effects of aging were similar to those noted in the able-bodied.",
"   </p>",
"   <p>",
"    A borderline effect of greater injury duration on decline in FEV",
"    <sub>",
"     1",
"    </sub>",
"    was noted in persons with more severe injury, ie, cervical SCI that was motor complete (AIS A and B) or motor incomplete AIS C. It has been hypothesized that the effect of greater injury duration on pulmonary function is attributable to a slow but progressive decrease in lung and rib cage compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. In contrast to the effect of injury duration noted in the cross-sectional assessment of FEV",
"    <sub>",
"     1",
"    </sub>",
"    described above, the borderline significance of this effect in the longitudinal study may be caused by the slow rate of change of lung and rib cage compliance relative to the duration of follow-up testing. These results suggest a model in which neurological completeness and level of injury account for a reduction in the level of FEV",
"    <sub>",
"     1",
"    </sub>",
"    and FVC (ie, assessed cross-sectionally), but do not appreciably influence longitudinal decline. Therefore, longitudinal change in FEV",
"    <sub>",
"     1",
"    </sub>",
"    and FVC in chronic SCI appears to be related to age and potentially modifiable factors, such as cigarette smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107204725\">",
"    <span class=\"h2\">",
"     Maximal inspiratory and expiratory pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, when the level of SCI is below C5 and thus spares the phrenic nerve, maximal expiratory force is impaired more than maximal inspiratory pressure, which remains within the normal range. In the VA Boston study, a greater maximal inspiratory pressure (MIP), as an indicator of respiratory muscle performance, was associated with greater total lung capacity (TLC) and was inversely related to residual volume (RV) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12087664\">",
"     'Impairment of ventilatory muscle function'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20308912\">",
"    <span class=\"h2\">",
"     Bronchial hyperresponsiveness and bronchodilator response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with quadriplegia, but not with low paraplegia, demonstrate airways hyperreactivity on bronchoprovocation testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , histamine, and ultrasonically nebulized distilled water [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The etiology and clinical significance of this finding remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21505275\">",
"     'Airflow limitation and bronchial hyperresponsiveness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Approximately, 40 to 50 percent of SCI patients exhibit significant responses to bronchodilator administration, even in the absence of demonstrable airflow limitation at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. However, the clinical benefit of routine use of bronchodilators to maximize the pulmonary function of individuals with quadriplegia, but no history of asthma or COPD, has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107204772\">",
"    <span class=\"h2\">",
"     Other etiologies of PFT abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;When interpreting pulmonary function test (PFT) results in an individual with SCI, it is important to remember that factors other than neurologic level and completeness of injury can affect pulmonary function. These other factors include cigarette smoking, obesity, other chest trauma sustained at the time of the SCI, and co-morbidities such as asthma, chronic obstructive pulmonary disease (COPD), and tracheal stenosis from prior intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/49/23321/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20308989\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary physiologic changes due to spinal cord injury (SCI) are related to the extent of neurological impairment. The American Spinal Injury Association Impairment Scale (AIS) is used to classify the degree of impairment that is based on strength in key muscles and on a sensory exam (",
"      <a class=\"graphic graphic_table graphicRef60383 \" href=\"UTD.htm?14/56/15243\">",
"       table 1",
"      </a>",
"      ). A worksheet for assessing SCI is available through the American Spinal Cord Injury Association",
"      <span class=\"nowrap\">",
"       (file://www.asia-spinalinjury.org/publications/59544_sc_Exam_Sheet_r4.pdf).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12087650\">",
"       'Assessment of level and completeness of SCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediately after SCI, flaccid paralysis affects all muscles caudal to the level of injury (also known as spinal shock). Subsequent improvements in pulmonary function are due primarily to functional descent of the neurologic injury level as spinal cord inflammation resolves, enhanced recruitment of accessory ventilatory muscles, retraining of deconditioned muscles, and the evolution from flaccid to spastic paralysis. (See",
"      <a class=\"local\" href=\"#H97774901\">",
"       'Timing of changes in ventilatory function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of ventilatory muscle impairment depends upon the degree and location of the injury, as well as the duration of time since the injury. The higher the level and more complete the injury, the more likely that there will be respiratory muscle dysfunction. Complete injury above C3 produces near total ventilatory muscle paralysis because the phrenic nerve, which innervates the diaphragm, arises from the third to fifth cervical roots. (See",
"      <a class=\"local\" href=\"#H12087664\">",
"       'Impairment of ventilatory muscle function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Posture has a significant impact upon lung mechanics in the majority of patients with SCI. Typically, individuals with SCI have an increase in vital capacity (VC) when changing from a seated to supine position, whereas the normal response to recumbency is a slight decrease in VC. (See",
"      <a class=\"local\" href=\"#H12087741\">",
"       'Technical considerations in measuring pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of supine length is preferred over arm-span or recalled standing height for use in the calculation of predicted pulmonary function values for persons with SCI. (See",
"      <a class=\"local\" href=\"#H6983258\">",
"       'Measurement of height'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When obtaining spirometry, American Thoracic Society (ATS) standards may need to be modified to accept expiratory efforts less than six seconds in duration, as long as a 0.5 second plateau is achieved (presumably at residual volume), and a greater degree of back-extrapolated volume (eg, ~7.5 percent of forced vital capacity), when volume-time curves and flow volume loops are otherwise acceptable. (See",
"      <a class=\"local\" href=\"#H6983298\">",
"       'Use of modified ATS standards'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among individuals with chronic cervical cord injury, spirometry typically shows a restrictive ventilatory defect with FVC and FEV",
"      <sub>",
"       1",
"      </sub>",
"      values approximately 55 percent of the values predicted for able-bodied subjects. (See",
"      <a class=\"local\" href=\"#H12087755\">",
"       'Expected values for spirometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung volumes following complete cervical cord injury show a marked reduction in expiratory volume (ERV), a mild to moderate reduction in total lung capacity (TLC) and functional reserve volume (FRC), and preservation of residual volume (RV). The main lung volume abnormality after incomplete cervical or thoracic SCI is a moderate reduction in ERV. (See",
"      <a class=\"local\" href=\"#H12087769\">",
"       'Expected values for lung volumes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Greater lifetime cigarette smoking (pack years) is associated with lower values for FVC and FEV",
"      <sub>",
"       1",
"      </sub>",
"      both initially after SCI and during long-term follow-up. (See",
"      <a class=\"local\" href=\"#H12087755\">",
"       'Expected values for spirometry'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H107204859\">",
"       'Longitudinal assessment of pulmonary function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, when the level of SCI is below C5 and thus spares the phrenic nerve, maximal expiratory force is impaired more than maximal inspiratory pressure, which remains within the normal range. (See",
"      <a class=\"local\" href=\"#H107204725\">",
"       'Maximal inspiratory and expiratory pressures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subjects with quadriplegia may demonstrate mild expiratory airflow limitation, which only becomes apparent during reversibility testing with inhaled bronchodilators such as beta2-agonists and the anticholinergic agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      bromide. However, the clinical benefit regarding the routine use of bronchodilators in quadriplegia for purposes of maximizing pulmonary function has not been established. (See",
"      <a class=\"local\" href=\"#H21505275\">",
"       'Airflow limitation and bronchial hyperresponsiveness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20308912\">",
"       'Bronchial hyperresponsiveness and bronchodilator response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Spinal Cord Injury Statistical Center. Spinal Cord Injury Facts and Figures at a Glance. https://www.nscisc.uab.edu/PublicDocuments/fact_figures_docs/Facts%202012%20Feb%20Final.pdf (Accessed on October 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/2\">",
"      Ho CH, Wuermser LA, Priebe MM, et al. Spinal cord injury medicine. 1. Epidemiology and classification. Arch Phys Med Rehabil 2007; 88:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/3\">",
"      Hartkopp A, Br&oslash;nnum-Hansen H, Seidenschnur AM, Biering-S&oslash;rensen F. Survival and cause of death after traumatic spinal cord injury. A long-term epidemiological survey from Denmark. Spinal Cord 1997; 35:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/4\">",
"      Lidal IB, Snekkevik H, Aamodt G, et al. Mortality after spinal cord injury in Norway. J Rehabil Med 2007; 39:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/5\">",
"      Kirshblum SC, Waring W, Biering-Sorensen F, et al. Reference for the 2011 revision of the International Standards for Neurological Classification of Spinal Cord Injury. J Spinal Cord Med 2011; 34:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/6\">",
"      Shavelle RM, DeVivo MJ, Strauss DJ, et al. Long-term survival of persons ventilator dependent after spinal cord injury. J Spinal Cord Med 2006; 29:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/7\">",
"      Watt JW, Wiredu E, Silva P, Meehan S. Survival after short- or long-term ventilation after acute spinal cord injury: a single-centre 25-year retrospective study. Spinal Cord 2011; 49:404.",
"     </a>",
"    </li>",
"    <li>",
"     American Spinal Injury Association. International standards for neurological classification of spinal cord injury (revised 2000), ASIA, Chicago 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/9\">",
"      McMichan JC, Michel L, Westbrook PR. Pulmonary dysfunction following traumatic quadriplegia. Recognition, prevention, and treatment. JAMA 1980; 243:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/10\">",
"      Ledsome JR, Sharp JM. Pulmonary function in acute cervical cord injury. Am Rev Respir Dis 1981; 124:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/11\">",
"      Wicks AB, Menter RR. Long-term outlook in quadriplegic patients with initial ventilator dependency. Chest 1986; 90:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/12\">",
"      Axen K, Pineda H, Shunfenthal I, Haas F. Diaphragmatic function following cervical cord injury: neurally mediated improvement. Arch Phys Med Rehabil 1985; 66:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/13\">",
"      Haas F, Axen K, Pineda H, et al. Temporal pulmonary function changes in cervical cord injury. Arch Phys Med Rehabil 1985; 66:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/14\">",
"      Claxton AR, Wong DT, Chung F, Fehlings MG. Predictors of hospital mortality and mechanical ventilation in patients with cervical spinal cord injury. Can J Anaesth 1998; 45:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/15\">",
"      Mueller G, de Groot S, van der Woude L, Hopman MT. Time-courses of lung function and respiratory muscle pressure generating capacity after spinal cord injury: a prospective cohort study. J Rehabil Med 2008; 40:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/16\">",
"      Bluechardt MH, Wiens M, Thomas SG, Plyley MJ. Repeated measurements of pulmonary function following spinal cord injury. Paraplegia 1992; 30:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/17\">",
"      Brown R, DiMarco AF, Hoit JD, Garshick E. Respiratory dysfunction and management in spinal cord injury. Respir Care 2006; 51:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/18\">",
"      Derenne JP, Macklem PT, Roussos C. The respiratory muscles: mechanics, control, and pathophysiology. Am Rev Respir Dis 1978; 118:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/19\">",
"      Urmey W, Loring S, Mead J, et al. Upper and lower rib cage deformation during breathing in quadriplegics. J Appl Physiol 1986; 60:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/20\">",
"      McCool FD, Pichurko BM, Slutsky AS, et al. Changes in lung volume and rib cage configuration with abdominal binding in quadriplegia. J Appl Physiol 1986; 60:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/21\">",
"      Banzett RB, Inbar GF, Brown R, et al. Diaphragm electrical activity during negative lower torso pressure in quadriplegic men. J Appl Physiol 1981; 51:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/22\">",
"      Mortola JP, Sant'Ambrogio G. Motion of the rib cage and the abdomen in tetraplegic patients. Clin Sci Mol Med 1978; 54:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/23\">",
"      Moulton A, Silver JR. Chest movements in patients with traumatic injuries of the cervical cord. Clin Sci 1970; 39:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/24\">",
"      De Troyer A, Estenne M, Heilporn A. Mechanism of active expiration in tetraplegic subjects. N Engl J Med 1986; 314:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/25\">",
"      Estenne M, Knoop C, Vanvaerenbergh J, et al. The effect of pectoralis muscle training in tetraplegic subjects. Am Rev Respir Dis 1989; 139:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/26\">",
"      Manning H, McCool FD, Scharf SM, et al. Oxygen cost of resistive-loaded breathing in quadriplegia. J Appl Physiol 1992; 73:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/27\">",
"      Scanlon PD, Loring SH, Pichurko BM, et al. Respiratory mechanics in acute quadriplegia. Lung and chest wall compliance and dimensional changes during respiratory maneuvers. Am Rev Respir Dis 1989; 139:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/28\">",
"      Goldman JM, Williams SJ, Denison DM. The rib cage and abdominal components of respiratory system compliance in tetraplegic patients. Eur Respir J 1988; 1:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/29\">",
"      Estenne M, De Troyer A. The effects of tetraplegia on chest wall statics. Am Rev Respir Dis 1986; 134:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/30\">",
"      Goldman JM, Rose LS, Morgan MD, Denison DM. Measurement of abdominal wall compliance in normal subjects and tetraplegic patients. Thorax 1986; 41:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/31\">",
"      Almenoff PL, Alexander LR, Spungen AM, et al. Bronchodilatory effects of ipratropium bromide in patients with tetraplegia. Paraplegia 1995; 33:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/32\">",
"      Schilero GJ, Grimm DR, Bauman WA, et al. Assessment of airway caliber and bronchodilator responsiveness in subjects with spinal cord injury. Chest 2005; 127:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/33\">",
"      Spungen AM, Dicpinigaitis PV, Almenoff PL, Bauman WA. Pulmonary obstruction in individuals with cervical spinal cord lesions unmasked by bronchodilator administration. Paraplegia 1993; 31:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/34\">",
"      Schilero GJ, Spungen AM, Bauman WA, et al. Pulmonary function and spinal cord injury. Respir Physiol Neurobiol 2009; 166:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/35\">",
"      Radulovic M, Schilero GJ, Wecht JM, et al. Airflow obstruction and reversibility in spinal cord injury: evidence for functional sympathetic innervation. Arch Phys Med Rehabil 2008; 89:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/36\">",
"      Grimm DR, Chandy D, Almenoff PL, et al. Airway hyperreactivity in subjects with tetraplegia is associated with reduced baseline airway caliber. Chest 2000; 118:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/37\">",
"      BERGOFSKY EH. MECHANISM FOR RESPIRATORY INSUFFICIENCY AFTER CERVICAL CORD INJURY; A SOURCE OF ALVEOLAR HYPOVENTILATION. Ann Intern Med 1964; 61:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/38\">",
"      Manning HL, Brown R, Scharf SM, et al. Ventilatory and P0.1 response to hypercapnia in quadriplegia. Respir Physiol 1992; 89:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/39\">",
"      Ben-Dov I, Zlobinski R, Segel MJ, et al. Ventilatory response to hypercapnia in C(5-8) chronic tetraplegia: the effect of posture. Arch Phys Med Rehabil 2009; 90:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/40\">",
"      Garshick E, Ashba J, Tun CG, et al. Assessment of stature in spinal cord injury. J Spinal Cord Med 1997; 20:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/41\">",
"      Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/42\">",
"      Kelley A, Garshick E, Gross ER, et al. Spirometry testing standards in spinal cord injury. Chest 2003; 123:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/43\">",
"      Tully K, Koke K, Garshick E, et al. Maximal expiratory pressures in spinal cord injury using two mouthpieces. Chest 1997; 112:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/44\">",
"      Estenne M, De Troyer A. Mechanism of the postural dependence of vital capacity in tetraplegic subjects. Am Rev Respir Dis 1987; 135:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/45\">",
"      Baydur A, Adkins RH, Milic-Emili J. Lung mechanics in individuals with spinal cord injury: effects of injury level and posture. J Appl Physiol 2001; 90:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/46\">",
"      Almenoff PL, Spungen AM, Lesser M, Bauman WA. Pulmonary function survey in spinal cord injury: influences of smoking and level and completeness of injury. Lung 1995; 173:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/47\">",
"      Linn WS, Spungen AM, Gong H Jr, et al. Smoking and obstructive lung dysfunction in persons with chronic spinal cord injury. J Spinal Cord Med 2003; 26:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/48\">",
"      Jain NB, Brown R, Tun CG, et al. Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury. Arch Phys Med Rehabil 2006; 87:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/49\">",
"      Stepp EL, Brown R, Tun CG, et al. Determinants of lung volumes in chronic spinal cord injury. Arch Phys Med Rehabil 2008; 89:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/50\">",
"      Stolzmann KL, Gagnon DR, Brown R, et al. Longitudinal change in FEV1 and FVC in chronic spinal cord injury. Am J Respir Crit Care Med 2008; 177:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/51\">",
"      Dicpinigaitis PV, Spungen AM, Bauman WA, et al. Bronchial hyperresponsiveness after cervical spinal cord injury. Chest 1994; 105:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/52\">",
"      Grimm DR, Arias E, Lesser M, et al. Airway hyperresponsiveness to ultrasonically nebulized distilled water in subjects with tetraplegia. J Appl Physiol 1999; 86:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/49/23321/abstract/53\">",
"      Singas E, Lesser M, Spungen AM, et al. Airway hyperresponsiveness to methacholine in subjects with spinal cord injury. Chest 1996; 110:911.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5119 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23321=[""].join("\n");
var outline_f22_49_23321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20308989\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11614706\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12087650\">",
"      ASSESSMENT OF LEVEL AND COMPLETENESS OF SCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12087657\">",
"      PULMONARY PHYSIOLOGIC CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97774901\">",
"      Timing of changes in ventilatory function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12087664\">",
"      Impairment of ventilatory muscle function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H269784144\">",
"      - Muscles of respiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12087671\">",
"      - Injury above C3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12087678\">",
"      - Injury at C3 through C5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12087685\">",
"      - Injury at C6 through C8",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12087692\">",
"      - Injuries of the thoracic spinal cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12087706\">",
"      Changes in lung and chest wall compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21505275\">",
"      Airflow limitation and bronchial hyperresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12087713\">",
"      Changes in ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12087727\">",
"      ASSESSMENT OF PULMONARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12087741\">",
"      Technical considerations in measuring pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6983258\">",
"      - Measurement of height",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6983298\">",
"      - Use of modified ATS standards",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6983322\">",
"      - Mouthpiece for pressure measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19500523\">",
"      Effect of posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12087755\">",
"      Expected values for spirometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12087769\">",
"      Expected values for lung volumes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107204859\">",
"      Longitudinal assessment of pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107204725\">",
"      Maximal inspiratory and expiratory pressures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20308912\">",
"      Bronchial hyperresponsiveness and bronchodilator response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107204772\">",
"      Other etiologies of PFT abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20308989\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/5119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5119|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/45/14047\" title=\"picture 1\">",
"      Flanged mouthpiece for pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5119|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/56/15243\" title=\"table 1\">",
"      Spinal cord injury grading scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/34/31274?source=related_link\">",
"      Evaluation and acute management of cervical spinal column injuries in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29060?source=related_link\">",
"      Muscle examination in the evaluation of weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10186?source=related_link\">",
"      Neuronal control of the airways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9141?source=related_link\">",
"      Reference values for pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=related_link\">",
"      Respiratory complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=related_link\">",
"      Spinal column injuries in adults: Definitions, mechanisms, and radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_49_23322="Tendon xanthomata";
var content_f22_49_23322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52572%7EPC%2F50109%7EPC%2F71083%7EPC%2F67239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52572%7EPC%2F50109%7EPC%2F71083%7EPC%2F67239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tendon xanthomata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tendon xanthomata on the dorsum of the hand in a patient with heterozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achilles tendon xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A xanthoma of the Achilles tendon in a patient with heterozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subperiosteal xanthomata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 386px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGCAQoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5z3jseMcc/WlViBuzhQcZpg+7jHB7fnQoPO0nHTGaCjQsXInGx8c8+4r0Dw5Kco5YkDHzc46c1wVlGdqF8Y9hziu18ORGSPYxAGeikZ/CtFtsXG53bzRtpy7SRtUs2c4P+3+FcneT7mKyRlGXkMBjI5+br1PWteaQQ2pX5TkDJCgDIA/SsK9Ia5McYG3I3bsEZyf0zUp3djVKyLFnLF5jSTKgBUD6dMf41tWMkDSkLGI2U5fGPyFYFiEZuTuVG+6cfj2/nWva4SctEpRF5JxuKjPQ/wCe9EvI0jfqdSjZtiqDaGxu8sgYGO1dBZqjSBzkgN1BHLZ/lXJ6bN9xEyNwyytnKj1BrrbBUK7GLqAeQPXP3f61zz3Lbtob+nRlBl32nORj15/StaHyossM/P365Fc/azmFfLYjnqCSfX5fpWjBMssjPEWLNgKcZGayaRk7sv2R2SOcHJ/HA5xV/TSis2UCnOeP4eOmawluTBI0jqx8tvugZ3HufpVnzQ+yS3cqmN3Pfj0qeoNXOnEzGNPk28DIPI+lNnGDwCQeMj+VVIrpWxu6kcfNVoSARl3GVAOM0dNzG+uw1w4k+VQkeDnB5rNmv/3uyWMncflJGQeO9Wbl2ZGlViqAEc+uKzLiPzCDISG7jHUdql6GkLdScypM+SVKHIUvjPXvVTU7SF7ZcbUUHIPH/fX1qtPNKkjFduTyCOj4P9Kzbq+kywZgrbtwYrkE+ppOzOiMWmrEU91EqsCpD54JOAOnf3psBiMaKX8wD7u0g4XJ+X6ms1b1EAa7cBpGbY4HymnRvFGwKPsZzlHHOBk8/WpVnZnQ00ayyRC0MhRCo6qg56cAVBc3O4oVAkEhBY4I3Htis6+nEcKouUk6nBx2+8Pc1XubrfDErfITjLDsPQVS1ElfU3Z5VEUnVyRwSTknHT2ArnpWHl4Z8tG5IB+v3s+w6VJLdI/mnfhgnYg8YzWReXexjGB+8HzZGCCcjp7UNX1LgmtDPeRobuZg24OpcEnHGD8/XrWBdXxkvHYMvzH+LHAyP1NWtSnZpJV3HBOTgY5x29qwbtiPmyNyg9//AK1C30OhkF5euZD8oAA4x6VkvIxl8wkYLAKDjp2/+vRO5crGuc9fX8aikcBhwwGCeM4Hv+NbJWOecrj5mClt2M55wBjvis+Rs4yeOuT0zgYqzMxZWCfdx0545/yapTj5epB6j9KuJhNmZe/f985z/kVAH4HMf4gVLe7s59DxntVbb7H8xW0djzZ7jZMjAABHT6/40hOFyvHGOtbs/hfVVXc1pKVGBkj9KpTaRfQkh7eQYxyRV8kuxCki5ZITaoACMc8np711Ph+ZkeIPJsCtxkH5f8/1rnbWFo7MK64Pv39vb/61a+lfNsIBBDZH+1z3q76GqO7vGMlnGihy6jhcHAGPu/jXO6sXScsVYAHG0Z6dl+nar8t4ptQlsGChclyc545rKvXa4d3OAM44xyKztY2Q62UmNvKXcSu4/iPr/P0rR06d1hlCgSkEHLN1bjise3Earz344+nT61ctZPs7OoA27d2wHqOOBx1+lErrYuJ0OmmQMkrjcWzt6eh6112nyMhRkkYx4JG7HTjP41xum3DTnzGJ3n+H+8OeOK6FLi8WHJhTHZwxwTxz+FYSerNrXOrt/JeUqjDpu3HHA/xq2rRoimJiPMYAgenB/OuYsriQyYeJ+u7ePutyef8A9da9jP8AaXR8uiBcIwz8w7n0rJyVxch08St5eZsujNjbnnqeB71NFa3MCsysQMAlD1YY/pVOF49yq7kLGMhjnpn731q5a363DSKzFVUAEgdBj+tLd6kNWLEDttLTBlB7jkH1NW7Z3niPlH5CM/N1b/8AVVBTJOSCwaMnGC2MgVdTytgUBUVBzs4qOhDSLnknAMrs4HOMVBfQjyiyqWZ+p7qPWnibehK7SgGGI6E4qFrhNgAPTPOf88VLb6kxjqYuqSlYvMgUZUfdYcge1c3ds0wcbGL5G4Zzg56V0mpXBE3mNtYLnYR6ccmsy6mAb5WQJncNvHf73vU9TthotjnJI8BlYAqcFl7Ajtn09aYwcYKkHBHygjlsnDD2FaEqSOzhtqRkbty5JX/9dYE169vKVkiYR5AQ9056Uk9jdalo3ExuTJKEZ0HyjI+bjrjHSoPtQdxsDIFTkucdT196z5bhp2Ys5KADO0YJODxUC3e6QNIDIpGwjIBB4wPoKq7KUEaNzdhV/csY26fQYPzdPwrnpZ5xqIO6RIwu0DuhwP51buLoJEFMaNyQGZeSef0rEugHiCqWwD0fGTx3OfyzTTTNVGwtzI6SNuJyCQ2c8e3vWLfShXIIxxwQOnHSpGkZEHHIYjnHI96zL1zI6kEY681cVqZzdkVZ8xkZ4yefb/61Nmy4GQOR1z7fypXZJsCMHJPHPX2qJnJXsTjAyentW6ORu47YBEd4AIOMceveq9yuyMfNnipGJDKORxzn60yXJX5t4OOnPP8AnpQmTLaxk34AZU3bueOenPP+RVMqM9G/T/CtzTtObVNSgtI85kfGeecf4c9K7P8A4VsP+fh/++P/AK9bx2PPkm27HoFwEEH3kYLyGbAJXA6j1qhNDHc/fiQpzu4UYGannUyvtUEgHOezHHXp0qrNdSK8kbI2W6Mp4PNd8n3PPSPO9XCLfTCMLjJCrxwPT/69Q2UqrnB4PVSfvc8D65pb9ma5lLZBXPr+f9KqxEKEGQOd3ckc/r6VzSO9HUaaw+xEOVDSYOCeGGP6VTaQK7mPO0fXk5/yaqi4cx5ATcyj+Lpx/LtU0UjSg7dpYcdMdai6TNVcIN6o7bTnOQOeuDz+FTsZBIG6LjPAPA4+b6j29aiVHDoFbdnHVR79P89q1LSFSqEgMB/ESOvr9MelZt2NYlmxLrJG7DywB82BnAz1rWF05LrHPkN1THA6cD0zWdbny90gIKKxK7sduOat6esJtTNPE5weD0YZA56dqyk+p0RublteZV42Jd2PzgDp81bNpI1rAsalpioz8gAHtzWPpijZseRdoYkrtwVGe5xzXSWgCQIyjbuXbg9VHPy1iOWhLZu24yyKS5bOCR1PXHtXQRu0caNGoz24HPHNYrR/uvunap5BJBHP3atxLOWUb9ynpzxgZ4/ClfoZyV9TctZJfK85EEZY5y3BA9SauBllwVZdwBBAbPP/ANesK0Wd3aPeNucAA9Tjp9K0YraeNOqsuOEYd+eam5i4mk8eyAquI+pYZ7Y6VQvWCFU3kFuFHr7ZqTBSAbgxOMgnH5n3qhc4+cSPmRshAGHA9fc1N9blxRFeQO6hC+1yOWB6n0+grPlt5FiA3BeQCx6Mc9PpV5zMEX5lKouNpGSPb61QuRON6B8BxyOvGRwPei6S1No3KlxKVCddxyuccH1z9O1cR4mlkVm8pg6MflbABB46+/pXV3iGK1dFZ2kCgOzn73PQfSuU1cSRQvsXzOmB6n16dKjmuzppRtqc7DfKdxDOuz5SGwCoweaFv1f5AQAoy23GccfrVTVWMbNNEN6jlk55HPP4VHFOjQb4WyQMlhnketVqa6Jmml6lxCQNrbuMZ7c/L9ao3cWyZhI7sCOQp44HQUnmiMnCkDcDnk9/vVBdOfLYksvGCBycUWHcp3ZIjI37gDyf72e1ZNxu2g9fTBPP/wCqlupHXIJUIDzjqKryswjwRgkZyF6fSt1E56khBlXG0lhnPQ8j1pwy6nZyMc5H1qIHnOVHP657etTRjaMkgH88n/CrMEQT5Uox+ufb86kIyMkdFz+H+NOu49wJK4GPyqJXCbOmPU5/PpTWwpaM0PBkHneKbJQ207yxIwO3+ele3E3GTzD+leM+BCyeLrQoSrAMQeu35fp3/rXtG2T/AJ9Affcea6KWpwVNzFVS64k+VAOVHODjpnPSkvwGUgAA55Axxz256VLGQEKo21Qpyx/h4PoOahmcC2kZs46Zxyo446V2s89HlWqM6X86MQzFzyOmf8Peq7sEJLY5OB9Rjmrd6pF7LuUKCxG0/wAPXg/zrMYhpSCBwec556f/AK655M7kXbKUGA+Zn0xntg1fG0KdinHscH6+2azI8CCMn5XXjvz14/rVtXKqrHgA4J9MAE/ln9az8jWJdhYNNtwQF6Y9Cee3etmwlJt5DGFYMNo5PPH3fx61znmkT7UyVJ4Hqc//AF+DWxYPi2ConPXbjPGOufrWUkzaFjod+2QRgkk+gJD5PTmtnTYkDRrhiQMn0J6AGubt2Xz1TcvmEc8gccfr7V1mjRLnaMquMOMjkc8CsZG+yNE2azbFXgseTt9+h9q2YoUMcW3PPCZH3xzyfeooBlCism9+qDuOOnvQsz20yNId7jgEcA8ms/UTk2XBDHDJtZFwoyMYzj1+tWVI2JsZ14yRj7q8/rVcOXjDADdkHPXn1+lSRzS72jCAI+SH5+Y85NFtSb6XLsORKJInGCMFAQMgDp9etaTTPKmxidiYU+Wwyx7D8Kwxdq0SnfsZcAZJ5GOWqaOZBKjL5aFfmz07dfxqbaXFuzduJRGpEsgkIPUDIPFZUqu5DSkHcfk4z35qvNMSz+bmNF6hemMdBz1qGa8WCIlXC7vfOPQVk2aRhbYluPNju2KqzxbflIJDE+pqndXI8oNMNiR/M5ydwHHzdaJryWabICR4I+7zk+3tVG7SKeSUSMu0HdJlsEsMcY9KH5FrpzFC5u4rtJfLUMgI9eB6/jXNas8ihkCbkA25P8PTit9l2ArtQIzkhgAB17/0rLnXcxCMVXoHHbjliMUjphJLY4rUrZVdiX3McZ6D6Cue+0fZnPICkcKMYB/wrqdbgETOwbLE5z178n8a5K5ZHlIfCoQSOc9un41rAVSVtUW0uEa3c5yFOc9+v8qa91iOIAg45ycdx39apxSN5R2D5OmTwPpUD+ZGenAGOf8APetOUj2g64O9vlH3T1Hb3+lRyfMgUZXpj260+VgIuM8fqfTrVYBywUEk56N+NUjKWrHou5htHfj/AArStLbcuSCOxyTx7VVtAVCkjgd/X610MEcaRKRtyegY9Oe9KbsXTjcxrtCg2MMHrjr9BVdUVtxbJY8jPc/4Vr3gUjGzjbxkis5k25yCQeCB1YZ6fWiMugTjrc0PhwgbxlbjI+YNjcM54+vavczDZZP+lfkDivE/hyBL4lTlsBCC3Xt0r2gT4A/eqPq//wBauqDPLq6SOTnchGDISWONwB5PpVW9MxgRVlOD2yfmxjr9KtvgSgMB06D+Ic4/GobsFLeV0AyQchSMEY7cV3NHnrc84v2d7iQNgjccM3Jxk8k+vascoWOS2R3OcA9P1+tbNxlrh5G6knpyCcnpWfMu1v7w7g/zrmerudy2CddsSlTkgkZI7Z4FIsu0BVGflxnj0/T3pZZN2GOGJPbjPPb61XjOMZJHG7J9cdfSpHcv2i/6WrjBUeo+9zXQQSZtt/OXUdCcZx/TpWLpu0sD69QfqPzz1rfTbFar/DuzkgZwMdP61nJK2pvT8ixpshkv0EgLZ4GM5+tdhps5iuCik4xkZBBHP3q4+xVWnDb9qrnnGT0H6V09ooZUlYjdC+QcjDHPc+n0rCfkdEY6anXQhischJ8xQSMZBAIHzY9TVlYxIoaWPnHCnkLz0rP05jJGrCYLnowwQDjv7VsQMI8I+MPjafTnr0qOhDVhkEXk/NIo2KPuqeR7CmzPLI7KYx1G8hffgCr2QSnKhFXcWU8j3PFU5OGQpIVBb5jk4QE9Dx1NS2CIYsyhldV3BsA+p5/8dp6XpRwkaK0ac8nBz689qLgMql1TzBjaoHPGD8v41VgQtGHFuxTIBYAnn+77YqbmkYrqbFvNJdxhCEQHLZYgADuarXMxy8aqjIuTzzx6+9Ma5C2+0KSxGC3vjpVUz7/mC+Y5yo42joM96ybKUB9xKY1UxDyyR90nAX2+prPVGt4p9xBlfJIb+Dp8ufX61PuOxTs3ksSGI5b3Iz2qlNiWF4pAXYguSccrjqfend31NVFFKS5aEOisR5mQI+WPXgVRuGmggQgk8AFTzz6Zz0q8ojSGVlUK+/CDA3Yz6eprGukAiwzmR1TAAYZ5zx9alM1UdbGFr7gbhjl8nb2JH+FcHcAeYeSFB6nvXY65Ky2rbwNwXv36cVx7uJN3T5+Qe2ea6KRhX6IA6mNh0APpz+dBLsq4IYdBjv7VXOcrzyO3vn9KmUH5WQsG/wAP8K1MU+g44KgDkZqS3XcxDA72PQH/AD9abHGX6kdM4H860IrdhkqmemQR78GpbsaRjfUls4QEZGyw6kgnBwOn9a09hjjXhmUnA7ZAP9KhRFOFI2jaMgDGOO3NXgi+WgLAsDyFxwM1k3dnQo6FKSHIDFieODg8j1/CqFwmVBLFiOT78jn61tSbV+QbWLdtowetZ93Eo3S7hxxgY68fpRGV2OUdDQ+GULv4hLKGA8s9unWvY0ZgijylOB3615N8LIz/AGxdkFcBec4z35r1yKWLy0+ZjwP+W3/1q646njVr8xx24h2wCVwSSc8c/eFY+oXCx27xvv4BJBydvHUc1qyk5KkqDnnkY3Z6/wC7WReRJ5ErllLFTjOOODXpNb2PMicWWLbmjAAB5B7cnp/nvVS4XCfMO2T7VZilVZiFBVQTgt/Dz1NV5iAzEZVF+bcwPyjmuZneipNgjBXDZ7etQDO3BUcZAJ9cdqs3D8bQOmNuM5Ht71C/LKDx278dePw6fjSQyezlCHkbSTgdMDkc1uxzsIwigqQOQfx9vWudtfmdN3QEHr9P/wBVb0DMxCMC2f6Ej1/Col2NaZt2DNgNuVMDgH6CultZmj3YTaoyCr8HGfu/jXMWDLsj3YkT+FWHXjnP+e1dTbFXYCM7ogCc47Z659awmtTpi9DSs7kxWzLHjZJ0Qk4P+z+HrWtFfMoJQMCPXo53dKxbRswmJtpJU/wgYX+hq0kgdgisBG2BgjOOe3rWNtSmjdgvdwAdgd2OvrzwT2FT28gW2VoxtbPBODkep5/KsWGR1kaN0Z0X5WDcZ6/KPQ1dEyyllBkwQNyldu4D0+lJ9CWgacAZDBRjABUHI5547/WmST/Z0EjlnVuThhjGO/vUv7vIWAPI78gY4Jyec+ntUM8LOVUlRj7ykH06/hSsWpE093HLAu4FWJywJByvoOvJpqSIynyhyRgjHUegx+dMSK2W5VYp4QmOWcEYHqO4NQ3UipnyScouQU6dPvVPoWopodNcQxoS+3A99u4g9qyJibeSSVmBLnf8x4Jx19h9atz7Jg4kVN68srDPcYArGnU7j9oQRJj7oPQDoBzxUdTSKstBbi7aNy8YbDnI9G561nzS78sThwAdw49efc0+6KLMo/dkE9FHA6Yx/Wqdy6qcYHXk8YJ5/MUkrm3Q5/XWIhcEAsRkfjjn6muRRcSjOevHH1rptXkPkvIy5IGeO/H8q5xGDS5Iyc8Y4x+lb09FY5626CcEAnj5ecehpI5OSp+8eQMdeasunmxqu0EYJ46jjrmoFtts4U4wTwe456/1rS6sZtO9ye1fy2DYAye/POP5Vt2JQyZKHvtOQMe9Z1jbMJSXGSB/F0z6f1rdS3CwqQoXnGefy/z61jNm9NaajjEhKlVIwufce9TCM+Vg8fxA88dOfxqRIyyjIIIO3dn9PpSXOTIiAEgc9fpx9KltGyQFSyjqAMDHp14981l352/LjGOMHPHTitQkKQcKQDgZx83Pf+QrJ1DlcgDAGM8dMULcHsdD8MIGNxfvj5MqMjt1r0yN08tfvLwOATx+teffC3C210w43OFVuMD1z/Su/ilxEgCgAAYyDmu2CVtTwq799nJSFxnKYIbG3nHUfKaz5gfsshbO5gw579eKuSFGkZcbhjjOOnHX3qrqKqkD7QAxUjA6Ec9OOtelK+6PNgcGADOx5yWP489+eP8A61NuFB3Ac8ZG7oevX/GiNFaZi3PJACnqPb3p1wOSpZyDnIx1Ga5j0DOKjYNvI4wTjJxjr71WuuR8pAGcBiOcc9asSH5myWwec8jPT/6x5qC5jOS+ckHGTnnnn/GldgOiwPm4xt9vQf5+taFvICyqoyT1APUfQd/estSVGBksF9enA/8A11ctGxIcrgrzn0561Ei4PU6bSTk/vcurnGF/i47cV1duxkkjCuH2ksSuecEc/hXK6cyS8OcBcD5e3B6f571uWSqsjuWAKcMqDvxx9PpWE3udkFdHQRuiN8rMzMTjH1OTj0qxaK581ph15UqOnI5Oaz7OUTfMjR+YP4RjB5PFW7X5ZM7Rt6k5xk8c/T61hJ63NUuhq2lu7yBgTgEEHJyOvI96uyeamGKDcvBJ/hBHH51nRzHMYGF+bccnvk8/SpvPaZwjlYxgYZf4RjqeO/ajYizbuySSUFg5UDGNpBBI68DB6VKpiaMvKhYkBdyEcnHA+lV1Ai3JjawyEZc4weufc02ymBLDaVKLkkbvlGP61mro00JWhSOUi3CyK3zMwI4P1PYVTOJUcKy7RknHU8YyfapmvbZ7nyP4/usAeO3yj2PWkllhhDPgkncqAfxEfwfQdaH1sWnbRma6hJzIxITpGG5IPHXiqM/7xmU7wQMsrj7uc89Kv/a1YEy7ZCuSgIwXxj9BWfgS3LseSc49Ccntmptui1LuUbsFY+AVKHA/2V4/U1TvC5WFBlccZ78n7tXJ3EoC7kwOQcjsP4v/AK9ZN3cMuZDkbTgHGeM9/ei5ojB15SI22biU5YE/d9qwIQzPwuSx4roNRmVomCYLEcgn278daxLWI+d8qjBOPw9PrW8NEctXWWhpWVuZANu1cNypPU46davfYEkUBRnAJB3DI9c/0qTSIA+FkTIBwgxy3B+Xp2ralUGQDyy3c7ONwGOPwrKUnc6IJWMqCBUXA6kcbj2561fWNQoUsCVBwc8A8H9avW9rHJtLEsOcpyPWoLiErO2AzqwyAOATxk1F76lq2w+0hO0Drjg5x69OnWkmjKyEkgq4+YEc4xwPrVq3Uq8ahyc/Nnv16/WoLvLqWOPmGTg9B/j60aJ3BFK4LZ2kb1ONp6ZPt9KxNSlZVKYZWHXBPJ9a2riQICCVyuOMDjnqK5nUpg+8OuCOSBjmtIK5E3ZHofwz3xaG7HP72RiOD82Opz2x/SuziuIvLTiZuBzk81yvgKNYvDVvvAcyEnII9eMf1ro9yjhmiJHU4612wVzw6jTbOYcsrcu0oJ35BPI4+aqup77i0l8t2DrnqTkDmr8yE53KuV5O3GM8fpVDU42ELlVUb+G24IPPX1r0Wt0eajz6Niu7YdoGcjGcdOevb29akmbluCRjJKjnr/kfjSY2l8YDHIH+JoB5KhgSD97Occ9T/LHrXK0ehcosiA/MeCDz17DA/wA9qr3O1QQpAXkc+uf89O1X3jxn5SvpgHgY/wAiqVzxIVXk55Bz+H+FJuxS1IkUeUQuCBjj8Ov0qWIkfKOOcgn1z1//AF0yziaV+nHQ4PTg8entV82rhAy7W56nI9OP/wBdTJlRRp6VP5MJbayuo+Uk9OvJ/wA966jTQJIQ6cIqltpByOny5rkLElZEDHIzgbunfg89P8K6XSJlLCKJlbGSrEd8DrzWE9WddPRHSaWIYi4w0ZcdMn5OTxmtNGBd8R7eNoQE8ZHSsK02/aiY5CMggnA457j61sFFnWMZCsowG4yR3/GsddzRrUsQJK04RCSVIwD82T/dzVsxusiRrkFyMgjrwffoKrJK1pcJHtdlfGWHUDPA9zW3aiO5Ad9hyR9eM8dKlS6MmSaVzPvJnMa+THKzrjKnB79cf40Ns8oSAFGKjO6MDnkHvz7CtiRIXRStspVRjO4qWHsKglinlPIBgJAYDnd1/lSjqriu1ocfutoZ5HiCbn4LcAgcZznoaqXl8R5yRMdo4C4B456e9dZcaDCDvZxmQ/L8uAw45z7dKw9VtY4VKw7Bz8oKkE4zzUSVr2OiE1JmD9r2vndh2HIx16cDinreNHvijYGYvlmBxnn7vtUK7TuAAUKOUwQSMdevWgW580ltqZ6jHIXPX69qDayYSF2Q5JUnhvm+/wC/4VXvBsjXam/ndkn73vWkka+WYy6IAoBywOM9MVUngCO5yrYIJU4PfsPSi6DU468iYyk4JiPzH3469arWceLnjOzrk8/j1re1G2QRSA85PIGOTz7VS02BgdwG5yegP6n2rRS0MpR9427JRhg4CMvIZTyBzyOetXIHeN1MykFepGMYwMY9/WpbSIq27aNykEg9Of4hx0qSVNyoM7TyeQeOBz+OKxvc3sSwICZHePbu4+XHHtUdwACoZAQSAcDljjp+FSb9hzgIw4VWyMDPWiOTdMzElVByoHO04/rU3HbW46ZlSQK4UE5O5TwTnr9Ki25TDMFx0bHHTk+wNS3EZmZ1CCMdxzjrwoqpcElGEi7SOw7dePYU1LW41HoZN6ohZlJyoJKsOwz1Nc9qboQCp6dK3dVf5CNgGT1x34/SucuwrSwou0HcBk465960pJMyr6RPXvCqCPR7WMggCMZxnEecf+hZq8Ulz/q/1NM09Ut7WAIApCbeSOOOc/0prLEGOUbOf71das3Zs8VJ9DOkJCmMjZhclTk7RjpVHUC7yGNRtHPr0yP51LOx2jZgIerNjI475qGRPlL4yCGAyRnGR1/pXp+R5pwM7ATSnZzu29fvHHT6d/wqJIcSMrNtLN0PGT1x/WppCBey5yY1JXB649Pr/Sp5YlckLk4XcMdeo4//AFdq53e53xM+SceUVAxnjPHpVC6PJC7MHOOQc+taIDD5eNpwSD261TvSUVlGRnjODyOOPfHWofQ0E0Y5ADEZXjr1HP8AkV0jWm+JDlckdFI4XA46cGsTw/E0jcK27ONuTz1/l6e9dhYWjG3OMhAuQrAgkY+8PpWc30NaUU1cwntnYbuiqeeO2elaNpmPlG3kn5tvRuOnT8an1K0WOQogO3sMHn361DaEQBophx1HAPbr161k0nodCVtUbdrLKz713SSu2ATxu56fhW9YXgkjD4IYHnIPJ5+b6Cuat5IjNG2doxhguDxkd8+tbcMiyxfu8cAbuBg9en9azkr9S+h0kflSIpkkyOocDHf71BukgAEb7SwBEnUBeck89axori3gj2xyK5ABYLzuP+FSRszFXdgWLbtvGD15+lTZXQWNJLpnIeRwUCYU7QNvuMHqfenz6kgwGY5GDJsPBHOO/J6VjNOH3YKoRzycdvvfSoorocxIR8p3DOcKSep9c9qiK0KcbmnLqzmB2Ow+YuMBuQMdB/Wufu55Gl+Qh/m4KHJHPAHtU5J8xgWaE7DnJPyjHI/GoZiFnzFgYHQA8ZPQUpNmkFbYia0lYgoAcMCxxnJx1zjpU8MJSRVeTcdxwcZ545+lPM/muscq7U7BQcbvzq9d2nmSYBbIbsuAGGMj6UhtvZld5BakJtUv/Ce69cn8aypiZVkM+5VGAGHVela8ls8suySPBXhCSBuO4+/GKoT24iQJvVcHPIBLH39al72HE5rUlfcAzNjuR2H/ANeq+lSRi5cKO+AAehx069K1b6MMJECEOOQRj8c1m2cbI+/aA+3gegx0PHBq1sN3bOpiSaX94kYfZgEDgZz93r096YxLEDKtlcgk9DjpVy1eCOKN0BKng4/9BPvUN6YirYQKrAZ2k4Bx92s27blxb7FK4jUlgzg5OOccHPX6UQqquuDkr0LfTnP8xTpQEiJIbehxwTzyPl9qWMfMDGN6EZ7/ADH0P0qXsUjTUKFYx7Si5yT6cdfesi7dPN+8FXGD/sjJq9by7oXYlWB5zk89OfwrMvSj5XAYH7rHuMnrRuwiZeonerLztHYH6cdK521jM2t2sSlm3SqoXn16f05rQv5XWAqxJxyPp7+9R+EbdbvxDETkxx/McdQM/oa6aUdTlxUvdPV4VwoAYtuULtbOCQO30qcRAjJuHBPUYFQZ+QKSNwAAK4JxjtT923jEPHHUVvFtHlmReIPL3DBOQN2TioJVEuWUn5j1yf3mMfyqzeAeWcBCWGSo9Dnnr1qlPIfuAYdlyVAHTjof516bZ5qRxV3EFvLhQC/zEhlzzyRnHb0oZ2ERdV2kjJOCMDjnr36UajLt1WdTjlz9wDGeelJKpaLb97dnIGOeB/niueS1O+BT5YByFYEgEE5z15/pUN8cwqHXB9u/p+NKqyOzRqygbuSDxnPXpRcr8nILMme/fHUfX3qNzS5peFYl3+YcEdc9G68Y/rXb2alrWNzGGUKAORxkduOgrkvCjZm2Nyc5BGeBnnP1ruoPOhg3YIzgAf3Rg8fjWE3qb09ihqNrGiPMGBQNx9eO2K5q4DmU7l42k5/Dgnj8K6XVJIJZC7xFGbjhjweOgzisu8gid3jZTGAcNg557KfbvU9zdLTUpQzMrYTcpUHjPKjjJ6d+mK1tOvHVfLCEKO2Dlck/zrCkhEfA4UnHspwMj2FTrcGNTHbsyAkKrsAMnJyfw9amWqKijf3DJXPmccg8Y9qkVp55NpJ8vcBnnA5OBms3TcKoWUqQecsQQTjr71rWkrrkA5DcDphRnv8AXNZ2LTHSwqRk4kQcMD1JxwB7U2OAJKwjTcDnCtxk8dfYdqmldRbuJBHwnAXjAAP5GpIJE8ldpLlsbmU844wBx1pDuRvCpk8sDf8ALkszDkY9aggt3UDaR1ICtjgccn+lW71BJGSW5JGWU8Hg8VbhiUxxsUVyPkCoxJc8YyP1rN63bLUrIksbdYwkZj+UcncAcDn9a1MHacRgK8e3HQ444PvToYJWQFmypG4lRywHfB9KmaKO5hLSBioBKvzkrx81LVaMzbTdzL8sbZHZShQ8dTkZOFz2rEuFVWIlAwexyNxPRRXWXqIIo5IsqAwPTrk9a53UYIpI9zHzFQHkjPGO3PWlFMuEk9zm9UJByoLMSeDnnBxjPtVCyVHx5bbSR1bPPB5/Cm6i4WaRV5AJBy3IGRj/AOvVXRPNYlmQHacY4GeuCP61f2TTZ2Opgm8lAmeHXdyMhunzdetOnx9l2AEHHH5H361BHkEvkHHbGCT6DjpUwdpR91WLHJweSPy7Vjqa+hHIG8kuow5XBGOq8dPepoArRSAIu1ACSOuOgwOxqtd3KRwBcfKScBjyp/v9OlNjneJQqt8q/Nn+vvQ9hWJrqNBuxhe/b5jwazZ7mNy5cfNnJAxhjnoKknmcs2+QYA9zjis28maNn3HaOnToM9j71dh9DC1ecM524wMHP8j+FbfwyhJ1C5lOBjA3Y9+vTpXMak25ztGAfc+/H4133w5hEeltKekkuMY9McYz0rppq1jzcVK51MS5LY3ISPl64Awefxp67do/0Ynjrk81Cp3OMAEDpnA9asKsO0ZJzjnAGKuLscbMuZXyuxxsJLZH/oXTpVSW3QAssmNw2gd19e3etWX92SGG0FtuefX7vXpVMpG8Y8wcjO1j34+temeZE4LWoRFq0qrlVB4HPy81XuQ4iPlM6LtGTz8vH+fzq94khC6wMHdg/Lnqeep/lVGaTcAVPJ7tjnjvWL3aO2GyZGgGGjA2ZPC9cHI4H55/Gs67aRHcZO4Ngj0IByOvStGQLHw2Qo+ZSSMge9Zpyz5GQOoJ7DB6981NjRNm94ek8mePCq2Dzkcda7+xEn2QszIY2+5nBPQ5zXA6PGG2AknOcg9+nH9K7vSwXhwELbSFwODxnj/9VY1Gb01oF3YwuVYY3EH7xHHQ5rPubVLWQS+ZuLnbhiPmU54x610jQlyjvCZFCnAORk46/h1qvdaejyb33O7HJDgnHP3vqKxbNos5tbRZjui43rgJk5xgYHT2qa20+CTLHBOedy8k5xjpWqNOAiMrrICSVOM4X3z71YhhZGVFQSxqCQNwO3nnB9alvUv0M1bDbGDHh93BVWIyQDxzV22tFO9RvWUr91yRuHGefarzW9uiCXIYgZaNiNyjnoKsCNp0D8sSR8gdSBzwBnn61NtULmZltYxSxBXi+YfKhGT2OWyKlmsnSYLC6jIDgYzu4HJzWyis8SgRhgpAIMYyDg9CO1PhtWuQzymIJEMnC8nAH8qm+yBNrUxETbKGni2SyDjA+UDnn61bsbWJ52llBjABU7RjH69fWrrxqrNs3MHIJ3DoRzuHtzVlBFHar5SsrpkoCfu8feNRLyNLkyhRHL+8yVHKgcHnoKpQx7pHk3+UgJIjVvlP6ZxVmKIRsfM3Lj+EEkpk/wCNMaGSabb5MqhV4bBwF54Botcm1iG/lVoiH3oU4XkYY57elc3qmbZC5YhwCwC9AefmrodSjxE24/Nxgdhz0FcjrEu4tEkjKpxwR3Gfl69KLdTSmjmb2SRoy+Pmfktzx05/Gp9DBjdMbgC27vwOelV75gwwE29iPp607TkZHi+UZB45+8cmh7aGvU6e5dHQRMwjXG4HacA4GKqJ+7Usx+XhSRnKeg/GoJnSQIECgLnJ49Kimma3iKNhUzzjnC+/uelK6Y1Foku8MHD87R26Hj7vXpWc8jDmNQEUnGe5z39qsQSrIpMY+XZgZI6Y6fX6VWu22gIT8gyP16Uncsc7JNGJAFBY+xOcfyrPv3LMdzICAQckU8ShIgqE7T/nFZmqSBVfk7WPX1x2/CriryJlKyM28O7aqN1GBn0568V6/wCGrWO20e1hdsEoCxQD5RwcHivHtOj+06vaw8lGbOcnt/hXtsAVYkVQclQQSuAQMcnmupKx5FWXMwXDTD5gcjCgHoMng8dasovyL82OOmBxVPaQ+7AUk/KemRk81dSEbF4lbjrgc0L+tzKRVuUSTzAp57buwz90+9VmAJZXbJC46jBGOg461Ynkd2lc5Lnk8EZ5+91qjKCw3qd0o/hb055r0bnmrY4/xeqrfq+Mhh2PJPpWJGpkVWAGSMNnPzdeP8+lb3jJA9xEsYwmC3HTt79a5tZThwynA+8AegwelZyWrO2m/dRcmYyxsWO4gD5+zdOfaqc2UkVcdVHb2PP9adw4LJt2hhkDp2zj0qG7cxyhSV5f9cnP/wCuoWhqbGjoRIMElXzknkDgc9fxrvtPl/cpjyvNCgZXk4/PrXD6IHR4ypOJBnHXnr+Vdjp5bbG4QCZ2zz1H+106VhUR003oa/2uVMZBwB95cEdOAP61OtyTI+/YGzyMAAMDxx6etZ08kyHbhVUAnqTtyOvTvSmXOyQlo2zhlGSByOPqfWsmtTXQ0vMM0cZZ4cnOCDkMefxwKYyi3+SURkDkNkYJyOfpVe38xGAD4OcYdCfXj8a0XEWxhNLChH3eOAePl+hqLBdJ2IvIieZHXy9/X7xX156VNFhJMrBMqAFfMI3hfp65pFKxXkSEI3PYcE88fSrUSblKrGxbPCj5g3Az3pWV9BOWhLBtABKgqBhv3RXaeflyO9WY2y4dF7ANhSBjHSmWMDpKDyUX7qk5ye5x0FSXURgORmHYv8QHQjqfr2qUrC5ugpR2tXlPy/MDjOBnsPcVWaKRSkiAMWBADgcnGcH2pABc3A8+R0jxmMEAZ9R9fSieSNkDGMkjCAqfvccD60WXcpNoux+UJcbGcn5lO3rzznmoruYh1UuATyMj680l1O4lAEeTjDPux6EDFZmp759rSAkg8HeQHx2x+tTZq9gi77kV1cRsxMBDkZAJ6jpnPvXK6om2QtyXA/iOOOePqa17q5eOFzwwYkKVJG44H8q5a9nkklZZNxA5LHknk/Nii2pvBmTdLvmOWwOpweo7fjU5LQovV1yBxnPXpVObGFxkljwe2MdatrJ5aqXI4HBB5I9frTcTRST2JUuWCg7CAflIOeeOntSzSOSXGSGOTyctg/0qu0yqkBBIDDuB0x/Om3EpUk9Af4SMDPbFQ4l3DzY0DtFvVsZ6nBP94jNQ3t3tdw5Uq4wPc8c018SbyeGPIKgdcVUupUknWN9p7ll7/pTUROVhxuAA0bj5cfe46c/rWNqc6uDjOO39PxrVuF2l3J4A7HGffpXPX0u73PUY9OOce9b01qc9edkdH8PLITas1zIqusIBxwOecV6lG+9SMgkjJBAGfpXJfDu08nSFmZcmRg5AyNoz1rsAm5SN2QBnjPyDHWt79DzZPUFVRh2IJdgOOh5PTjoKFEe0fvSeOoP/ANakYblGN/XH3s7Oeg+tSqGCgFI+nY//AF6z5b7oLkdx80LjavLHLADg8cj2qq6lgqyfMVPGAM9+fpWnGMbdyMjEbcZJ28Co7hAjg7cFTjjJxk9K9Js8xW2OE8bBVEJEaq3Xd3J4wTx0rmI1AXABDE4yf4eTz0rsvHUKrFEQoBzjcO5/unnp9a5hEUEDjeSMA9Ovfnpis5bnZTXulSW3MH7wfLgA7MkY4H/6uKoSqTKcEleo4yBzx/hWxcwGSU+XzuG1Ccdhz39KoSK0YJABQMQOB+v+etZvQ2SNrw+WZk2OSvAZgT8px0/pXeWgZot7jeSduffjj6Vwfhfyy6lgVU4yfTjofqP1rvNL2AEbHUZwO+P9n61hUeptAsBA8nl5LjqM45ODnPt6U+W08z5cGSP7xGBkdPmPpVqSDcoyoYZ69CeuB+HekBdCWAPQ58snnpWTepqn2KexodrGQqQSoDAA/U1et48xKw3NE3srMnTg+57Uk0QZ/NxJJv4AA+99fpS2qXCzgeaY4gMq5z83HLfh6VLfYq6ZYjSITMLnYTxyy42rk/Lx0NT2t3AQfIaPzhhQQx7Dt64pt1FIqsJmDPncrEcHn7x569qXTLYLEcxR4AxyOR1pdRO1rmhbNPIwYbmUnDMMjJ9KGSJ5lEzkkDG1jx09PapI0Xy40ZBuXoVGM4PAp6xiVZYpFVlO0Hj5h1wB/WltYnQpXCMsu62kV1Y/eII4/vc+lNKJIu3fIMjOX79eevWr8NoN7ZKqMgDByM8DgenrUFw0cQwzk4PUgYz6/Sktirq5UmbYQhOAFySTjaOOayb/AHztIA6iLgcHgjPb3qzqrGRflmJiUHdgc9Bz0rmNQd4WL2bsFLEkEZ5z94jHGaLbmkSPVnaO2Z3dNoIOBgduMflXM3b7m+WRWcsWZhjrnt7VNqV9LLKkcwdYwDgnPy8c1nvIzLnLBFYgDuBn1p2szVOysNkVdwdmQnqB1ye56VagmSXDSKo24YnPGc9elU1+ZWXpnrjtwehzSuxAVIgAA/PPQccdelJlLcsEGWWRVGAo689efm+lIsryRGOQnC5IP+etLbxCRNsakN1Azjnnjr0p6x4aNRgkgsDkcn86nQpDZUZFXA8s7fQ/IOf/ANdZ08ZRyCozjBOOUrVjk3HbJtypxubAB+tZ2oyDaI1ABxnJH/1qI9glsUNYuWIwuECkgjPT2FY0cLTXEEHO52H6/jVq5kBJAztU4XPYflWv4A05L3Wg0g+SNCRkZ5xwK6oKyPPrScmeo6JarZ2UVuoIWLC54xnP8qsshLABlJPAPHHB5PtUseUChgV5wyjOeo+X8aJMjZ8hGcAL13dflquZnKRBR8uOMfcOR8vPf+lOEceB80g/D/61Pidt2Bne/KggndjGe/GKOBwXckdyv/16IegxhDyRkq2H7E4z0HB96C4RSDgH0JAHWp4o3IPO8EfKRn0H606WLdhmUsASM/3ueT17V23PMRyPjMiTTsKMbSNwb6dBx175rmIU3SKNpPYgd+enT8fpXW+J40azIEhLhdxLKcY9c561zNup37GYbeoI6gZHPXk9qiTsdlLVWJvKX5ixYjAKjnDHH0qlNCVil+UkbtvORnv6duvNdAqmUxCPH7td+B2xkVFc2/mwyuyrtU8hcZ7c1k5I6VEwtA++4eRYwqk7WBIfGeOO/f0r0TTXVreB0JDOASDjkYHzdetecxwG2vnAVQCQSGxzknGP616DoYM8UIyqngAAdTgfpUSKidDsYhkwAB8xwP1+ppVSJ1fzkKcfNt47DFXIbZh0wcds9ferSQyxodpKjHK4yRxnJrBsaZieVJbS+U7FopTtUbRjGeBmpby3RJlV5H5IXGNvOD09vWte4t5ZYU3JGV3ZBBzhc9aHtS6mOfKbEJUNnKAnoD3zUydti+a5nQpKs2ZGzg/dJ4znqPar+nM8QIMbFCf7wGM9SOOlS2Fk8QkQPuyQNrOTt5HGewqc2kywdGBbAAznOMj16UR8iZNMgh8uW4LyTy7V+UKTyPf0qW+haML9nlw3UYHTg9/eo44ZY8w5z3H17g89Khwyr5ZDSAk9eMHPr6elIEVBIIwWPmxPtwVxnbwP59ao3szszrKTnGAAfvDnitXYz7di445DR9eO/wDSq2oWYXEysMDJIIA/yeaXQ0T1MZt4g2hSuTkuB04+716Vk6tJGyrHwGLnLY6nPTGenvWvNKg+YbgAOQTnAx06VjahPFcOyJEiuo6kE5GfugevvT3NYpnHahG/mNt2eWDx0OTjnP61SOEykB6nI4HHPOTWzPGzRySMuSTt3cgEcjA9azZImHMYLAHjOcN0pmjKA2naYwST8rZI469amtg0DgsrFTwUxgqPyqytsSQEIDMeQM8/r+NXLZWSNsfM4IZAf4+PvdaTkgincdJC0cPmQk7sjOP/AEH61GJHZW3p8zDG4Z54q+o2hBKME4YZPuevv3qp5f75VC4LDI9hislvqbEM7KY1Q5JBxj++c9Kxb0vGchg3HcferauiqybeFY9uOBnnHvWPdjaspfByOQMHd9BVx3JnsYVyfMkYgksTnv8ANzXonw9svs+n+fMvzTnKnA+7jqOetcBsNxdiEIDlucd+a9j0WGKLTLaJChCLjvgn1Fda0Vzy6jsa+xiUcMCMg546ZH60koBf5juVgMkDkLk/kak8gGMhCeDvBzjP+107elNRG87IJ3ZHckDk/N/Si1jG+hDDtBkbapOOcDB6cY/rTtrHnz4ef9qn+W/IGGXbwcn5eOv41CyfMenX1NEUn0uNOxeljBQqH5bnK46bagmKqoZgAM4BXvyOn9anUN5eVIGMkgA8ccn/AD60jkmMgZyuRgZ+TOOn1rqlc89HMeMW22xzgMDk4PBPrXP26HKybTuDbtx6duenPpW94wLR6eqFdpUnHt14/rXOWUytDgkknggnoeD69O/NTJnZR2Oj08iNTM3AbCk44zk/NVi4t40sfMjkKAjkgH060abCht8SKuUwAOvzZ4/CtBv39tlVDHsnbOP5VzM6U0ebaqjx36sclQR0zxkn+ddr4aZzDEEXIwMNu5HHFcnr1sVbeNwG/gZHHPI/wroPCt3JtTaqA4APQjODz0py1jcpbnqFmR5QLsC68PjnvwK0FjZYmdWGTnLZHHt9Ky7JkeJfl2MBgsR+h9c1ct0aNW8tyvYru6DH3a5+oya1mHliNBlC3yg4yDnnPtVm4kSSHfFIVZDkFkyR9aagBjO1mUEcrznPHSrBMwYiV1eMgBgmRzUtsm6bKazlZo96IGI5IHA+vHWrSXCeW2zapzgBh056UrRuzQsXYrnBAGcmnTxMLsSZXbnLg/xfX0pbBdFWVeELKAo7KOcf3frTMRF2DqCTjgA8+34Vr3KRSCFFTb0PzL+v1qnfWStKibMN2x2FGpUZIoRsssTKVy+RxnAPFZ98wVWBG5Sc9ep9K0pkZYWZU2HoSBjjHTHqazb1i8JjdUPPLjv04HvSfdmsbX0OcmTy9qINwI8wF+OOc5+lZF2sYDy7QcqSoI6DI5PvXQXscrvIX+YLyXHQ47Disy7IYO/VSOcj7xwMkDsKtPdGqfU4y5IabaBiMjGARyMnp71HbQq4YYDYBLchTjjge9XXgZX3K3IY7c555xn8jUc0kiN86qoGSWCsT6b6aZpcga0KxsUU7UI4XB4J+lPDqr7Qd6EDnbgE46jitO2gmYl1w64OAQQV5+9+PSqkm5m8hk8uVR90jOOOg55yKllJolQCZ1AZi7c/MMZOeucVnu+TsA24BIyMnoefoKvoVaYISdv8RA+7/sjmqt4qlZSFAxwEPY89KXLYdzMuywZcK2QB84B45+9WJqLk52jpx9OvNb8jfugY1yCcDdjBPH6e9c1qfyyELjOe56dcVcFqZVXZGx4Gshf6w0twOIgSc568Yyc816Xb2ccabkGFByVHHc471zHw2sTFpz3LDLSvjnsuByeK70Rlfu7SqkkA89+T0710uOh5c5+8RLG3zAnD/wAS8EdsAc9KaikPjjJbnOOOf5VKSUARR+76EPnK5H3fxpjE+fgYwcDAyNgz92ly2JuRqVIXaAOwHGGOOppxMGfmZs9/nH+FAWQKGUEjhScHJ4PFR73HG5R7c/41CuXoWArsjAKCucDJxzzx9KrtHNGTs2svO0N26d/5VdTHQdeNuSR6/L/Wq14xETFAxOcKRkbjjp+Fdj11PPj2OW8ayuLVIWUqv3lyAdvJ49zXLWcbMCFU9iM9sfh+NdL4ykyEb73Uc9Cc96xdEHyArtkfJPPGRipb3udlNe6joLOaYny5ULQoQG9Tk/d6Vv2r+ZAqQQtnHKkkg8H5KyYV5UnhDhlJ64z169a6XR4owOQEGzJI7jnn61zt3Zvsjz7xLaSxJG8nzK7EAnI3c/0qHwyTGwWLucBDnk46/hXX+L7FLu0VFVTKrAjZg8dhXG6PHJFefOFyuAQABjr+tOOsS13PWbaFxaIFx83PB5OMZJ561u2Vo7uFyeVOcj5vrn1rA0KXdDErlSOMgDknA/l3rt4Nq7WQAgdSB+v0rnnoJ3IrS3yigp0znPUfStV7KORD+6CuQck96rRzr9qJbIQggHnqO/0rYiZTEvIx39amJjO6ZnpaK0QQxhSOCc9aiNkRFMXQM2QQPUdq05MoVLcrxnnG0etBTMoVugHZulNISbM5kMlukxJOcFh056ZqvOB56Mowx9en51ouvlxMoztB5H9Khv5I4oY3zkHAwOv4VLZpFamdd2sjI/GCemD7daxZLVV3ZJUqucAZA6fNmuvdDJEHUKwAyAR7VlXpMCE+WpUnkEY5x1+lS+5pCfQ464SMSZbchzhwBwPaue1lRA8kkYKbvlIIyvQcAZroNdEb3KPErIRztzgcc8jvWLKI5owyGNSVIAPOwEYyRQtTqic1diRJ/OWNQG6gYIzngg1UlVWhQRRlpickNgDOP/Qa25I4wzIY/LkjyDnoMn096zzatbSJEE+fkHLH5Rk/IfetG30NYpDrNmjgRmjBkboRjBOe/tUF3b+bOWP7obBg5BPfqa0UDN94Mx4Gzpj/AGaZcqDKqkZCgBx6tz79KV7JAtGYkfmQ3KRs3zryGJyAvvxU11DJlWJKE9uw68fjT9StwrxtCQccnHfge/pUUsqSpEUfIGSN3Q9ck80XKsZF+TEG+VgvQdfb5a5TD3N5tGZXZsY9c54rf1aUCM87h2HHI7k+9V/B1qJ9et2b5VR8ngdM9PrWlOKsznxD0PVtB0/ydIt1B/eFMAgkhzgcH0rWjVgjYXLZxk9Cc9Dz296baRhU4wUI6YGQMfzq6ULq+Nx43ELxkZHA966G7Ox5RSeLci4XOOdw/i9zz1qNlw43DAGMHjJGev1rQYMOMDf95iM4Y9sVFMruN4GXY5x2Jz1FS30KRnkbuFwM9DgcDn9aVUyo+bPuTVlC6u2QeT8p5w3XJpFC7RmYk45ODUXfYsrx7yow/wAzc/MvUZ6/WqdyW2knapGAw4Hb+dXfNlBBY7yTnCn/AMeHHSq9wocsBu9SAenHUV1vVHBE5DXypnIdlZiCW6cc9qraDFsbHy8nkDufajXIimoSKS2A2c8/KM803SUlimjJBRQ2WByNo55H/wBb1rOT3O6C0R1Ue2QsE6DGfQnI+YewrUilaBECbmk6A9iefm+lZe5beNWRcHcMqT0PBwM+tX7IARjzlLMzgsp9ecDPoOKy00NL6Fq6cxQySNG8e5cA5zjjlq4qxZv7SZ2DKiNnO08jJ+YfWum1f7QY5syBumQSASMdAc9KwQZRdokCIu2T5cqD3/8AQaFsaRO80XamGiGI2+96jI4/M12cWVYBwV3nkf0+lcBoYuQQiKr4HOcDnHOa7O1LCPlG5J4/ujv/APWrGUddRSLupQtN/qVGUG4nOOnQVq6fMyqVlGGzy3UGsfeYR5yHEOzacnnBrRtpN0IBWQspOQB0HpU6XM5NuJrKxbhgCDxyOlVywicAK5CjAI/h+tShiVDAMgJyc9qhlkZZ1OIyORnH3qtxjYyTd7Ed1OiwO4OG4OR1zWfFdPPKyyrtbYrLkfdHP51cMTsTvySOmBjn1PvVC4SRb6NnjaQKCCTkcEVla9jaL0sXp7zyoWAQcDHoPpXO6jfM9sqhAzjICqOTx0rSJ/0d9rZYjC7z+tczeKYn3SOq+WCeO4I61Orsa04q9zPv5mMW6RXdyw+63Gey5rEjnSUO4Xcclf8AgWDkHngVrX0qtEygDcxORxgDg4+prmZERLy43qwzgHDADb/dA9auOx0rUsPuL7o8SjHXGdw45PPbtUF4n7vbtDxt8xbvjn5vrVmF9mYo0KkYDhMBX6f/AK6ZOxaUoUIfcMf3WOTx9Kdr7DuygIpWO8MpjABBJAYD1+tVZZHWUZcMpGMEDOMnI+tTXszrchQzAsOijg8DBHtUNxMBcowj+4+fMAOCM8tQ0WpMgnfIkXhPkB6j5hjjHHX6VieZIWKliHY7Sv8Ae54PStPUSHnUqxRGGQ4ByBj72O+aybtk85ywwAeCB+uPfriktCrlG9f93jGGI5znJOOvSt/4cW5N5cPs3qMDGPfrXMXMyuwXgkcH8q9B+HkZgtXkkU4dstt9O3/163pxOPFS907WKUCM5O484ODwMfep8ZIVtmQuSevTp8w/nSOryKWVcPvyCpGM/wDxNKkQ8oFUX5MsGyD83HP0rR7nnBPvwOMY5Zc8qc9uajmdBExCq2MbuRkDjgc1YK8KgLYB4PUjnv6imOhVWONp6b2H3fepauyk2VGcKCUORnBU4OOT0qRYXKglFJI6jGKfFG6suOitx/sc+nvTQxx9zHttNZyuraGi1KTjaMlCDnjHY+nXpUEiHzmZ87AMcep9anR0SItGwA6KSc+nHSqjXRYkgsBjByOvXjpXbbQ4EchrCs2pyOUDc8njg+/tUmmoxl3hgD/DnHqetRzyhbq5OeWyCGJORx8n1P8ASrFpgt5kxZR0AwcPyflrOd7M7oPY3gFmtxK6k+XxHjBI6ZJ96s2UslwhDfUHpjBPt1qK0YSWSYyVY7gM43cdas/JbuNisVDZ4U4Y56/rWL0ZsrEWsHKhmO3cgXKnpx0PHesq1QpL+7BOMBSRnv8Ad/8Ar1f1CXzIMSkh2XgdsY69eoqppSotw5kyqdc47Z69etPoNHZeH3JUbiCcHjH3uP6V1FnIyqd3z7z1Ht3/AArjrF1RAflOdp4xwMHH/wBeustrhGQ42/MM47ZwMAfWsZK7Gy/5SSIeSEyenQ565H41fgt1tYv3b/uwcnqcc1nwSxqdjnA6EdMn0/CrglVojzk9Gxnk8VEkQ2aNqwUkO+R1APpmpZQoH3VHPJHH5VSV1KBjtzxnk8c9RU1xMgt+uAOmDjn1px7GT3LJZRGCuD+NZ2CVcjkenXPtTprtREMEg4GPx71WWVQmGcgevXGf8aTd7IqKsjMvpP3ZKMGVT16/N/gKw7u7M80ZWMKQMkHnJx976V0F5EoWRQOc9QMYHp+Ncxd7Y5wrkhDgEgcjrgVCiddOSZg61MwIYFiWJ4JPtzxVKAN9mlZyMcbQM8dfnqXU3VnfJUjgswxxxx3+mapyyqpG3BUZPAA+b/CmvU6emhKG3x/J8mxSSp/h6fzqm0skbPmFuTuwGzgZ6DmokufK8ph80ZHKcE5I6n/69Lc3aBFkRwASQCwHAz9KqwzPlmjSRmC5C8AZwVPbH8qhR5VZmkUYDZZBjG7P8qbOymIc/Kg4boVJ9eO9R3E2xkTlQATjOfTjp1ptPYNCSe5EsScosg6A4AJwf0rGuXUAlQuCcZJHHIzn/wCvWxEDcWaqUwANoHOR1G2sW4U+Y6kuccY556cUatg7IzZoTkEcHGAc4HOa9j0OyNnp1msYVW2ZY9lzjj8a8ps4fP1GBcOw3qMevWvaooRHbQ7ELgrwpB54Byee1dENjzsU1dIt27ZiIVdpBx34B/h/GrKW52YPGF4XHHbiqcflxHC5fk4J9PX681LMw8oFG4/Mkf41er3OP0Jp4mUgZDMTyGHB56Gqjb3+ZSN2MfMOG9uvSpnxK2dpYEfNjqQD/OoyQSQQCMBSOmV9B71NtSkyDBznPIOBxw3PJPNIlvEVBG/BHf8A/XUoCgHgnnJ2kfPzxj0quZVJ+ZlJ7/5xWbfLuWUpEaUIEw6vnAP8XA5+tQzAhCFyVGcqeh65PWrAeJXKmT52GNox6VBqr+TbNkpnOPkPJ+ntXazijq0jhr+GN3Lgl9wJI749evX6VpWNsQzmQ+YFGVGenzdvU/rUV5EyKpxyBkFQCM4+906dq2tPAe2SWQ5Oc5B6c9elZSukdyLln5ctrI7+XwBwSMjjpVtNjRMiKSz4Ldu/alitd1qSilU4Ixx681ZW2KnMhYMw5IJO0cc1jqijk9Xd4+qAjPOO5wcEew71Dp1w2V2kdd3IxuPHzdOlaXiiEtA0YDZGAoUfdHPH41iaPOQp89Pu5wR9Bx9Ko1jZncWkY3xcswP/AI779O/at20mCH7pAORnPbA5rlrG7AAyodX6n8+Pwrdtbkyh3RVZgOhOD/8AqrKV3oUkbsM0bzZLYIAxn/PerCSuAQ7Kq56cfL6AHrzXPLMrkER8qxIyQCD/AIZq60uYgAc/KTlhnA9ah2G6Z0C3ixK28s2TjpjB9KimuA8AEjqcHOGHTBrCS8HmgZVhnIUP0Aq0lxbtFIzl0HUL8rBef8ai99RexsTXMwaaMqR8pHU43Ef0p7TO0BZkVM/MCW498ioJLi1aNY40G7I3fL2/u1TupXjgbZtO442jPqeB9KSZXJcWe6Mgk2uo2/dweDxyawb2aMuiyMYyq7i3+NS+eIE2Zyu7GTyd2OV+lUL2TE/H731yep54/D3pR1saqHKzEu5FMz7cDeDwc5UY+7+NVb64aJVRI9pHG3rtGfu1W1S5bzYVRWIfnJ/iAB5PPaq5kXzhkgp26Z7datWtqbWsJJcLHGoZmDqck8kNx93/APXSyy/aHCmLaS2SwbGeR8v0qOVGZAIigA5AbHTnr7/Wlt3tzGQ3DJkFCB9zjp71aTExkrmRMiM+YBtwx++Rn37VQjbaV+VWRDuVup6g5PNaJKswUEhT93tkc9MdxWdNuhmk81EkJUE7OjHjpRYauWY7jDvtOFYZJOPU8/Ws7VECKrhVz1HQ4Hv6GrjqyxqwVmd8ZHQN19v84qlfyBscH1zk8n19sU7vqDYnhWAS61F8odQdxAxkD6+te0WM2YYy4QsFAI/vYHp7d68m8FRSf2mJFHyoNzDkZyfvV6tZLlBKqhO5wT8oI6/jXRBaHk4l3kWXjJBIUFid2QeM+o46ClhLNGTuBHOSvr61OQxLcEAc9Mbc+nNEdunzrL8ueSFbAHp37980n1OdCPxKCG5I5Iz0yOR9KgmZgQxP3eQQDwOfmFWhAkK+WSu5PvYHHYj8KJtpGdg3Z+XgHnPr6UnuUimI+WITABDBs8pz1H1qHeP76/l/9erx2kfK3I+7kDAPvVd41Lsdx6+grNytY0SuY7EeUZAjDaPlBJyDjrmsvV5xIIhkROrYIOf3fI/nV5Wk2nZGfLJxzjIOO/tWRr0O+aMABgWOQcDjI6/0rtexyU/iRAGVpxEWwenscj7tadiscbuGyoLYRe2cjg89KybaMRy/KoyRjkglV9PrW/YoqhS33ugzjn/69ZT3sdibNu0VHtfn+RjwAejHnj2FJemONkjDbXIy2SAM8fpUeSYSicKMA54yeeOnFUpR5kzhSZY9oBTsx/uisrO44u5iay++Jeyg7V3Y5HIOa5m22IMFx5owwJIwBj7v146GunvY/PmO1zL/AAAY+9g9fwrlLhTFuG8tggADJyMdc+1OK0N4s6PTZx5iK0mOcbR069K6KwnzufIWQjaOThuOgNcNaTmMAeYc7sgEdeeuc8YrYt7yRVUqSCTyMc4xy31qGktWap30R18F4POKuoZQcbgduTn7vpxTlkWV+JRkk/eDKG/L06Vz8eoGFXOf3Y5wVBGMjn61ajmEhDFEZWBLeScY9ODWU0aQNr7bInMoLRlsbsb/AMeO3anuYSgZZlAU5AIOT15zWTbhJvMe33nIG5AuCV44yKWW7ijZkEvlsGwQWyOvb2qWnuwfZGlEy7d7MvI3bs849frWfJqSfahG7rsZgF2kcDnn8az9SvUHBuI23DkqeN2OuMVg3F2rOGR2VycrgH16mi1rFJX3N3UtRjhQqQhTHAOM9OlZE15h2jPKkfOvHIzx+PrWa1+rqC+VKZ6gnPHL5xVCW6BcuSwLHKkgn0+bFNrYtNIsm8Wa5cv2XrkEHjGBQsRkZ2U7hxjGcE5HfFU7RRK0m1SshABwThQc/wA60IsqPmjcFe6/hxVW0/r+v6RLaFvCY4QxG0Y5VRw3X5vwqC4+a3jkYYP30k5BH+0farbozM6sNqlgfp6AVXu4ZIFcBAVP8OM88cfT3p+QJ9R0MsTQN9paQbM/LH1jOfvYPrWQZg5QFcgfe6/KOOnP+c1buXUvE8aZd8g5IAY+h9qhjifyFLHCHlW4yDj+LiqsCbLKyLIqEsQOgx/CMketZl7b7S+GUx5Bx3Bx256VNbYNwY1Oxwc4zjAz1NPmVnTg4RRgD06+3eoV0ynsafgR9l9IWUmPI6kdc/yr1HTwiRjJUseQfQ4715/4EhS3S7LRuzbhhsnB6fLXc2chCxxoCdwHJznGDx+FdK+E8nEO82bAZX64X5jt3dR0qRokO4KwVeSQex/+vUO05w/DDgOc8n0p6jhiTuwCMj9Qeab3Oe9thsqoCgUkZ6g8Ef7P41G5AmAG7sAv4n5alkXdHuwHGM56EjufwqN0zIrHncOCP4hnqPeoktdSkyNc/cPTHKnPPtUbMpYnb1P92p5IhtySFHc5Gf8A9dVTHCSTu6+orN9DSLMNmIQNjHy7TuPJGPumubv7ktcmM/OBzu5w3T+Vb1w0flFt23Kjbj0/vfWuauVhS6kw4JIGdoGDwOnPWu2WiOaluOG97hVJbDuPmBOe/NdRZBIXYHLEA4Iz7c9a5a3icFGYgEuM9OmTit23QS3Kyv8AdThcN944/lXPUudaRvSNvt1ZMBS2NxOOM9frWR5bu8giR1hPzMe6j+8PetNo3UooPGdxUHjIPUewqbT1L2e+PCuGLHPOffHpUalrQxZrYrvCoGCkEkdue3r71yN3CuZGdVJPPBHBxXo94BC5kYNEoHGex9a4/UbZ3BMuRH14zweeTTTLg7nLXEeyZVyjFz27Eew/pU9reCKFzJtlDfKV6Ybnnp2/nV02RmmViGjZM+vydOfxrOvLbaX2o6qe+TweeAc4OetN6q5rF2ZpG/MdscO4YjBwf4sDnp0x2q9Y3zwIrRMAwHzlMqV9/euODPCQ7sxVB82PwwOv41pR6hAzr5iOuM/Mgxk5+vSocOjNFJWOmj1KRn8xJpFO0nIJ3KP71LLqSmNg+52HC9TjLdj71yS3iNK+HdUYY+YAgED+X0q5JfuoBiIZF4DKQcHPfP6UlHqNyRYuZwwIWTClslG6qcfd68iqU8r+WXVySp2jAz34796o/alLhRj/AHu/I5yakUlkb5MdxyQFGeeO1FiuYQPiPy3OX7jHGccD2BogjR485Ujd0BBGeP096mitPbagHTk56/zqzbwuzBWHyuMZHJwMfLS+Qr9SbTbYlFYABieOR79f/r1es7MOjGJwqjhQeecDJNW7a0LyqWZipwCq5568VdgtXMjJlin8A6bjt+6aQuZFC4UwGF2XkHGT0Xnv9ajvosLckqELQ8Kx6D+79a2Lm180GPHntz1JGcHvz2rn9TlZI9sh8xiDgleq45Y80P8Ar+v61HGzMs23mKGwSAcYyRnnpU6IrwAj+EYIbPJ9MVam8u3hRR80ZAIY+mR+vaqjTAZjjAJVgcjGQhzwfc0jVELQbrguq7ZMAY5G726/jUSyQhjkHLDp2bryeeorcnhiQIXQtGwH3ACQMjp71iMUErEgMjnBx3POOgoS1DdHaeBoY2hmbGcNuOTnPTnr1rsra3RZicBSwyuRwRg9K4zwUm6ynKkgA7mXPJOByOK7K1eTjkODyBzzXTHSJ49f42XlILYIVl6jJ4xj+dS+WpR94G3GT7jtj3quJ2ZyMDHPBPTj71WsMAzZx1JAGMc/e/Gk2zAgfJDDglh1X8ORQE4I25Y4xj1z1FSBNihWXaeygfcH9c9aeOJCWG1R0GOBz2qbsqxV2Khz1U+vU9eRTTA5JO4H3BNTHGcD5QOo4688fSjyZe2wfRKynfSxojhLp5vl8plEaj5m98feHtXKlZvPkf5fkyNufpzXZXj+XbuFVtgyN3v/AHfpXI2xYEZO4EfK5Ht0P0rvlqjCiaFip3CIM2DwcZ4963bRTMkMY3KgGDx0JHb69KzrRU3qdvzZ4bAB69a29MAkdSpACtkcD05yP5Vzz3Z0l9YSs0aybl2nBzng54X2BqawBhDQBtjKMYI478A+lXhEu0M6jah9Ogzz+NRXcC5BYNz0XHOOePrWV+4LXQw9QkZpjFbqZA3ADL1PoT6VzmpSESrBkEkZGepIzke1drLbtICQuSMDnv7Vk3ujtcSAyIGCkYI6g8/KKaehtFnPw2+YpGSQo2MhXA64HX2rPu7Ysu1CQWHAI4B54ro2srmESxmd5AMZjZfvfKDkH0FQG3QEjHmMRlWbJ78n8KLmiOLW0XymWNgJMcA5weOc8etINPeBCJUZAATgfN36dOtdkunY8yT5XUnIB6Nx1q4mlNI6fugVYMBlgMerc96ptA3Y4BrfGQjSbSoB+X7vyn5enWoZIH8xtxIIIG4E/Mcjj04rtLjTZIJzIseBjDADqvPzfWkl08uqqE3xjkhgDjkfrU8yuM5S00xrkEB8YwACeM88e3FbMen+URGoXcfuAD73Tv7VpW1kUaQLFGR0MYC8deB6Gr5QJbsxV1CqpzgH8B7+tTcrVHPy2hRthDDaM7ePn65JNQXMJEsWMRMEBLDHIx6+tdY9qWlDvhzw4brk8+3QU2+05JF8wRtvCZK468cn6UJ9ENS7mbbu8wKIUDoThQQeP8TUt0zRETQ7cKuCvUHjp9aIbUQzkxl9rjIznjB61MiSR2it82QCNxJxnB+ale6GkrkkLi4hleRWyT823+LpjHpjvXPaupmibzciVjlSBw3Xnp0rYa4FtOBcMY45TgjJwh4xj696j1KAtbOxyhUEgE5x1wB7ULUqOjMG5hLWaAncFGMc+oyelN0WMyK6EdDuLcjHB5//AFVrR20czxyuNrBccchjxgZz05qnaILK7KEjy3fcpGAM88fQUtzVbE16rzWmQcIRk7ScgcfNj3rDu4FE7AbkVRwBng8/nmuqWJkz5bKGcZTcBgHHX6Vh61AI3RiwRx93jOOecn+VAI3PAj5WeMhjtbJODnO0cda9BtAjr8v8XXnofT6V518PVz55bt3x0GOlejxIgyE+X6jP4GuhbHkYj+IyWQEyhsAEAjg9/T6U4OTkYGBnk46/4UBQ27kggbSDngY+79ackZUkENnBHP1Hy+1NtanONUAsoj6Y3LnsPenOg+Y7gW7Z6jnv+dL5YyrDlj/EOA//AOqnGMNl1yGJxzkbqT8ykVthDKPuqp4OenXIpVBCgeWBx0JOamIzyRkg4BP8XXr6VWERIBBcg8jI/wDr1nK2haOKu5F+zP8AMEVBgZ7e31rmLOcb1Tdzj7zfTp0610+sYSxnBOCVJBx973z61y1qUYRqoVnxkg8cYPP1711S1RnR2ZtwvuKbclugbkA9OOnWul0mI54HzHgAfx+34VzGmgOZMKMDkA+nHPXrXU6dIqW6nlcfexjj0x7+tYS6m97HRJgx/MQxXlm9ff8ACoEKXF0c7vVTjOeuTVZDcugfcgT+IDjPPSnqJIG/cqFdiCpOPU1k4ji9C3K6x3QQoQCM898d6oTYS5yxAAG44PBGeo961GhMjLh25GScfe4xxVSO2WVgMcxtkk9zn71JrYuMkZ1xbrI+9QVZl5HHA2/zqitmGdSoAcfJhMf5/wD110BiAYooblflJHA460yGN1VlMe0k5BIxn3/Gh6FqTMgWDRMd6LyM5X1x0p4SczuLgxnALZRcZPGCPYd62lhCR7gSjck4BO33/Gs65iaUzK7+XzgADkEgcfjQwUrmZPavdQBmaUgDIKnAJ55xjkVOLKQWy7lJQLkN78c/StI/cUbQmV24I4H/ANarTRKsClWyR98AdSMY/Cldajcmc4NN+y3G+LOCdzYzgHP3iKdbSb/MSdCU7FRnaOmce9bUysxMkaEDOcZ4/wD1VhRjZcySR7tjkcLg7T3JHpST1LTuTqpgSQKCYwwAU8jOTgZ96hdnMjxyhCQoGV7cHjr09ag1SUWsqFCVQnAJI555zTjJHLDFM4cSbRgjnAweD9cULzH5kEtsFLKo3ZP7o46H0PPSoXRli8mVtygkMMDhuevtWo00bmRTlMjHPBXOOPbPrWNqT3EVxG8RaSEkI3JGf9n3o0auy4yHvbQzWn2fjaCShOODx1/pWXLJIkjW5/1gUqgfH3Ocg8da1ztjxnJlZ9w4OH4Hf2purwi5CzAAuv8AHg+vNUuxSlqV/D7iTTvKJGRwobqPbOOtVryzaOORZELlSNpJwQMn5elWNLt2QybeQhyp6EjHXrV+4YTxoGLYPOCOQM8/jS1skNSs9ClBmfT148xiAAADzgfdxWPrCvKpJJYD+L++c/0rSeI2y7RnyyucjAZVx/OsO+ykrB8EZ5/+t/M0dTReRo/Dp3W6miPzbsEDB5+X69q9JgU+ZhACX4UMP1NeV+C+NXIXggZypHHB4Ar1VG3R7iC27GQDjOAOQcfia6EtDysRpNlqEP5kgVtxXuRjj1+tTAjynJYSY5YfiP1qK1fe77yWZcng9/73vTkwYyWbagJyQc88c5qmtWc1xx+Vcrye4IHAz2qXdwWc4UgDA9M/zqJzgYYsAB1zwPemb2dSCThR0x0/2hUtXY0x0i7XJ3FsnLYxhue3/wBaohIuBuf5u+FFOy0cm1lYjIOcfd5/z+dRZmHHkEY7bxWU7aXLWpwniIAabJvIYE5zwOeOlcxB5ZjjTgkjPygdeeeB2rrfEB8vT2LfKPugc/L049a5SPEbYwQVAOR+g/GuyeiJoao6PR1DDuCe/vx83TpW6kQVgM/Kjbsg9z/FjvmsHSnaKNXlG1m6MBnnA457V0Nqiu6sVwdxAwRg89PoK55Pc2tqatoWjQbiwVRkZ6j2q3HbNPE8su75TyDwRzVfjdCoCsB/F6+uTVkyGFmjAAB5zx0zUPTcLPoSQHawkIZQuAFPYf8A16ZBG6XLEldjkE56hs9PpUyL5gQ7SqdVDdvrViGBBdKWGGAAB645+7U3K2JbizPlqybW298VBNaCWBXwVII577sfyq4rNHMVYDcDxzkY9KbLKYlJdPkPAA5HTpSuJJoyrlC8YjjcGTB5J6eufb0pyWANs3k5LqnGecepOa0JLcQ25eLYAODjnPHT8KZaqIrhdzcMp+jdM/lU3L9DMvUdrKKdCpmU42n0/wAau20ILbGAA7ZOOvarE0QeKXy9pPUcc9ar2j7YAuc7Tg5Iz9alt3G9UJJYrEZlBwx4Vc9v7tcvqtlPEXlQNyNvl5I3D0/DrmuwaMSOTJIXk2DBHBxnr7GszUYjJECowcbSxwdoyccetF7Mqm7HH3Esd1YMsuf3fLAg5fGP0FPs5Lc6fw2Vf5iMcgYPP4VoapYeUQssQ2kZbA4Y+gxWFpSrFEYXKFJCwU55Vhnj2pq6sbWTV0XrhY3XzIhztxyO3HJ9xULxkyOI1UIFJKMO2Tzn1qaF8RtEEdynIbHB4HzdOg6U0OZIJWjJCxtz65z948fhVbCM+6U/ZZFeP5iAdq44+hqeGVZYYd6rkEqwBGevT8KlMLbXUkZjBOeflGOpPv0rKEjxXAaUHBbbxn5MnrQtSy6VMbFkI2t1Gevp27VavIWVo7hD8+8Fh2PPUew9KoRzt5xiIPlovQZJHXH51qxXUcsYttpBBGd314H09abdhJala7t/tKCRXYcZB5xjBy2B0Fcrq8JUNtUqyDIwzdM9a66UnKvFwVwpU4A75HXp9a5bXWRXlKqCF6BgMnp+lCd5I1htYz/Cry22swtk4Zc53Hjg8/jXrNjcHIaVDHn/AMc4A4+vSvI/DdxHFrVuXwF3YwQCM817BahZ1DJnaehbHHAzn+ldEHoedi17xZJYSs8fyjOMAd/T6U5RtBXKg85BAIzxxUVvGyO/l52gkfNzkE9D9akBwoyQAM49enSm9LnISomEIYA85Ax0Oen0oZAcDKjuDnADe/tSb/mwowCMbTnrnpUgwWJAHZSmOp9KTGiEr0yQoB/i/r/So/JY8hDg9KsOCGPzFjx1P3+elV2Lbj8/6VjN36GsTjPFyqdNkyoOEJHHTpWDYxobJMopyjE8deKKK7pmdHYuwACIY4/0Un8cV12lgFIsjOSuffrRRXLLdHQzUthwx7+YFz7elXLsD7PKcDOyiikStyeyUGK3BAwygn3NOf8A4+W91yfeiis1sil1LtsAWyQCcCluAPM24G0JwPTiiil0H1/rzE1ZV+wP8o+4p6VAVG2E4Gcpzj/ZoooY1sPm+W/kA4BB4H1FU9TVROxCgEunIFFFS92EdjYRFEr4Ucc9KoXwHmoMcHJP60UU+o4mG7M1jbFiSS5ByeoxXBanxFe442bNuP4eT0oopx+FHRR6mzas3nINxx9nHGf9kVQsmLE5JO5yDnuPeiiiQ4mjdIvlj5Ryzg8dRtqrJGn2hPkX73p70UU4fEw6f15GZYc3cxPJ/wDrGtp1X7MjYG4W7kHHOciiilPr/XcFuhigfbIBjg2oYj1PrXL+ICf3ZycliCfXgUUU47mkNznrdmXUl2sRyo4Psa9j0Vj5si5O3yUOO33aKK2jv9xw4rdF6J2aeIMxIYHdk9ee9Szcx5PXe38qKKqWzONCt/X/AAqa2+5N/u5/U0UUpAgl4S5x2TI+vFVwOBRRWXRG8T//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subperiosteal xanthomata in a patient with heterozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Planar xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Planar xanthoma in the antecubital fossa of a patient with homozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23322=[""].join("\n");
var outline_f22_49_23322=null;
var title_f22_49_23323="Muc melanoma HN stage group";
var content_f22_49_23323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM anatomic stage and prognostic groups for mucosal melanoma of the head and neck",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Primary tumor (T)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Regional lymph nodes (N)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3-T4a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVB",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23323=[""].join("\n");
var outline_f22_49_23323=null;
var title_f22_49_23324="WHO MEC for thalassemia and sickle cell disease and anemia";
var content_f22_49_23324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization medical eligibility for contraceptive use: Anaemias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        COC",
"       </td>",
"       <td class=\"subtitle1\">",
"        CIC",
"       </td>",
"       <td class=\"subtitle1\">",
"        P/R",
"       </td>",
"       <td class=\"subtitle1\">",
"        POP",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         DMPA",
"        </p>",
"        <p>",
"         NET-EN",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         LNG/ETG",
"        </p>",
"        <p>",
"         Implants",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        LNG-IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Thalassaemia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sickle cell disease",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Iron-deficiency anaemia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1: A condition for which there is no restriction for the use of the contraceptive method.",
"    <br/>",
"    2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.",
"    <br/>",
"    3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.",
"    <br/>",
"    4: A condition which represents an unacceptable health risk if the contraceptive method is used.",
"    <div class=\"footnotes\">",
"     COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.who.int/reproductive-health/publications/mec/summary.html. Copyright &copy; 2006 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23324=[""].join("\n");
var outline_f22_49_23324=null;
var title_f22_49_23325="VTE risk in pregnancy by thrombophilia";
var content_f22_49_23325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of venous thromboembolism in pregnancy with different thrombophilias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence in general population (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        VTE risk per pregnancy (women with",
"        <em>",
"         no history of VTE",
"        </em>",
"        ) (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        VTE risk per pregnancy (women with",
"        <em>",
"         previous history of VTE",
"        </em>",
"        ) (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percentage of all VTE in pregnancy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V Leiden heterozygote",
"       </td>",
"       <td>",
"        1-15",
"       </td>",
"       <td>",
"        &lt;0.3",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V Leiden homozygote",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin gene heterozygote",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"       <td>",
"        &lt;0.5",
"       </td>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prothrombin gene homozygote",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        &gt;17",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor V Leiden/prothrombin double heterozygote",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"       <td>",
"        &gt;20",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antithrombin deficiency",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        3-7",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1, 5, 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein C deficiency",
"       </td>",
"       <td>",
"        0.2-0.4",
"       </td>",
"       <td>",
"        0.1-0.8",
"       </td>",
"       <td>",
"        4-17",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        1, 5, 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein S deficiency",
"       </td>",
"       <td>",
"        0.03-0.13",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        0-22",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1, 8-10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VTE: venous thromboembolism.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109:369-84. (Level III)",
"       </li>",
"       <li>",
"        Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374-80. (Level II-3)",
"       </li>",
"       <li>",
"        Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol 2003; 16:243-59. (Level III)",
"       </li>",
"       <li>",
"        Haverkate F, Samama M. Familial dysfibrinogenaemia and thrombophilia. Report on a study of the SSC Subcommittee on fibrinogen. Thromb Haemost 1995; 73:151-61. (Level II-2)",
"       </li>",
"       <li>",
"        Carraro P. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. European Communities Confederation of Clinical Chemistry and Laboratory Medicine, Working Group on Guidelines for Investigation of Disease. Clin Chem Lab Med 2003; 41:382-91. (Level III)",
"       </li>",
"       <li>",
"        Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor deficient women: implications for prophylaxis [published errata appear in Ann Intern Med 1997; 127:1138; Ann Intern Med 1997; 126:835]. Ann Intern Med 1996; 125:955-60. (Level II-2)",
"       </li>",
"       <li>",
"        Vossen CY, Preston FE, Conard J, Fontcuberta J, Makris M, van der Meer FJ, et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost 2004; 2:592-6. (Level II-2)",
"       </li>",
"       <li>",
"        Paidas MJ, Ku DH, Lee MJ, Manish S, Thurston A, Lockwood CJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005; 3:497-501. (Level II-3)",
"       </li>",
"       <li>",
"        Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001; 113:636-41. (Level II-3)",
"       </li>",
"       <li>",
"        Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002; 126:1349-66. (Level III)",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: ACOG Practice Bulletin #124. Inherited thrombophilias in pregnancy. Obstet Gynecol 2011; 118:730. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23325=[""].join("\n");
var outline_f22_49_23325=null;
var title_f22_49_23326="High vs low transport in peritoneal dialysis";
var content_f22_49_23326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    High versus low transport in peritoneal dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Twardowsky ZJ. Nightly peritoneal dialysis. ASAIO Trans 1990; 36:8. Copyright &copy; 1990 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23326=[""].join("\n");
var outline_f22_49_23326=null;
var title_f22_49_23327="Acetabular index";
var content_f22_49_23327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acetabular index",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The acetabular index is the angle formed between Hilgenreiner line (a horizontal line through the upper margin of the radiolucent triradiate cartilage) and a tangential line to the lateral ossific margin of the roof of the acetabulum. The acetabular index changes with axial and sagittal plane rotation of the pelvis and is helpful in measuring the development of the osseous roof of the acetabulum. In the newborn, the acetabular index must be over 40&deg; to be significantly abnormal.",
"    <div class=\"footnotes\">",
"     DDH: developmental dysplasia of the hip.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_49_23327=[""].join("\n");
var outline_f22_49_23327=null;
